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Blood-dwelling or blood-feeding parasitic helminths, 
such as Schistosoma and Fasciola species, interact for 
prolonged periods with the haemostatic system of 
their host. As a result of their blood-feeding behavior or 
presence in the veins, these parasites are expected to be 
potent activators of the haemostatic system. However, 
the longevity of parasites in their host implies that they 
have developed strategies to modify activation of the 
haemostatic system to survive in continuing interaction 
with their human host. In this thesis, the author discusses 
the complex interactions between host haemostasis 
and parasitic helminths. The results of the studies 
provide novel insight into mechanisms underlying 
coagulopathy during schistosomiasis and the strategies 
used by helminth parasites to modify coagulation 
activation. Identification of new strategies for coagulation 
modification by Schistosoma and Fasciola species may 
have implications beyond parasitic disease, such as in the 
development of novel antithrombotic or thrombolytic 
agents in haemostatic disorders.
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Chapter 1 
Introduction to parasites in human disease
In biology, the term “parasitism” describes a relationship between two organisms in 
which one organism (the parasite) lives at the expense of the other organism (the 
host). The parasite benefits from the relationship through easy access to nutrients 
and a very constant environment. The loss of nutrients to the parasite and damage to 
the host, either mechanical or through stimulation of a damaging immune response 
that results from this relationship, are disadvantageous for the host. 
Parasitism is a highly common way of living: it is estimated that between 30% and 
71% of all named species are parasitic [1]. Although many viruses, bacteria, and fungi 
have a parasitic lifestyle, the term “parasite” is limited to protozoa and multicellular 
eukaryotic organisms with a parasitic lifestyle. Humans alone can be infected with 
hundreds of different parasite species and evidence of parasitic infections in humans 
has been dated back to prehistoric times [2]. Parasites can be divided into three main 
categories: 1) unicellular parasitic protozoa, such as malaria, 2) multicellular parasitic 
worms (helminths), such as schistosomes and Fasciola, and 3) ectoparasites, such as 
ticks and mosquitos. This thesis will only focus on helminths, and more specifically on 
schistosomes and Fasciola parasites, and therefore protozoa and ectoparasites will not 
be discussed. Schistosomiasis, caused by parasitic helminths called schistosomes, is 
the world’s second most important parasitic disease of public health importance after 
malaria [3]. Schistosomes are responsible for over 200 million infections worldwide 
and an estimated 280,000 deaths yearly in sub-Saharan Africa alone [4]. Additionally, 
parasitic infections of cattle cause major economic losses and zoonotic parasitic 
infections affect human health [5]. In tropical regions, fascioliasis, caused by parasitic 
helminths called Fasciola, is considered the most important helminth infection in cattle, 
affecting 30-90% in Africa, 25-100% in India, and 25-90% in Indonesia [5,6]. Not only 
cattle is affected by this parasite: the WHO estimates that worldwide at least 2.4 million 
humans suffer from fascioliasis, with several million people at risk in over 70 countries 
[5]. However, this may be an underestimation as the global burden of fascioliasis is 
approximated to be between 35 and 72 million people [7]. It is thus clear that parasitic 
infections form a serious health and economic burden worldwide.
Schistosomiasis
The tropical parasitic disease schistosomiasis, or bilharzia, is caused by blood-
dwelling parasitic trematodes (flatworms) of the genus Schistosoma. Although five 
schistosome species can cause infection in human, the major disease-causing species 
are Schistosoma mansoni, Schistosoma haematobium and Schistosoma japonicum [8,9]. 
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Morphology of the adult schistosome
Schistosomes have separate sexes and the adult worms live in pairs in blood vessels 
of their host. The male worm will fold its body into a groove in which it embraces the 
slightly longer and thinner female, which gives the worms their cylindrical appearance. 
Adult schistosomes vary in length from 7 to 20 mm and have two terminal suckers 
required for attachment to the blood vessel wall. The outer surface of the worm is 
formed by a complex tegument layer, which is a 1 to 3 μm thick syncytial layer covered 
by a double lipid bilayer (the membranocalyx). This tegument layer is thought 
to play an important role in evasion of host defence systems by the parasite [10]. 
Schistosomes have a blind digestive tract in which digestion of blood components 
takes place, after which degraded products are expelled into the host bloodstream 
by regurgitation [11]. 
The schistosomal life cycle
Human Schistosoma species have a complex life cycle (Figure 1) which involves two 
different hosts: a tropical freshwater snail as the intermediate host and humans as 
the final host. Adult worms live in the mesenteric (S. mansoni and S. japonicum species) 
or perivesicular veins (S. haematobium species) of their human host, where they mate 
and produce hundreds to thousands of larva-containing eggs per day [8]. About half 
of the eggs get trapped in the tissues of the liver (S. mansoni and S. japonicum species) 
or wall of the urine bladder (S. haematobium species), where they elicit a strong 
immune response leading to granuloma formation and tissue damage [8]. The other 
eggs migrate through the vessel wall and lining of the intestine (S. mansoni and S. 
japonicum species) or urinary bladder (S. haematobium species), after which they 
are excreted with faeces or urine. Water contact triggers the release of the ciliated 
larva, called miracidium, from the egg. The miracidium infects fresh-water snails 
that function as the intermediate host. Each Schistosoma species infects a specific 
snail species; S. mansoni infects Biomphalaria snails, S. japonicum infects Oncomelania 
snails, and S. haematobium infects Bulinus snails [9]. Inside the snail, the miracidia 
reproduce asexually to produce sporocysts that mature into cercarial larvae. After 
4-6 weeks, the cercariae leave the snail in search for their definitive host, humans. 
Humans are infected after contact with infected water, upon which the cercariae 
will penetrate the skin. Skin penetration results in the loss of the cercarial tail and 
transforms the larvae into migrating juvenile worms, the schistosomula. These 
schistosomula migrate through the bloodstream to the lungs and then to the portal 
vein, where they mature into adult schistosomes. The adult schistosomes mate and 
migrate to the perivesicular or mesenteric veins, where they live on average 3 to 5 
years, but their lifespan can be as long as 30 years [8]. 
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Symptoms of disease
Three distinct disease stages can be distinguished during the course of an infection 
with Schistosoma species: swimmer’s itch, acute schistosomiasis and chronic 
schistosomiasis [8]. Although, schistosome infections often occur without notice, 
symptoms may be present at all stages of the disease [8,9].
Penetration of the skin by cercariae can trigger a local skin reaction which is called 
swimmer’s itch [12]. Symptoms arise shortly after contact with infected water and may 
persist for several hours up to a couple of days [13]. Also non-human schistosome 
species, in particularly bird schistosome species, can cause swimmer’s itch. Due to the 
similarities in symptoms, it is often difficult to distinguish whether the skin reactions 
were caused by bird or human schistosome species [14]. 
Acute schistosomiasis, also called Katayama fever, can occur 2-10 weeks after a 
primary infection [15]. Symptoms are flu-like and include fever, fatigue, muscle 
pain, and non-productive cough. Acute schistosomiasis results from a T-helper-1 
cell (Th1) mediated hypersensitivity response towards the migrating and maturing 
schistosomula. High eosinophilia and patchy infiltrates on chest radiography are 
characteristic of this stage. 
In chronic schistosomiasis, symptoms are not caused by the adult parasite, but by 
entrapment of eggs in the lining of the intestine or bladder during egg-excretion, 
or entrapment of eggs that fail to extravasate in organs such as the liver, spleen, 
lungs or central nervous system. The entrapped eggs elicit a strong immune response 
leading to granuloma formation and fibrosis [8]. The severity of symptoms is therefore 
determined by both the intensity and duration of the infection as well as host factors 
that determine individual immune responses. 
Several forms of chronic schistosomiasis can be distinguished, based on the 
Schistosoma species that causes the infection. Infections with S. haematobium, which 
reside in the perivesicular veins, causes urinary schistosomiasis. Urinary schistosomiasis 
is, in early stages, characterized by the presence of blood in the urine (haematuria). 
Later symptoms include calcification of the bladder, urodynamic disorders, and renal 
dysfunction. Additionally, there is a strong association between urinary schistosomiasis 
and the development of bladder cancer [9]. Intestinal, hepatic, and hepatosplenic 
schistosomiasis are mostly caused by S. mansoni and S. japonicum infections, although 
hepatic and hepatosplenic disease can also occur in severe cases of schistosomiasis 
haematobium [16]. Intestinal schistosomiasis is characterized by abdominal pain and 
diarrhoea with or without bloody stools. Hepatic schistosomiasis or early inflammatory 
schistosomiasis is caused by an early reaction to entrapped eggs in the liver, leading to 
mild or diffuse fibrosis and enlargement of the liver. Hepatosplenic schistosomiasis or 
fibrotic hepatic schistosomiasis develops after years of chronic infection. It results from 
periportal collagen deposition, leading to periportal fibrosis. Periportal fibrosis leads 
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to the development of portal hypertension, splenomegaly, and gastro-oesophagal 
varices, which can result in fatal bleeding [8].
Ectopic schistosomiasis can develop in tissues that are accidentally reached by 
adult parasites or eggs. Ectopic schistosomiasis includes pulmonary, genital and 
neuroschistosomiasis, and symptoms are caused by inflammatory responses and 
fibrosis in response to the parasite or eggs [8]. 
Diagnosis
The gold standard for the diagnosis of active schistosomiasis is the detection of viable 
eggs in urine (S. haematobium) or faeces (S. mansoni and S. japonicum). As direct 
microscopic detection of eggs is not very sensitive, sample concentrations methods 
are usually required, although even then light infections can still be missed [8].
Figure 1. The life cycle of Schistosoma species.
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Seroconversion usually happens between 4 to 8 weeks after infection, so at this stage 
serological tests could confirm schistosomiasis. Serological tests are highly sensitive 
in detecting antibodies against soluble worm antigen or, later in infection, crude 
soluble egg antigen with ELISA, indirect haemagglutination, or immunofluorescence 
[8]. However, a major drawback of serological tests is that antibodies may be present 
long after the infections has been cleared, at least for two years, making discrimination 
between a past or ongoing infections difficult. 
Alternatively, detection of circulating schistosomal antigens, in particular circulating 
cathodic antigen (CCA) and circulating anodic antigen (CAA), can be performed 
in urine using lateral-flow (dipstick) tests [17]. As these circulating antigens are 
only produced by viable schistosomes, detection of these antigens can be used to 
detect active schistosome infections. Recent improvements in sensitivity and sample 
concentration methods have led to recommendations by the WHO for the use of 
these dipstick tests in mapping and monitoring programmes [9,17–19]. 
Other diagnostic tools include detection of parasitic DNA by real-time PCR, and 
visualization of tissue pathology through endoscopy, (contrast)radiology, CT, and 
MRI. However, due to high costs and technical issues these techniques are rarely 
performed routinely in low-income endemic areas [8,9].
Treatment and control
Praziquantel is the drug of choice for treatment of schistosomiasis, as it is low-cost, 
safe and effective in a single oral dose against all schistosome species [8]. While 
praziquantel is effective against adult worms, it has little or no effect on eggs or juvenile 
worms [9]. Although the antihelminthic activity of praziquantel has been discovered 
in 1972, its working mechanism is still not fully understood [20]. It is known that the 
drug initiates a rapid influx of Ca2+ and causes paralysis in the mature parasites. This is 
accompanied by blebbing of the tegumental and subtegumental structures, resulting 
in disruption of the tegument and exposure of parasite surface antigens. This is thought 
to lead to recognition and clearance of the parasite by the host immune system, and 
would explain why an effective host antibody response is required for full efficacy of 
praziquantel [9,20]. Praziquantel does not prevent reinfection, therefore, in endemic 
areas where reinfection is likely, treatment is given at regular intervals in mass drug 
administration programs. In travellers or patients suffering from Katayama fever, two 
doses of praziquantel are administered with an interval of 4 to 6 weeks to eradicate 
all parasites, including maturing juveniles. Additionally, corticosteroids can be used to 
dampen immune responses in Katayama fever and cases of neuroschistosomiasis [8].
Control and elimination of schistosomiasis could be achieved by implementing 
(preventative) mass drug administration programmes, combined with interruption 
of transmission by behavioural changes in hygiene habits, providing access to safe 
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water, sanitation and snail control [8,21]. Also, the development of vaccines against 
schistosomiasis could be beneficial in control of schistosomiasis. However, despite 
promising results of some candidates in animal models, these candidates still have 
to be tested in human safety and efficacy trails and a vaccine is unlikely to become 
available before 2025 [22,23].
Fascioliasis
Fascioliasis in humans is a zoonotic parasitic disease caused by two liver fluke species: 
Fasciola hepatica and Fasciola gigantica. The final hosts of the parasites are mammals, 
mostly sheep and cattle, however, human infections are increasingly reported and the WHO 
estimated that worldwide at least 2.4 million people are infected [5]. Fascioliasis is of great 
veterinary importance and in tropical countries it is considered the most important helminth 
infection in cattle [6] causing economic damage by limiting productivity of livestock [5]. 
The life cycle of Fasciola species
The life cycle of Fasciola species involves a final host (a mammalian species), an 
intermediate host (a freshwater snail), and a carrier (a (semi-)aquatic plant) (Figure 
2). Adult Fasciola reside in the bile ducts of their host where they feed primarily on 
blood and also on bile duct epithelium. In the bile duct, they produce immature 
eggs that are transported with bile into the intestine and subsequently excreted with 
faeces. In fresh water the eggs mature and a miracidium hatches from the egg. The 
miracidium will infect the intermediate host, a freshwater snail of the genus Lymnaea, 
in which it develops into sporocysts, rediae, and finally cercariae [7]. Cercariae leave 
the snail and will encyst on leaves of (semi-)aquatic plants, such as water cress, 
forming metacercariae that are protected by a tough cyst wall. Metacercariae can 
infect the definitive host when plants with attached metacercariae are consumed [5]. 
After ingestion, immature flukes excyst from the metacercaria in the small intestine 
[24]. Immature flukes will penetrate through the intestinal wall and migrate through 
the peritoneal cavity to the liver. They migrate through the liver and finally reach 
the bile duct [7]. In the bile duct the parasite becomes sexually mature and starts 
producing eggs [24]. Because the estimated life span of the adult parasite is between 
9 and 13.5 years, infections may last for many years [5,7,25,26]. 
Symptoms of disease
Fascioliasis can be divided into two disease stages: acute hepatic fascioliasis and 
chronic hepatic fascioliasis. Acute fascioliasis is caused by migration of the juvenile 
flukes through the liver, resulting in symptoms such as fever, nausea and abdominal 
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pain. Usually eosinophilia is observed and the liver can be swollen [5,7]. Chronic 
fascioliasis arises when the adult parasites are established in the bile duct. This causes 
biliary obstruction resulting in symptoms such as intermittent pain and jaundice. 
Blood-feeding by the adult parasite results in the development of anaemia [5]. 
Diagnosis, treatment and control
Although eggs can be produced and secreted with faeces in chronic fascioliasis, 
detection of eggs in faeces is considered not a reliable diagnostic tool [27]. In the 
early stages of the disease, up to three to four months after infection, no eggs are 
produced yet and in chronic human fascioliasis egg shedding can be intermittent or 
very low [28]. Serological techniques are currently most often used for the diagnosis 
of fascioliasis. Anti-Fasciola antibodies can be detected in serum as early as two 
weeks after infection with ELISA. However, antibodies may persist for at least four 
to five months after successful treatment, making discrimination between past and 
present infection challenging [27]. Approximately eight weeks after infection, parasite 
antigens can be detected in serum or faeces of patients and could be used for 
diagnosis of active infection [27,28]. 
Triclabendazole is currently the drug recommended by the WHO in the treatment of 
fascioliasis [7]. Triclabendazole is effective against both the juvenile and adult stages 
of the parasite and the cure rate exceeds 90% after a single oral dose [7,29]. Although 
biliary colic is frequently observed after treatment, as a result of the passage of 
dead parasites through the bile duct, adverse events of triclabendazole are usually 
temporally and mild [29].
Control of human fascioliasis could be achieved by applying preventative chemotherapy 
using triclabendazole. Additionally, interruption of transmission through behavioural 
changes, snail control and treatment of infected livestock could attribute to control of 
human fascioliasis [5]. However, resistance against triclabendazole is emerging and 
forms a potential threat to control of human fascioliasis [7]. Vaccines for F. hepatica in 
livestock are under development, but despite the progress made, a vaccine against 
fascioliasis is still several years away [30–32].
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Figure 2. The life cycle of Fasciola species.
Host-parasite interactions in schistosomes
Schistosomes can reside in their human host for up to 30 years [8]. During this period 
they are under continuous attack by host defence mechanisms. The immune system 
and, since schistosomes are blood-dwelling parasites, the haemostatic system form 
the major sites of interaction between the host and the parasite. The interaction 
between schistosomes and host defence systems has been the focus of many past 
and ongoing studies.
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The immune system
Immunology
During infection with schistosomes different stages can be discriminated, likewise, the 
immune response against the parasite can also be divided into three phases. During 
acute schistosomiasis, as the immature parasite migrates through tissues of its host, 
the dominant immune response is a Th1 response [33]. This response is characterized 
by the production of cytokines typical for a Th1 response, such as TNF, IFN-γ, IL-1, and 
IL-6 [33,34]. At around 6 weeks after infection, when the schistosomes have matured, 
mated, and started to produce eggs, the immune response shifts dramatically 
towards a strong Th2 response which peaks at 8 weeks after infection [33,35]. 
Specific soluble egg antigens that affect dendritic cells induce this shift toward a Th2 
response, characterized by the production of IL-4, IL-5, IL-13, and anti-Schistosoma 
IgE [33,35]. Regulatory feedback mechanisms of Th2 responses, such as alternatively 
activated macrophages, IL-10, and regulatory T-cells, downregulate the Th2 response 
at around 12 weeks after infection [35]. This mild Th2 response characterized by IL-10 
and regulatory T-cells is typical for the chronic stage of the infection.
Immune evasion strategies
Adult schistosomes reside in their host for many years and are, despite of an ongoing 
host immune response, not cleared. This clearly indicates that the parasite employs 
immune evasion strategies. The properties of the outer surface tegument are thought 
to play a crucial role in immune evasion. It has been proposed that high turnover 
of membranocalyx, the outer double membrane layer of the tegument, could be 
involved in rapid clearance of bound immune complexes or cells from the surface 
[10]. The membranocalyx could also function, similarly to a glycocalyx in bacteria, 
as protection against the activated complement system. Also, the acquisition of host 
molecules, such as MHC antigens, immunoglobulins, and low-density lipoprotein, 
to the schistosomal tegument could shield immunogenic epitopes and thereby 
prevent immune recognition of the worm [10]. Additionally, the surface acquisition 
of host decay accelerating factor, which prevents activation of complement, could 
further prevent complement activation at the parasitic surface [10]. Adaptive 
immune responses are also actively evaded by the adult worm. Schistosomal lipids, 
in particular lyso-phosphatidylserine, are responsible for the modulation of the 
Th2 response into a milder, regulated immune response in chronic schistosomiasis. 
Lyso-phosphatidylserine acts through Toll-like receptor 2 and polarizes dendritic cell 
maturation which could skew the adaptive immune system towards a Th2 response 
characterized by IL-10 and regulatory T-cells [36].
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The haemostatic system
Principles of platelet plug formation, coagulation, and fibrinolysis
Haemostasis is a tightly regulated physiological mechanism that maintains blood in 
a fluid state in intact blood vessels and responds with coagulation at sites of injury 
to limit blood loss [37]. It consists of three elements: 1) platelet plug formation, 2) clot 
formation/coagulation, and 3) fibrinolysis. 
Platelet plug formation, or primary haemostasis, at sites of injury is a first response in 
order to reduce blood loss. Damage of the endothelium exposes collagen fibres that 
form a binding site for the multimeric plasma protein von Willebrand Factor (VWF). 
Binding of VWF to collagen induces a conformational change in VWF, which results 
in exposure of platelet binding sites on VWF [38]. The interaction between collagen-
bound VWF and platelets, slows the platelet down and allows interaction between 
collagen and platelets. Binding of platelets to collagen induces activation of platelets, 
resulting in release of two types of secretory granules, alpha and dense granules 
[37]. These granules contain a variety of molecules that amplify platelet activation, 
stimulate coagulation, induce vasoconstriction, and inhibit fibrinolysis. Platelet 
activation also leads to activation of the fibrinogen receptor, which allows binding of 
fibrinogen to platelets. The fibrinogen protein consists of two identical binding sites for 
platelets, which facilitates binding of fibrinogen to two different platelets resulting in 
platelet aggregation. Platelet aggregation is characterized by spreading of platelets 
and results in the formation of a platelet plug. Additionally, platelet activation also 
leads to the exposure of anionic phospholipids on platelets, which creates the optimal 
membrane surface to propagate coagulation activation [37,39].
The formed platelet plug needs to be stabilized in order to withstand forces caused by 
flowing blood [37]. The platelet plug is stabilized by a cross-linked network of fibrin fibres, 
thus converting the platelet plug into a clot. Fibrin is generated by cleavage of fibrinogen 
as a result of an orchestrated sequence of cleavage reactions of plasma coagulation 
factors, which is called secondary haemostasis or coagulation. Many of these plasma 
coagulation factors are primarily synthesised in the liver and impairment of liver function 
can have pronounced effects on blood coagulation [37]. 
The main activator of coagulation is the transmembrane protein tissue factor, which 
is present in the sub-endothelium and exposed upon vessel damage, but can also be 
expressed on activated endothelial cells and monocytes [37,40]. Tissue factor binds as 
a co-factor to activated coagulation factor VII (FVIIa), resulting in the formation of the 
TF-FVIIa complex [37]. In this complex, FVIIa can activate both FIX (at low tissue factor 
concentration) and FX (at high tissue factor concentration). FIXa will together with FVIII 
form the tenase complex, which activates FX to FXa. FXa forms together with FVa the 
prothrombinase complex which will convert prothrombin into thrombin, the enzyme 
20
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responsible for the conversion of soluble fibrinogen into insoluble fibrin. In addition to 
the tissue factor mediated activation pathway (intrinsic coagulation), high-molecular 
weight kininogen, kallikrein, and FXII can assemble on an anionic surface, resulting in the 
activation of FXI, which is called the contact activation pathway (extrinsic coagulation). 
FXIa can subsequently activate FIX, which is part of the tenase complex consisting of FIXa 
and FVIIIa. Thrombin is a key player in coagulation, as it converts fibrinogen monomers 
into an insoluble fibrin clot that is cross-linked by FXIIIa, thereby stabilizing the platelet 
plug. Additionally, thrombin is crucial in amplification of the coagulation cascade through 
activation of factors V and VIII which is essential for both the tenase and prothrombinase 
complex. Accumulation of thrombin over time induces anticoagulant mechanisms, that 
prevent uncontrolled clot formation, and induces antifibrinolytic pathways that ensure 
the clot persists long enough to allow initiation of tissue repair mechanisms.
Once tissue repair is initiated, the insoluble fibrin clot must be broken down in a process 
that is called fibrinolysis. This is initiated by the local secretion of tissue-type plasminogen 
activator (tPA) from the endothelium. tPA activates plasminogen by cleavage into 
plasmin, which directly cleaves fibrin into specific degradation products. Fibrin itself forms 
a crucial co-factor in activation of fibrinolysis by co-localizing enzyme and substrate. In 
the initial phase, tPA and plasminogen bind to binding sites on intact fibrin, which leads to 
slow activation of plasminogen to plasmin. Limited cleavage of fibrin by this low amount 
of plasmin will result in the exposure of additional binding sites (C-terminal lysines) that 
enhance both tPA and plasmin activity, resulting in a burst of plasmin that degrades the 
fibrin network and solubilizes the clot [37].
The haemostatic system is tightly regulated in order to prevent uncontrolled clot 
formation (anticoagulation) and allow the clot to persist long enough to allow 
endothelial damage to be repaired (antifibrinolysis). Anticoagulation is established 
through the actions of several peptidase inhibitors that inhibit coagulation factors, 
such as antithrombin, tissue factor pathway inhibitor, and activated protein C. 
Additionally, endothelial cells release nitic oxide and prostaglandins and express ecto-
ADPase on their surface, which inhibit platelet activation and prevent coagulation in 
the absence of vessel damage. Also plasmin has anticoagulant functions as it is able 
to degrade many coagulation factors, thereby preventing further coagulation.
Key antifibrinolytic components are the serine protease inhibitors α2-antiplasmin and 
plasminogen activator inhibitor 1, that associate with the fibrin network and inhibit 
plasmin and tPA, respectively. Additionally, thrombin activatable fibrinolysis inhibitor 
acts to prevent a burst of plasmin activation after initial plasmin formation, by 
removal of C-terminal lysine binding sites from fibrin that would enhance tPA activity. 
Together, these mechanisms allow fine-tuning of haemostasis and prevent unwanted 
coagulation [37].
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The haemostatic system and parasitic infections
Many blood-dwelling or blood-feeding parasites are expected to be potent activators 
of the haemostatic system. Their blood-feeding behaviour or presence in the vein 
could induce endothelial damage, provide a foreign surface, or could cause changes 
in blood flow, all of which normally activate haemostasis. However, the longevity 
of many parasite in their host indicates that parasites have developed strategies 
to modify activation of the haemostatic system and thereby survive the continuing 
interaction with haemostatic system of their human host.
Schistosomes
Adult schistosomes reside in the vasculature of their host for years, yet platelets do 
not adhere to the outer surface of the parasite [41] and thrombotic complications are 
relatively uncommon in hepatosplenic schistosomiasis patients (5% of hepatosplenic 
patients) [42]. Therefore, schistosomes are proposed to have numerous mechanisms 
that impede clot formation and promote the degradation of blood clots that do form, 
which will be described in detail elsewhere in this thesis. In contrast, binding of VWF 
[43] and massive platelet adhesion and aggregation is observed on the surface of 
schistosome eggs [41]. It is suggested these capacities of the eggshell are important 
for anchoring eggs to the vessel wall and subsequent egg extravasation [41,43]. 
Despite modification of the haemostatic system by adult schistosomes, abnormalities 
in haemostasis are common in patients suffering from chronic hepatosplenic 
schistosomiasis [44]. In particular, bleeding from gastro-oesophagal varices is a 
common fatal complication in these patients. Haemostatic abnormalities observed 
in these patients are linked to reduction in liver function, as a result of granuloma 
formation around trapped eggs, and include: reduced levels of both plasma 
coagulation and anticoagulation factors, lower numbers of platelets, impaired 
coagulation in vitro, increased thrombin production, and enhanced fibrinolysis [44]. 
Thus, in schistosomiasis both local effects on haemostasis by the adult parasite and/
or eggs, and systemic effects on haemostasis as a result of liver pathology are present.
Other blood-feeding or blood-dwelling parasites
In addition to schistosomes, many other blood-feeding or blood-dwelling parasites 
interact with the human haemostatic system and have developed their own strategies 
to survive. Some examples will be discussed below.
Malaria is the most important disease-causing parasite in humans and its life cycle 
is characterized by a blood stage that causes the characteristic fever symptoms of 
malaria. In this stage, the parasite infects red blood cells and promotes binding of these 
cells to the vessel wall, to avoid clearance of infected cells by the spleen. Haemostatic 
changes are observed during malaria infection, which includes: increased levels of 
22
Chapter 1 
VWF, reduced activity of the VWF-cleaving peptidase ADAMTS13, enhancement of 
extrinsic and intrinsic coagulation, and attenuation of anticoagulant mechanisms 
[45]. Accumulation of VWF during infection is suggested to facilitate binding of 
infected red blood cells to the vascular wall. The strong coagulation activation 
observed during malaria has been suggested to play a role in malaria pathogenesis, 
however, currently it is unclear whether coagulation activation actually modulates 
malaria pathogenesis or whether it is a consequence of infection [45].
Also in lymphatic filariasis part of the parasitic life cycle is located in the human 
bloodstream. While the adults reside in the lymphatic system, the microfilariae 
they produce enter the blood vessels. Microfilariae have been described to inhibit 
collagen and ADP-induced platelet aggregation, possibly through secretion of anti-
aggregatory eicosanoids, and the parasite secretes an inhibitor of coagulation factor 
XII, which may prevent coagulation initiation [46,47].
Not only blood-dwelling parasites but also blood-feeding parasites must produce 
anticoagulants in order to allow prolonged periods of blood-feeding. Adult Fasciola 
can reside in the bile duct for over a decade and clear changes in host haemostasis 
are observed during infection. The parasite seems to interfere with ATP, ADP, and AMP 
hydrolysis, which could affect platelet aggregation during infection [48]. Additionally, 
excretory/secretory products of F. hepatica are shown to accelerate intrinsic blood 
coagulation, while the extrinsic coagulation pathway is delayed, however, the 
mechanisms underlying these coagulation changes and its effect on pathogenesis 
need to be further elucidated [49]. Furthermore, examination of the components of 
the excretory/secretory products of F. hepatica showed the presence of host-derived 
products, including antithrombin and α-2-macroglobulin, that are involved in 
regulation of the haemostatic system [50]. Re-use of host-derived inhibitors may thus 
form another strategy to modify host coagulation.
Not only internal blood-feeding parasitic worms combat the haemostatic system. 
Blood-feeding ectoparasites, such as mosquitos, ticks, and leeches have also been 
described to contain inhibitors directed at different stages in the coagulation cascade. 
Especially leeches are interesting, since one well-known antithrombotic agent, 
hirudin, has been isolated from medicinal leeches [51]. Hirudin is a potent inhibitor 
of thrombin. However, this is not the only anticoagulant protein that leeches secrete 
[52]. Leeches are well adapted to their host haemostatic system and have a broad 
arsenal of agents that increase blood flow, inhibit platelets, and have anticoagulant 
properties, to ensure blood-feeding for prolonged periods [52].
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Aim and outline of this thesis
The focus of this thesis is on the interaction of parasitic helminths, in particular 
schistosomes, with the blood coagulation system of their host. Prolonged presence 
of the adult schistosome pair in the vasculature is expected to activate the blood 
coagulation system. The interaction of schistosomes with blood coagulation 
has been investigated by many other researchers [41,53,62–71,54,72–75,55–61]. Also, 
coagulopathy that is observed after prolonged (hepatosplenic) infection is described 
in detail (reviewed by Tanabe et al. [44]). However, so far a complete overview of the 
mechanisms schistosomes utilize to interfere with human haemostasis is missing 
and it is unknown whether there are any yet undiscovered strategies the parasite 
applies for evading blood coagulation. Furthermore, insights in the presence of 
coagulopathy in non-hepatosplenic schistosomiasis is currently not available. The 
aim of the work in this thesis is to (1) present an overview on the blood coagulation 
modification mechanisms of schistosomes, (2) provide insight in coagulopathy 
in schistosome infections without hepatic disease, and (3) identify yet unknown 
mechanisms of modification of blood coagulation by schistosomes and other blood-
feeding parasites.
Schistosomiasis: interactions with the haemostatic system and 
haemostatic changes during infection
As the adult schistosome worm pair resides in the human vasculature for prolonged 
periods, this forms a potential prothrombotic threat. Activation of coagulation is 
negative for both the host, leading to thrombosis, and the parasite as coagulation 
around the parasite can restrict movement of the worm pair. It is therefore clear that 
schistosomes must counteract the activation of blood coagulation. So far there is 
no complete overview on the mechanisms that are used by schistosomes to modify 
blood coagulation. In Chapter 2, we have summarized the studies on the interactions 
between schistosomes and the host haemostatic system to present a comprehensive 
overview of the mechanisms currently known. This literature overview also showed 
us that, although much research has been performed on coagulopathy in 
schistosomiasis, most studies have been performed in hepatosplenic schistosomiasis 
patients. Many coagulation factors are synthesised in the liver, and it is therefore 
difficult to discriminate between the effects of the schistosome infection and the liver 
damage on blood coagulation of the host. In Chapter 3, we performed a pilot study 
aimed at unravelling the contribution of solely the parasitic infection on changes 
in blood coagulation by studying coagulation parameters in a group of Gabonese 
school children suffering from urogenital schistosomiasis haematobium. As 
mentioned above, adult S. haematobium reside in the perivesicular veins, so infection 
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with this species does usually not result in liver damage. This allowed us to determine 
the specific effects of the parasitic infection only, and showed that inflammation 
mediated endothelial activation results in increased plasma VWF levels, without 
increased activation of coagulation in these patients.
Alternative pathways to regulation of VWF function 
The finding that plasma VWF levels are increased in S. haematobium patients without 
apparent activation of coagulation, led us to further investigate the interaction 
between VWF and adult schistosomes. Interactions between VWF and schistosome 
eggs have already been studied thoroughly [43]. This revealed that VWF binds directly 
to the egg shell and this is essential for the adhesion of the eggs to the endothelium, 
leading to extravasation of the eggs from the circulation. The interactions between 
adult schistosomes and VWF have not been investigated before, but the increased 
plasma VWF levels during infection, without coagulation activation, suggests that 
the adult parasite has evolved mechanisms to regulate VWF function. Chapter 4 
describes the discovery of a S. mansoni peptidase that is capable of cleaving both 
a substrate that is used to measure VWF-cleavage, FRETS-VWF73, and purified VWF. 
This peptidase belongs to the class of cysteine peptidases and is inhibited by the 
peptidases inhibitors N-ethylmaleimide and leupeptin, but activated by the chelating 
agent ethylenediaminetetraacetic acid (EDTA) or the reducing agent L-cysteine. Using 
a combination of anion exchange chromatography and mass spectrometry the S. 
mansoni cathepsin B2 gene, SmCB2, was identified as the prime candidate to encode 
the S. mansoni VWF-cleaving peptidase. Although reduction of SmCB2 expression in 
adult worms by RNA interference did not affect the proteolytic activity towards VWF, 
recombinant expressed SmCB2 (rSmCB2) could cleave the FRETS-VWF73 substrate, 
which contains the A2 domain of VWF. This confirmed that SmCB2 is a schistosomal 
cysteine peptidase that can cleave human VWF. 
After investigating alternative pathways to regulate VWF functionality during 
schistosomiasis, we next focussed on alternative pathways for regulation of VWF 
functionality during normal haemostasis. Direct cleavage of VWF by peptidases 
other than ADAMTS13 has been described in several studies [76–81]. However, to date 
regulation of ADAMTS13 is still unknown. Several studies suggest that the fibrinolytic 
enzyme plasmin can cleave and thereby inactivate ADAMTS13. In Chapter 5, we found 
that plasmin is capable of inducing truncation of ADAMTS13, leading to increased 
activity of this peptidase. Plasmin may thus form a physiological mechanism to 
enhance ADAMTS13 activity.
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S. mansoni and the fibrinolytic system
Plasmin also forms a key player in the fibrinolytic system, where it functions in the 
breakdown of formed thrombi. Many studies have been performed on activation of 
plasminogen into plasmin by schistosomes [71–75]. These studies show that schistosomes 
have the capacity to bind and enhance activation of plasminogen to plasmin, however, 
the plasminogen activator tissue-type plasminogen activator (tPA) is required for the 
enhancement of plasminogen activation. The interaction between schistosomes and 
tPA is therefore the subject of Chapter 6. In this study we investigated if schistosomes 
have proteins that can bind tPA, especially at the host-parasite interface, which could 
aid in the enhancement of plasminogen generation by schistosomes.
Cleavage of coagulation factors by F. hepatica
Not only blood-dwelling parasites interact with blood coagulation, also blood-feeding 
parasites have to modify blood coagulation to allow blood-feeding for prolonged 
periods. We therefore investigated the effect of several secreted peptidases of the 
blood-feeding parasites F. hepatica and S. mansoni for effects on proteins involved in 
coagulation in Chapter 7. This led to the discovery that cathepsin L peptidases of F. 
hepatica cleave fibrinogen and fibrin. We suggest that this could aid in preventing blood 
coagulation in the parasite gut, thereby allowing blood-feeding for extended periods. 
The conclusions and implications of these studies are summarized and discussed in 
Chapter 8.
26
Chapter 1 
References
1.  de Meeus T, Renaud F. Parasites within the new phyologeny of eukaryotes. Trends Parasitol 2002; 18: 247–51. 
2.  Cox FEG. History of human parasitic diseases. Infect Dis Clin North Am 2004; 18: 171–88. 
3.  Kincaid-smith J, Tracey A, Augusto R, Bulla I, Holroyd N, Allienne F, et al. Whole genome sequencing and 
morphological analysis of the human-infecting schistosome emerging in Europe reveals a complex admixture 
between Schistosoma haematobium and Schistosoma bovis parasites. bioRxiv 2018; 387969. 
4.  van der Werf MJ, de Vlas SJ, Brooker S, Looman CWN, Nagelkerke NJD, Habbema JDF, et al. Quantification of 
clinical morbidity associated with schistosome infection in sub-Saharan Africa. Acta Trop 2003; 86: 125–39. 
5.  Ibrahim N. Fascioliasis: Systematic Review. Adv Biol Res 2017; 11: 278–85. 
6.  Spithill TW, Dalton JP. Progress in development of liver fluke vaccines. Parasitol Today 1998; 14: 224–28. 
7.  Nyindo M, Lukambagire AH. Fascioliasis: An ongoing zoonotic trematode infection. Biomed Res Int 2015; 786195.
8.  Gryseels B, Polman K, Clerinx J, Kestens L. Human schistosomiasis. Lancet 2006; 368: 1106–18. 
9.  Colley DG, Bustinduy AL, Secor WE, King CH. Human schistosomiasis. Lancet 2014; 383: 2253–64. 
10.  Skelly PJ, Alan Wilson R. Making sense of the schistosome surface. Adv Parasitol 2006; 63: 185–284.
11.  Skelly PJ, Da’dara AA, Li XH, Castro-Borges W, Wilson RA. Schistosome feeding and regurgitation. PLoS Pathog 
2014; 10: e1004246.
12.  Barsoum RS, Esmat G, El-Baz T. Human schistosomiasis: clinical perspective. J Adv Res 2013; 4: 433–44.
13.  Nederlandse Vereniging voor Parasitologie. Medische parasitologie. 5th ed. Syntax media; 2017.
14.  Kolářová L, Horák P, Skírnisson K, Marečková H, Doenhoff M. Cercarial dermatitis, a neglected allergic disease. Clin 
Rev Allergy Immunol 2013; 45: 63–74.
15.  Puylaert CAJ, van Thiel P-P. Katayama fever. N Engl J Med 2016; 374: 469–69. 
16.  Nooman ZM, Nafeh MA, El-Kateb H, Atta SM, Ezzat ES. Hepato splenic disease caused by Bilharzia haematobium in 
Upper Egypt. J Trop Med Hyg 1974; 77: 42–8. 
17.  Corstjens PLAM, De Dood CJ, Kornelis D, Fat EMTK, Wilson RA, Kariuki TM, et al. Tools for diagnosis, monitoring 
and screening of Schistosoma infections utilizing lateral-flow based assays and upconverting phosphor labels. 
Parasitology 2014; 141: 1841–55. 
18.  Utzinger J, Becker SL, van Lieshout L, van Dam GJ, Knopp S. New diagnostic tools in schistosomiasis. Clin Microbiol 
Infect 2015; 21: 529–42. 
19.  World Health Organization. Expert consultation to accelerate elimination of asian schistosomiasis. November 2017.
20.  Cupit PM, Cunningham C. What is the mechanism of action of praziquantel and how might resistance strike? 
Future Med Chem 2015; 7: 701–5.
21.  Sokolow SH, Wood CL, Jones IJ, Swartz SJ, Lopez M, Hsieh MH, et al. Global assessment of schistosomiasis control 
over the past century shows targeting the snail intermediate host works best. PLoS Negl Trop Dis 2016; 10: 1–19.
22.  Toor J, Alsallaq R, Truscott JE, Turner HC, Werkman M, Gurarie D, et al. Are we on our way to achieving the 2020 
goals for schistosomiasis morbidity control using current world health organization guidelines? Clin Infect Dis 
2018; 66: S245–52.
23.  Molehin AJ, Rojo JU, Siddiqui SZ, Gray SA, Carter D, Siddiqui AA. Development of a schistosomiasis vaccine. Expert 
Rev Vaccines 2016; 15: 619–27. 
24.  Mas-Coma S, Bargues MD, Valero MA. Human fascioliasis infection sources, their diversity, incidence factors, 
analytical methods and prevention measures. Parasitology 2018; 1–35. 
25.  Chatterjee KD. Fasciola hepatica. In: Parasitology (Protozoology and Helminthology). 10th ed. Calcutta: Sree 
Saraswaty Press Ltd; 1975. p. 146–8.
26.  Dan M, Lichtenstein D, Lavochkin J, Stavorowsky M, Jedwab M, Shibolet S. Human fascioliasis in Israel. An 
imported case. Isr J Med Sci 1981; 17: 430–2. 
27.  Sarkari B, Khabisi SA. Immunodiagnosis of human fascioliasis: An update of concepts and performances of the 
serological assays. J Clin Diagnostic Res 2017; 11: OE05-10. 
28.  Mas-Coma S, Bargues MD, Valero MA. Diagnosis of human fascioliasis by stool and blood techniques: Update 
for the present global scenario. Parasitology 2014; 141: 1918–46. 
27
General introduction
1
29.  Marcos LA, Terashima A, Gotuzzo E. Update on hepatobiliary flukes: Fascioliasis, opisthorchiasis and 
clonorchiasis. Curr Opin Infect Dis 2008; 21: 523–30. 
30.  Toet H, Piedrafita DM, Spithill TW. Liver fluke vaccines in ruminants: Strategies, progress and future opportunities. 
Int J Parasitol 2014; 44: 915–27.
31.  Molina-Hernández V, Mulcahy G, Pérez J, Martínez-Moreno Á, Donnelly S, O’Neill SM, et al. Fasciola hepatica 
vaccine: We may not be there yet but we’re on the right road. Vet Parasitol 2015; 208: 101–11.
32.  Cwiklinski K, O’Neill SM, Donnelly S, Dalton JP. A prospective view of animal and human Fasciolosis. Parasite 
Immunol 2016; 38: 558–68.
33.  Pearce EJ, MacDonald AS. The immunobiology of schistosomiasis. Nat Rev Immunol 2002; 2: 499–511.
34.  Dunne DW, Cooke A. A worm’s eye view of the immune system: Consequences for evolution of human 
autoimmune disease. Nat Rev Immunol 2005; 5: 420–6.
35.  Colley DG, Secor WE. Immunology of human schistosomiasis. Parasite Immunol 2014; 36: 347–57.
36.  van der Kleij D, Latz E, Brouwers JFHM, Kruize YCM, Schmitz M, Kurt-Jones EA, et al. A novel host-parasite lipid 
cross-talk. Schistosomal lyso-phosphatidylserine activates toll-like receptor 2 and affects immune polarization. J 
Biol Chem 2002; 277: 48122–9. 
37.  Pryzdial ELG, Lee FMH, Lin BH, Carter RLR, Tegegn TZ, Belletrutti MJ. Blood coagulation dissected. Transfus Apher 
Sci 2018; 57: 449-57.
38.  Lenting PJ, Pegon JN, Groot E, De Groot PG. Regulation of von Willebrand factor-platelet interactions. Thromb 
Haemost 2010; 104: 449–55.
39.  Zwaal RF., Comfurius P, Bevers EM. Lipid–protein interactions in blood coagulation. Biochim Biophys Acta - Rev 
Biomembr 1998; 1376: 433–53.
40.  Amer A, Amer ME. Enhanced monocyte tissue factor expression in hepatosplenic schistosomiasis. Blood Coagul 
Fibrinolysis 2002; 13: 43–7.
41.  Wu YP, Lenting PJ, Tielens AGM, de Groot PG, van Hellemond JJ. Differential platelet adhesion to distinct life-cycle 
stages of the parasitic helminth Schistosoma mansoni. J Thromb Haemost 2007; 5: 2146–8.
42.  Leite LAC, Ferreira R de C dos S, Hatzlhofer BLD, Correia MCB, Bandeira ÂP, Owen JS, et al. Portal vein thrombosis 
associated with protein C deficiency and elevated Factor VIII in hepatosplenic schistosomiasis. Blood Coagul 
Fibrinolysis 2016; 27: 210–12. 
43.  Dewalick S, Hensbergen PJ, Bexkens ML, Grosserichter-Wagener C, Hokke CH, Deelder AM, et al. Binding of von 
Willebrand factor and plasma proteins to the eggshell of Schistosoma mansoni. Int J Parasitol 2014; 44: 263–8.
44.  Tanabe M. Haemostatic abnormalities in hepatosplenic schistosomiasis mansoni. Parasitol Int 2003; 52: 351–9.
45.  O’Sullivan JM, Preston RJS, O’Regan N, O’Donnell JS. Emerging roles for haemostatic dysfunction in malaria 
pathogenesis. Blood 2016; 353: 2281–89.
46.  Foster CB, Flanigan TP, Kazura JW, Dumenco LL, Ratnoff OD. Inhibition of the activation of Hageman factor 
(factor XII) and of platelet aggregation by extracts of Brugia malayi microfilariae. J Lab Clin Med 1991; 117: 344–52. 
47.  Liu LX, Weller PF. Intravascular filarial parasites inhibit platelet aggregation. Role of parasite-derived prostanoids. 
J Clin Invest 1992; 89: 1113–20.
48.  Fracasso M, Da Silva AS, Baldissera MD, Bottari NB, Gabriel ME, Piva MM, et al. Activities of ectonucleotidases and 
adenosine deaminase in platelets of cattle experimentally infected by Fasciola hepatica. Exp Parasitol 2017; 176: 
16–20. 
49.  Joachim A, Ali SF, Daugschies A. Fasciola hepatica alters coagulation parameters in sheep plasma in vivo and in 
vitro. Parasitol Res. 2003; 89: 53–58.
50.  Di Maggio LS, Tirloni L, Pinto AFM, Diedrich JK, Yates JR, Benavides U, et al. Across intra-mammalian stages of the 
liver fluke Fasciola hepatica: A proteomic study. Sci Rep 2016; 6: 1–14.
51.  Tsoucalas G, Chevallier J, Karamanou M, Papaioannou T, Sgantzos M, Androutsos G. Historical hallmarks of 
anticoagulation and antiplatelet agents. Curr Pharm Des 2016; 22: 1857–61. 
52.  Sig AK, Guney M, Uskudar Guclu A, Ozmen E. Medicinal leech therapy—an overall perspective. Integr Med Res 
2017; 6: 337–43.
53.  File S. Interaction of schistosome eggs with vascular endothelium. J Parasitol 1995; 81: 234–8. 
54.  Silva CL, Morel N, Noël F. Portal veins of mice infected with Schistosoma mansoni exhibit an increased reactivity to 
28
Chapter 1 
5-hydroxytryptamine. Mem Inst Oswaldo Cruz 1998; 93 Suppl 1: 153–5. 
55.  Da’dara A, Skelly PJ. Manipulation of vascular function by blood flukes? Blood Rev 2011; 25: 175–79.
56.  Oliveira SDS, Quintas LEM, Amaral LS, Noël F, Farsky SH, Silva CLM. Increased endothelial cell-leukocyte interaction 
in murine schistosomiasis: Possible priming of endothelial cells by the disease. PLoS One 2011; 6: e23547.
57.  Ngaiza JR, Doenhoff MJ. Schistosoma mansoni-induced thrombocytopenia in mice. Trans R Soc Trop Med Hyg 1987; 
81: 655–6. 
58.  Bhardwaj R, Skelly PJ. Purinergic signaling and immune modulation at the schistosome surface? Trends Parasitol 
2009; 25: 256–60.
59.  Cesari IM, Simpson AJ, Evans WH. Properties of a series of tegumental membrane-bound phosphohydrolase 
activities of Schistosoma mansoni. Biochem J 1981; 198: 467–73. 
60.  Araujo-Montoya BO, Rofatto HK, Tararam CA, Farias LP, Oliveira KC, Verjovski-Almeida S, et al. Schistosoma 
mansoni: Molecular characterization of alkaline phosphatase and expression patterns across life cycle stages. 
Exp Parasitol 2011; 129: 284–91. 
61.  Bogitsh BJ, Krupa PL. Schistosoma mansoni and Haematoloechus medioplexus: Nucleosidediphosphatase 
localization in tegument. Exp Parasitol 1971; 30: 418–25. 
62.  Vasconcelos EG, Nascimento PS, Meirelles MNL, Verjovski-Almeida S, Ferreira ST. Characterization and localization 
of an ATP-diphosphohydrolase on the external surface of the tegument of Schistosoma mansoni. Mol Biochem 
Parasitol 1993; 58: 205–14. 
63.  DeMarco R, Kowaltowski AT, Mortara RA, Verjovski-Almeida S. Molecular characterization and immunolocalization 
of Schistosoma mansoni ATP-diphosphohydrolase. Biochem Biophys Res Commun 2003; 307: 831–38.
64.  Carvalho WS, Lopes CT, Juliano L, Coelho PMZ, Cunha-Melo JR, Beraldo WT, et al. Purification and partial 
characterization of kininogenase activity from Schistosoma mansoni adult worms. Parasitology 1998; 117: 311–19.
65.  Cocude C, Pierrot C, Cêtre C, Fontaine J, Godin C, Capron A, et al. Identification of a developmentally regulated 
Schistosoma mansoni serine protease homologous to mouse plasma kallikrein and human factor I. Parasitology. 
1999; 118: 389–96. 
66.  Tsang VC, Damian RT. Demonstration and mode of action of an inhibitor for activated Hageman factor (factor 
XIIa) of the intrinsic blood coagulation pathway from Schistosoma mansoni. Blood. 1977; 49: 619–33. 
67.  Tsang VC, Hubbard WJ, Damian RT. Coagulation factor XIIa (activated Hageman factor) inhibitor from adult 
Schistosoma mansoni. Am J Trop Med Hyg 1977; 26: 243–7. 
68.  Foster CB, Flanigan TP, DeStigter KK, Blanton R, Dumenco LL, Gallagher C, et al. Inhibition of the activation of 
Hageman factor (factor XII) by extracts of Schistosoma mansoni. J Lab Clin Med 1992; 120: 735–9. 
69.  Lin YL, He S. Sm22.6 antigen is an inhibitor to human thrombin. Mol Biochem Parasitol 2006; 147: 95–100.
70.  Blanton RE, Licate LS, Aman RA. Characterization of a native and recombinant Schistosoma haematobium serine 
protease inhibitor gene product. Mol Biochem Parasitol. 1994; 63: 1-11. 
71.  Ramajo-Hernández A, Pérez-Sánchez R, Ramajo-Martín V, Oleaga A. Schistosoma bovis: Plasminogen binding in 
adults and the identification of plasminogen-binding proteins from the worm tegument. Exp Parasitol. 2007; 115: 
83–91.
72.  de la Torre-Escudero E, Manzano-Román R, Pérez-Sánchez R, Siles-Lucas M, Oleaga A. Cloning and 
characterization of a plasminogen-binding surface-associated enolase from Schistosoma bovis. Vet Parasitol 2010; 
173: 76–84.
73.  de la Torre-Escudero E, Manzano-Román R, Siles-Lucas M, Pérez-Sánchez R, Moyano JC, Barrera I, et al. Molecular 
and functional characterization of a Schistosoma bovis annexin: Fibrinolytic and anticoagulant activity. Vet 
Parasitol 2012; 184: 25–36. 
74.  Yang J, Qiu C, Xia Y, Yao L, Fu Z, Yuan C, et al. Molecular cloning and functional characterization of Schistosoma 
japonicum enolase which is highly expressed at the schistosomulum stage. Parasitol Res 2010; 107: 667–77.
75.  Figueiredo BC, Da’dara AA, Oliveira SC, Skelly PJ. Schistosomes enhance plasminogen activation: The role of 
tegumental enolase. PLoS Pathog 2015; 11: 1–22. 
29
General introduction
1
76.  Tersteeg C, de Maat S, De Meyer SF, Smeets MWJ, Barendrecht AD, Roest M, et al. Plasmin cleavage of von 
Willebrand factor as an emergency bypass for ADAMTS13 deficiency in thrombotic microangiopathy. Circulation 
2014; 129: 1320–31. 
77.  Wohner N, Kovács A, Machovich R, Kolev K. Modulation of the von Willebrand factor-dependent platelet 
adhesion through alternative proteolytic pathways. Thromb Res 2012; 129: e41-6.
78.  Raife TJ, Cao W, Atkinson BS, Bedell B, Montgomery RR, Lentz SR, et al. Leukocyte proteases cleave von Willebrand 
factor at or near the ADAMTS13 cleavage site. Blood 2009; 114: 1666–74.
79.  Chung M-C, Popova TG, Jorgensen SC, Dong L, Chandhoke V, Bailey CL, et al. Degradation of circulating von 
Willebrand factor and its regulator ADAMTS13 implicates secreted Bacillus anthracis metalloproteases in anthrax 
consumptive coagulopathy. J Biol Chem 2008; 283: 9531–42.
80.  Kunicki TJ, Montgomery RR, Schullek J. Cleavage of human von Willebrand factor by platelet calcium-activated 
protease. Blood 1985; 65: 352–6. 
81.  Berkowitz SD, Nozaki H, Titani K, Murachi T, Plow EF, Zimmerman TS. Evidence that calpains and elastase do not 
produce the von Willebrand factor fragments present in normal plasma and IIA von Willebrand disease. Blood 
1988; 72: 721–7. 
Chapter 2
2
Interference with the host haemostatic system by schistosomes
2
 CHAPTER 2
 
Interference with  
the host haemostatic system  
by schistosomes
 
Mirjam M. Mebius1, Perry J. J. van Genderen2, Rolf T. Urbanus3, 
Aloysius G. M. Tielens1, Philip G. de Groot3, Jaap J. van Hellemond1
1 Department of Medical Microbiology and Infectious Diseases, Erasmus University 
Medical Center Rotterdam, The Netherlands
2 Department of Internal Medicine and Institute of Tropical Diseases, Harbor Hospital 
Rotterdam, The Netherlands
3 Department of Clinical Chemistry and Haematology, University Medical Center 
Utrecht, The Netherlands
Published in PLoS Pathogens 2013; 9: e1003781.2
32
Chapter 2
Abstract
Schistosomes, parasitic flatworms that cause the tropical disease schistosomiasis, 
are still a threat. They are responsible for 200 million infections worldwide and an 
estimated 280,000 deaths annually in sub-Saharan Africa alone. The adult parasites 
reside as pairs in the mesenteric or perivesicular veins of their human host, where 
they can survive for up to 30 years. The parasite is a potential activator of blood 
coagulation according to Virchow’s triad, because it is expected to alter blood flow 
and endothelial function, leading to hypercoagulability. In contrast, hepatosplenic 
schistosomiasis patients are in a hypocoagulable and hyperfibrinolytic state, 
indicating that schistosomes interfere with the haemostatic system of their host. In 
this review, the interactions of schistosomes with primary haemostasis, secondary 
haemostasis, fibrinolysis, and the vascular tone will be discussed to provide insight 
into the reduction in coagulation observed in schistosomiasis patients. 
Interference with the haemostatic system by pathogens is a common mechanism and 
has been described for other parasitic worms, bacteria, and fungi as a mechanism 
to support survival and spread or enhance virulence. Insight into the mechanisms 
used by schistosomes to interfere with the haemostatic system will provide important 
insight into the maintenance of the parasitic life cycle within the host. This knowledge 
may reveal new potential anti-schistosome drug and vaccine targets. In addition, 
some of the survival mechanisms employed by schistosomes might be used by other 
pathogens, and therefore, these mechanisms that interfere with host haemostasis 
might be a broad target for drug development against blood-dwelling pathogens. 
Also, schistosome antithrombotic or thrombolytic molecules could form potential 
new drugs in the treatment of haemostatic disorders.
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Introduction
The haemostatic system consists of procoagulant and anticoagulant mechanisms 
that stop bleeding at sites of blood vessel injury and play an important role in innate 
immunity [1-3]. Procoagulant mechanisms of the haemostatic system can be further 
divided into primary and secondary haemostasis. Primary haemostasis involves the 
activation and aggregation of blood platelets, whereas secondary haemostasis 
involves a cascade of proteolytic reactions that lead to the formation of a stable 
fibrin clot. Anticoagulant mechanisms of the haemostatic system include inhibitors 
of primary and secondary haemostasis and the fibrinolytic activity of plasmin that 
leads to degradation of formed fibrin clots [2]. According to Virchow’s triad, three 
conditions can contribute to the initiation of blood coagulation: normal blood flow 
is disrupted or altered (stasis); the endothelium is damaged or dysfunctional; and/or 
the coagulability of blood plasma is increased (hypercoagulability) [4-6]. In order to 
maintain and propagate themselves in blood vessels, many blood-dwelling pathogens 
not only require adaptations to evade the actions of the host immune system but also 
need to avoid blood coagulation through interference with the haemostatic system 
of their host. Schistosomes, blood-dwelling parasitic flatworms, are the cause of the 
tropical disease schistosomiasis [7]. On average, adult schistosomes reside in their 
host’s bloodstream for three to five years, but their individual lifespan can be as long 
as 30 years [7]. Schistosomes can be expected to activate coagulation according to 
Virchow’s triad by inducing stasis and alterations in endothelial function [8,9]. The 
adult schistosome pair disturbs blood flow due to the large size of the worm pair: 1 
cm long with a diameter of 1 mm (Figure 1). Light microscopy images of adult worms 
inside the mesenteric veins showed that the worm pair occupies the major part of 
the lumen of the blood vessels in which they reside [8,10]. This obstruction will induce 
turbulence in the vein and increase shear stress along the vessel wall. Turbulence 
has been described to contribute to the formation of thrombi [11]. Furthermore, 
endothelial cells can be activated by oscillatory blood flow, which is characterized 
by forward–reverse flow cycles and disrupted blood flow downstream of sites where 
the vessel lumen is narrowed [12]. This leads to increased expression of molecules 
involved in blood coagulation and modulation of the vascular tone, such as tissue 
factor (TF), von Willebrand Factor (VWF), tissue-type plasminogen activator (t-PA), 
nitric oxide (NO), and prostacyclin (PGI
2
) [13-18]. Turbulence and changes in shear 
stress, induced by the presence of the adult schistosome pair in the blood vessel, 
could potentially activate platelets and blood coagulation [4,11]. In addition, although 
there is no direct evidence of endothelial damage caused by the presence of the adult 
worm pair in the vein, several studies suggest that schistosomes disturb endothelial 
cell function, and it has been suggested that the presence of the adult worm in the 
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vein induces endothelial damage [9,19-21]. In murine schistosomiasis, the expression 
of endothelial NO synthase as well as the production of NO are decreased, which 
indicates endothelial dysfunction [9,19,21]. Furthermore, plasma soluble intercellular 
adhesion molecule-1 is increased in hepatosplenic schistosomiasis patients, which 
indicates endothelial activation and inflammation [22]. Extravasation of schistosome 
eggs may also contribute to endothelial damage or dysfunction, since this disrupts 
the polarization of the endothelium and causes mobilization and migration of 
endothelial cells [8]. Therefore, it is likely that parasite-induced alteration in endothelial 
function or endothelial damage plays a role in activation of blood coagulation. 
Besides alterations in blood flow and endothelial function, schistosomes have many 
electronegative charges on their surfaces that could potentially activate platelets 
and the coagulation cascade, leading to hypercoagulation [23]. Thus, schistosomes 
have all the characteristics to be potent activators of blood coagulation. However, 
schistosomiasis patients do not have an increased risk of thrombus formation [24]. 
In contrast, studies on blood coagulation in hepatosplenic schistosomiasis patients 
(reviewed by Tanabe [24]) showed that patients have prolonged coagulation times 
[25]. In infected humans, major haemostatic abnormalities are only observed in 
hepatosplenic schistosomiasis patients, but murine studies observed changes in the 
activity of several coagulation factors already during the early phase of schistosomiasis 
[26]. Hepatosplenic schistosomiasis patients have a reduced activity or reduced 
levels of the coagulation factors II, VII, IX, X, XI, XII, fibrinogen, high–molecular-weight 
kininogen (HMWK), and prekallikrein, as well as the regulatory proteins antithrombin 
and protein C [27,28]. Furthermore, the levels of thrombin-antithrombin complexes, 
prothrombin fragment 1+2, plasma fibrinopeptide A, D-dimers, and other fibrin 
degradation products are increased in these patients [25,29]. The elevated levels 
of both markers of coagulation activation (e.g., prothrombin fragment 1+2 and 
plasma fibrinopeptide A) as well as markers of fibrinolysis (e.g., fibrin degradation 
products) indicate a continuous activation of both blood coagulation and fibrinolysis 
in hepatosplenic schistosomiasis patients. Therefore, the observed hypocoagulable 
and hyperfibrinolytic state of these individuals is the result of both increased 
consumption of coagulation factors and decreased hepatic synthesis of these factors 
and cannot solely be attributed to hepatic dysfunction [24,29]. Also, research showed 
that blood platelets do not adhere to adult schistosomes or isolated outer surface 
membranes (tegument) of adult worms [30]. It is thus clear that schistosomes must 
have mechanisms that suppress the haemostatic response of their host. In this review, 
the interactions of schistosomes with primary haemostasis, secondary haemostasis, 
fibrinolysis, and the vascular tone will be discussed in order to provide insight into the 
reduction in blood coagulation that is observed in schistosomiasis patients.
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Figure 1. Images of adult schistosomes.
Panel A shows a schematic drawing of an adult worm pair. The large adult male embraces the smaller female 
worm and both worms have two suckers by which they attach to the blood vessel wall. Panel B shows a scanning 
electron microscope image of a single S. mansoni adult male, which is about 1 cm long with a diameter of 1 mm. 
Panel C shows a cross-section of an adult S. mansoni worm pair (m, male; f, female; arrows mark the vessel wall) 
in a mesenteric venule of a mouse. This cross-section illustrates how close the worm pair is to the vessel wall and 
suggests the extent to which the worms must disturb blood flow (Panel C is adapted from D. G. Colley and W. E. 
Secor, PLoS Neglected Tropical Diseases 2007 [10]).
 
Identification of schistosome mechanisms that interfere with the haemostatic system 
provides important insight into the maintenance of the parasitic life cycle within its 
host. Insight into survival mechanisms of the parasite could provide important clues 
for novel anti-schistosome drugs or reveal vaccine targets. In addition, other blood-
dwelling pathogens face similar survival challenges and may therefore employ 
similar survival strategies as schistosomes. These mechanisms that interfere with 
host haemostasis may, therefore, form a broad target for drug development against 
blood-dwelling pathogens. Also, potent antithrombotic drugs that are currently 
used in the clinic have been isolated earlier from pathogens, such as streptokinase 
from Streptococci [31]. Schistosome antithrombotic or thrombolytic molecules could 
therefore form potential novel drugs in the treatment of haemostatic disorders.
Interference with primary haemostasis by schistosomes
Primary haemostasis consists of the activation and aggregation of blood platelets. 
Platelet activation can be triggered by endothelial damage, which leads to exposure 
of the underlying collagen, or by the presence of soluble activators, such as thrombin 
or ADP. When the vessel wall is damaged, platelets will adhere to collagen-bound 
VWF through glycoprotein Ib (GPIb) present on their surface, followed by their 
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activation and degranulation. Under pathophysiological conditions VWF also binds 
to surfaces of pathogens, such as Staphylococcus aureus, and triggers platelet 
activation [32]. Activated platelets release factors, such as ADP and thromboxane 
A2, which induce vasoconstriction, stimulate secondary coagulation, and promote 
further platelet activation and aggregation, resulting in the formation of a stable 
platelet plug [2]. Several mechanisms have been described that could explain the 
ability of schistosomes to prevent primary haemostasis (Figure 2). 
Ngaiza and Doenhoff observed a decreased platelet count, also called 
thrombocytopenia, during schistosome infection in mice [33]. This was suggested 
to contribute to the observed decrease in platelet aggregation around the adult 
schistosome pair. In schistosomiasis patients, a decreased platelet count was 
also observed, but symptoms that are commonly observed in patients with 
thrombocytopenia, e.g., gingival bleeding, are not present in these patients, indicating 
that platelet aggregation is not fully impaired [34]. Schistosomes must therefore have 
evolved additional mechanisms to prevent primary haemostasis.
Extracellular ADP induces platelet aggregation. ADP-mediated platelet aggregation 
is normally controlled by ATP-diphosphohydrolase (ATPDase) proteins, such as CD39/
ATPDase1, that are present on endothelial cells [35,36]. These ATPDases hydrolyse 
ATP to ADP and ADP to AMP and subsequently to adenosine. This degradation of 
ADP and the subsequent formation of the inhibitor adenosine leads to inhibition 
of ADP-mediated platelet activation and aggregation [37,38]. The schistosome 
tegument contains several enzymatic activities that could lead to the degradation of 
extracellular ATP or ADP [39]. Alkaline phosphatase activity is present in the tegument 
of Schistosoma mansoni, and recombinant S. mansoni alkaline phosphatase (SmAP) 
has been characterized [40,41]. Alkaline phosphatase enzymes are present in many 
organisms and hydrolyze a broad spectrum of substrates, including ATP, ADP, and 
AMP [42]. S. mansoni alkaline phosphatase (SmAP) has structural homology to 
human placental alkaline phosphatase, which suggests that its substrate specificity 
is similar to human alkaline phosphatases. In addition, investigation of the S. mansoni 
tegument revealed phosphodiesterase (SmPDE) activity, which hydrolyzes, among 
others, ATP and AMP [43]. Furthermore, a tegument-localized S. mansoni ATP-
diphosphohydrolase-1 (SmATPDase1) activity was characterized, which is capable of 
hydrolysis of both ATP and ADP to AMP [44,45]. Therefore, these tegumental enzymes 
could, by mimicking human ATPDases, form a potential strategy to inhibit platelet 
activation. 
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Figure 2. Proposed modulation of primary haemostasis by schistosomes.
Primary haemostasis consists of the activation of blood platelets and the formation of a platelet plug. Exposure 
of subendothelial collagen, due to endothelial damage or the presence of soluble activators or surfaces of 
pathogens, can facilitate binding of VWF. Platelets adhere to VWF through GPIb present on their surface, followed 
by their activation and degranulation. Platelets release molecules, such as ADP, thromboxane A2, serotonin, 
and platelet factor 3, which stimulate further platelet aggregation and activation, stimulate vasoconstriction, 
and activate secondary haemostasis. Primary haemostasis is inhibited by PGI
2
 from endothelial cells, which 
inhibits degranulation of platelets, and by the degradation of extracellular ADP to AMP and subsequently 
to the inhibitor adenosine by endothelial ATPDases, such as CD39. Schistosomes interfere with the primary 
haemostasis through the proposed degradation of extracellular ADP by SmAP, SmATPDase1, and/or SmPDE, and 
potentially stimulate the release of PGI
2
 through up-regulation of the production of bradykinin by sK1 or SmSP1. 
Stimulation is indicated by green arrows. Red lines indicate inhibition. Schistosome proteins are indicated in the 
shaded boxes. Abbreviations: glycoprotein Ib (GPIb), High-molecular-weight kininogen (HMWK), prostacyclin 
(PGI
2
), Schistosoma mansoni alkaline phosphatase (SmAP), Schistosoma mansoni ATP-diphosphohydrolase-1 
(SmATPDase1), Schistosoma mansoni phosphodiesterase (SmPDE), von Willebrand Factor (VWF).
Furthermore, the actions of an S. mansoni protein with kallikrein-like activity, sK1, and 
a protein with homology to mouse plasma kallikrein, SmSP1, may form a mechanism 
through which schistosomes inhibit primary haemostasis [46,47]. Kallikrein is able 
to convert HMWK to the small vasoactive peptide bradykinin, which is a potent 
vasodilator [20,48]. Bradykinin can trigger the release of prostacyclin (PGI
2
) from 
endothelial cells [48]. PGI
2
 is another potent vasodilator but also inhibits platelet 
degranulation. Exposure on the surface or secretion of the tegumental proteins sK1 
and SmSP1 has been suggested, and it has been shown that sK1 is able to convert 
HMWK to bradykinin in vitro, which suggests the production of bradykinin by these 
proteins also during schistosome infection in vivo [46,47]. Kallikrein-like activity has not 
been described for SmSP1, but its homology to mouse kallikrein suggests kallikrein-like 
activity. sK1, and potentially SmSP1, could thus play a role in the inhibition of primary 
haemostasis by the parasite, although such a role has not been demonstrated.
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Interference with secondary haemostasis by schistosomes
Secondary haemostasis consists of two pathways: the tissue factor (TF) pathway 
(extrinsic pathway) and the contact activation (intrinsic) pathway [2,49]. The extrinsic 
pathway is considered to be the physiologically most relevant pathway and is induced 
by the exposure of TF after endothelial damage, but under pathophysiological conditions 
it can also be activated by TF expressed on immune cells or endothelial cells [3,50]. The 
intrinsic pathway is activated by binding of coagulation factor XII (XII) to collagen or 
negatively charged surfaces [51,52]. Local accumulation of XII leads to its auto-activation 
and induces a cascade of cleavage reactions that activate other coagulation factors 
[53]. Finally, both the extrinsic and intrinsic pathways lead to the cleavage of fibrinogen to 
fibrin by thrombin and the formation of a stable fibrin clot (Figure 3). 
Interference with the activation of secondary haemostasis by 
schistosomes
Schistosomes are potential activators of the extrinsic pathway due to the induction 
of turbulence and endothelial damage and/or alteration of endothelial function 
induced by the adult parasite and/or the eggs [8,9,16]. Furthermore, elevated levels of 
tumor necrosis factor alpha (TNF-α) are present in schistosomiasis patients, and high 
TNF-α levels are known to induce TF expression on endothelial cells in vitro [50,54]. 
In addition, increased TF expression is present in monocytes from hepatosplenic 
schistosomiasis patients, compared to monocytes of healthy donors, suggesting 
the involvement of monocyte TF expression in the prothrombotic state observed in 
schistosomiasis patients [54]. However, to date there is no evidence that schistosomes 
interfere with extrinsic coagulation [55].
On the other hand, in vitro experiments show that schistosomes can inhibit the 
activation of secondary haemostasis in at least two steps: the activity of thrombin 
and the activation and activity of XII, a factor of the intrinsic pathway, suggesting 
inhibition of secondary haemostasis during schistosome infection in vivo [55-58]. 
Both the extrinsic and the intrinsic pathway lead to the activation of thrombin. The 
inhibition of thrombin activity by schistosomes could therefore be a potential strategy 
to prevent the formation of fibrin clots. The S. mansoni antigen Sm22.6 discovered by 
Stein and David is expressed in the cytoplasmic layer of the schistosome tegument 
but is also present in the host circulation [59]. The exact role of Sm22.6 in the parasitic 
life cycle is unknown, but the protein interacts with thrombin and inhibits its protease 
activity [58]. This suggests that Sm22.6 could prevent the formation of fibrin clots 
around the adult parasite [58]. Furthermore, thrombin plays an important role in 
the amplification loop of the coagulation cascade through the activation of XI by 
thrombin; blocking this protein could interfere with this positive feedback mechanism. 
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Figure 3. Proposed modulation of secondary haemostasis and vascular tone by schistosomes.
Secondary haemostasis can be activated through two different pathways: either by the presence of TF or by 
contact of coagulation factors with collagen, pathogens, or other negatively charged surfaces. This triggers 
a cascade of cleavage reactions, ultimately leading to the cleavage of fibrinogen to fibrin and the formation 
of a stable fibrin clot. This process is regulated by antithrombin, TFPI, and protein C. Schistosomes potentially 
interfere with secondary haemostasis at several steps in the cascade. Schistosome whole worm homogenate 
blocks the conversion of XII to XIIa and inhibits the actions of XIIa. The proteolytic activity of thrombin is inhibited 
by the schistosome antigen Sm22.6. Furthermore, schistosome heparin-like glycosaminoglycans may enhance 
the activity of antithrombin and, possibly, TFPI, and the schistosome serpin SHW 4-2 might mimic human 
antithrombin. The vascular tone can be influenced by schistosomes through the production of both vasodilating 
and vasoconstricting eicosanoids and the presence of sK1 and SmSP1 that could potentially convert HMWK into 
the vasodilator bradykinin. The green arrows indicate stimulation. Inhibition is indicated by the red lines. The 
shaded boxes indicate schistosome proteins. Abbreviations: activated coagulation factor XII (XIIa), coagulation 
factor XII (XII), High-molecular-weight kininogen (HMWK), tissue factor (TF), tissue factor pathway inhibitor (TFPI).
Schistosomes have also been observed to interfere with the intrinsic pathway. Whole 
worm homogenate of S. mansoni inhibits both the activation and activity of XIIa [55-
57]. The molecules responsible for this inhibitory activity have not been characterized, 
and their localization in the adult worm is, therefore, not known. Further investigations 
are required to confirm this suggested activity. Furthermore, the importance of XII in 
coagulation in vivo is still debated [60]. XII deficiency does not result in a bleeding 
tendency in vivo, in contrast to a decreased coagulation time observed in in vitro tests 
[61]. The reason for this discrepancy remains unclear, but it led to the assumption 
that XII is not required for normal haemostasis, although a role has been suggested 
in pathological thrombus formation [60]. It should therefore be stressed that the role 
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of inhibition of XII in prevention of coagulation during schistosome infections might 
be very limited. Another possibility could be that inhibition of XII by schistosomes is 
not involved in interference with haemostasis, but instead functions in the evasion of 
immune responses by the parasite. XII is involved in the activation of the complement 
cascade, and inhibition of XII by schistosomes might thus be an example of an 
immune-evasion strategy rather than a strategy to prevent blood coagulation [62]. 
Interference with regulatory mechanisms of secondary 
haemostasis by schistosomes
Secondary coagulation is regulated by the actions of three proteins: antithrombin, 
tissue factor pathway inhibitor (TFPI), and protein C. Stimulation or mimicking of host 
mechanisms for the regulation of blood coagulation could form a potential strategy 
employed by schistosomes to interfere with haemostasis.
The serine protease inhibitor (serpin) antithrombin is the major inhibitor of coagulation 
proteases [61]. Antithrombin is constitutively present in blood plasma and binds and 
inactivates thrombin, as well as coagulation factors IXa, Xa, and XIa. The efficiency 
of thrombin binding increases 2,000- to 10,000-fold when antithrombin associates 
with its cofactor heparin [61]. Schistosomes could potentially increase antithrombin 
activity by expressing heparin or heparin-like molecules, such as heparan sulfate. 
Heparan sulfate is a heparin-like molecule that is present on the surface of endothelial 
cells and is responsible for the anticoagulant properties of the endothelium. Heparin-
like glycosaminoglycans, i.e., heparan sulfate and dermatan sulfate, are present in 
tegument fractions of S. mansoni [63]. However, the localization of these heparin-like 
molecules on the outer tegumental membrane and the capacity of these molecules 
to interfere with the haemostatic system have not been determined. 
Furthermore, Blanton et al. identified a serpin in S. haematobium, SHW 4-2, with 
high sequence similarity to antithrombin and glial-derived nexins, which can both 
bind and inhibit thrombin [64,65]. Surface localization of SHW 4-2 was shown by 
immunolocalization, suggesting that S. haematobium serpin may mimic the actions 
of antithrombin and could play a role in the inhibition of secondary haemostasis.
TFPI, the natural regulator of TF activity, is present in blood plasma and platelets, and is 
synthesized by endothelial cells. Its mode of action is peculiar; TFPI binds and inhibits 
coagulation factor Xa. This TFPI-Xa complex subsequently binds to the TF-VIIa complex, 
thereby inhibiting further activity of coagulation factor VIIa. TFPI present in plasma is active, 
but present in low concentrations and only able to delay the coagulation cascade. TFPI can 
be released by degranulation of activated platelets and/or from the endothelium by heparin 
and thereby regulate TF activity [2,66]. The presence of heparin-like molecules on the outer 
surface of adult schistosomes suggests that the parasite may stimulate the release and 
local accumulation of TFPI from the endothelium, although this has not been confirmed. 
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Stimulation of fibrinolysis by schistosomes
Besides interference with primary or secondary haemostasis, schistosomes may also 
reduce thrombus formation through stimulation of fibrinolytic pathways. Fibrinolysis 
by plasmin controls the degradation of fibrin clots to fibrin degradation products 
(Figure 4). The proteolytic activation of plasminogen to plasmin is stimulated by 
plasma kallikrein, but mainly by urokinase and t-PA, which are slowly released from 
damaged endothelium [2,67]. Although several reports show no enhancement 
of fibrinolysis by S. mansoni [55,56], more recent reports indicate the presence of 
activators of plasminogen at the surface of S. bovis [68-70]. Ramajo-Hernández et al. 
screened tegument fractions for proteins binding plasminogen and demonstrated 
that tegument fractions enhanced the generation of plasmin by t-PA [68]. Ten proteins 
that were able to bind plasminogen were identified; the most prominent ones were 
enolase, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), and actin. Surface 
localization was shown for GAPDH and enolase but not for actin [69,71]. Enolase is 
expressed on the surface of male schistosomes only, and recombinantly expressed 
enolase has been shown to bind plasminogen and enhance its conversion to plasmin 
in the presence of t-PA [68,69]. Similarly, Yang et al. discovered a plasminogen-
binding enolase in S. japonicum, indicating that plasminogen-binding by schistosome 
enolases may be a common feature of schistosomes [72]. The role of GAPDH and 
actin in the conversion of plasminogen is still unclear, but it has been described that 
interaction of plasminogen with other molecules induces conformational changes in 
plasminogen which could aid in the conversion of plasminogen to plasmin by t-PA 
[73]. Further research by de la Torre-Escudero et al. revealed on the parasitic surface 
the presence of a schistosome protein belonging to the family of annexins [70]. 
Annexins have many functions, and some annexins, such as human annexin-A2, are 
involved in the regulation of fibrinolysis [74]. Schistosome annexin binds plasminogen 
and enhances the t-PA mediated conversion of plasminogen to plasmin [70]. The 
schistosome surface annexin may thus have a role in local activation of fibrinolysis 
during schistosome infection, thereby stimulating the degradation of thrombin clots 
that could be formed at the parasite’s surface.
Interference with the vascular tone by schistosomes
Besides a possible activation of blood coagulation by the parasite, the parasite faces a 
second problem in the bloodstream. The eggs deposited by the female are laid in the 
small veins surrounding the intestine, and the parasite pair is known to wander between 
the large portal vein and these small veins [75]. This migration could, due to the large 
size of the adult worm pair compared to the size of the blood vessels, temporarily cause 
obstruction of blood flow, and the resulting changes in blood flow could potentially 
damage the endothelium and surrounding tissues. Manipulation of the vascular 
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Figure 4. Proposed modulation of the fibrinolytic system by schistosomes.
The fibrinolytic system inhibits blood coagulation through degradation of the formed fibrin clot by plasmin. 
Plasminogen is cleaved to plasmin by plasma kallikrein, but mainly by t-PA and urokinase, which are inhibited 
by PAI-1 and PAI-2. Furthermore, plasmin activity is inhibited by TAFI. Schistosomes may stimulate fibrinolysis by 
the presence of enolase, GAPDH, and annexin, which bind plasminogen and facilitate its conversion to plasmin 
by t-PA. Green arrows indicate stimulation. Inhibition is indicated by the red lines. Schistosome proteins are 
denoted in the shaded box. Abbreviations: tissue-type plasminogen activator (t-PA), plasminogen activator 
inhibitor 1 (PAI-1) and 2 (PAI-2), thrombin-activatable fibrinolysis inhibitor (TAFI), glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH).
tone, e.g., by inducing vasodilation, could prevent damage caused by obstruction of 
these small blood vessels, and such a strategy would therefore be advantageous for 
the parasite. Several mechanisms have been proposed by which schistosomes could 
modulate vascular tone (Figure 3) (reviewed in detail by Da’dara and Skelly [20]). For 
example, schistosomes are able to produce and secrete eicosanoids. Eicosanoids 
have diverse functions; among these is influencing the vascular tone. S. mansoni 
produces eicosanoids that stimulate vasodilation (e.g., the cyclo-oxygenase products 
prostaglandin D
2
 and prostaglandin E
2
), as well as 5-lipoxygenase products that are 
able to induce vasoconstriction [e.g., leukotriene C
4
 and 15-hydroxyeicosatetraenoic 
acid (15-HETE)]
 
[76]. It has been shown that schistosome vasoconstrictors are released 
in smaller amounts than the vasodilators [76,77]. This suggests that eicosanoids play 
a role in the stimulation of vasodilation during infection. However, this difference in 
production of vasoconstriction-promoting and vasodilation-promoting eicosanoids 
could also merely reflect differences in biological activity, and therefore, the true impact 
of schistosome eicosanoids on the vascular tone during infection remains unclear.
Another potential mechanism to induce vasodilation by schistosomes is through the 
actions of the schistosome proteins sK1 and SmSP1 [46,47]. sK1 is a schistosome protein 
with kallikrein-like activity, and SmSP1 has homology to mouse kallikrein, but kallikrein-
like activity has not been described for SmSP1 [46,47]. As discussed before, S. mansoni 
sK1 and, potentially, SmSP1 convert kininogen to the potent vasodilator bradykinin [46]. 
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Concluding remarks
According to Virchow’s triad, schistosomes are expected to be potent activators 
of blood coagulation. However, the parasite has evolved several mechanisms to 
actively inhibit blood coagulation and manipulate the vascular tone, ensuring 
long-term survival in the host’s bloodstream (Table 1). Many experiments showed 
that primary and secondary haemostasis can be inhibited by the parasite through 
a combination of schistosome-specific mechanisms that inhibit key steps in the 
coagulation cascade and by schistosome proteins that exploit host mechanisms for 
regulation of haemostasis. Furthermore, schistosome proteins may actively stimulate 
fibrinolysis and manipulate vascular tone. The many strategies used by schistosomes 
to interfere with the haemostatic system of their host reflect the complex host–
parasite relationship. Although some major discoveries in manipulation of blood 
coagulation by schistosomes have been made, additional studies are required 
to further understand these mechanisms and determine their importance during 
infection. This would provide more insight into pathways involved in maintaining the 
parasitic life cycle within the host and may reveal new targets for the development 
of anti-schistosome drugs or vaccines. Furthermore, mechanisms described here 
might also be applicable to other blood-dwelling pathogens and may reveal broad 
targets for the development of drugs to be used against these pathogens. In addition, 
schistosome molecules that interfere with the haemostatic system could form 
potential new antithrombotic or thrombolytic drugs for the treatment of haemostatic 
disorders.
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Table 1. Proposed interference with the haemostatic system and vascular tone by schistosome 
molecules.
Target Schistosome molecule Effect
Hypocoagulation mechanisms
Primary haemostasis
 ADP SmAP [40,41] Hydrolysis of ADP to AMP and adenosine, a competitive inhibitor 
of platelet aggregation and degranulation.
SmATPDase1 [44,45] Hydrolysis of ATP and ADP to AMP.
SmPDE [43] Hydrolysis of ATP and AMP. 
 HMWK sK1 [46] Conversion of HMWK to bradykinin. Bradykinin stimulates the 
release of PGI2, an inhibitor of platelet degranulation, from 
endothelial cells.
SmSP1 [47] Homology to mouse plasma kallikrein. 
Secondary haemostasis
 Factor XII Schistosome homogenate [55-57] Inhibition of the conversion of coagulation factor XII to XIIa and 
the actions of XIIa.
 Thrombin Sm22.6 [58] Inhibitor of thrombin activity.
 Antithrombin Heparin-like molecules [63] Potential increase of the activity of antithrombin.
SHW 4-2 [65] Sequence similarity to antithrombin. 
Hyperfibrinolytic mechanisms
 Plasminogen Enolase [68,69,72] Binding and conversion of plasminogen to plasmin by t-PA.
GAPDH [68] Binding of plasminogen.
Annexin [70] Binding and conversion of plasminogen to plasmin by t-PA.
Vascular tone
 HMWK sK1 [46] Conversion of HMWK to bradykinin.
 SmSP1 [47] Homology to mouse plasma kallikrein. 
 Vasodilation Eicosanoids [20] Both vasodilating and vasoconstricting effects.
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Abstract
In many tropical areas schistosomiasis is a major health problem causing 
hepatosplenic, intestinal, or urogenital complaints. Hepatosplenic schistosomiasis 
mansoni is also characterized by blood coagulation abnormalities. Liver pathology 
plays a role in development of hemostatic changes and the parasitic infection may 
directly affect coagulation. However, these contributing factors cannot be studied 
separately in hepatosplenic schistosomiasis infections. 
This pilot study provides insight in hemostatic changes in urinary schistosomiasis by 
studying coagulation parameters in schistosomiasis haematobium infected Gabonese 
schoolchildren. Selection on urinary schistosomiasis patients without hepatosplenic 
complaints allows investigation of direct effects of the parasite on hemostasis. Levels 
of von Willebrand Factor (VWF) antigen, active VWF, and osteoprotegerin were 
elevated, indicating inflammation-mediated endothelial activation. In contrast to 
hepatosplenic schistosomiasis, thrombin-antithrombin complex and D-dimer levels 
were not affected. Despite its small sample size, this study clearly indicates that 
S. haematobium directly alters the activation status of the endothelium, without 
initiation of coagulation.
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Introduction
The tropical disease schistosomiasis is caused by blood-dwelling parasites of the 
Schistosoma genus. The major disease causing species in humans are Schistosoma 
mansoni, Schistosoma haematobium and Schistosoma japonicum [1]. With almost 
800 million people at risk of infection, schistosomiasis is the second major parasitic 
disease after malaria [2].
The various species of Schistosoma reside in blood vessels at different locations in the 
body and these specific locations determine pathology. Schistosoma mansoni and 
Schistosoma japonicum reside in the mesenteric plexus and chronic infection results in 
the development of intestinal or hepatosplenic schistosomiasis, affecting intestine, liver, 
and spleen [1]. In contrast, Schistosoma haematobium resides in the perivesicular plexus. 
Infection with this species results in urogenital schistosomiasis, affecting mainly the 
urogenital tract although hepatic disease may occur in severe infections [1,3].
In addition to intestinal and hepatic disease, the blood coagulation system is affected 
in schistosomiasis mansoni patients [4]. These individuals are prone to bleeding as 
a result of coagulation factor deficiencies, and often have reduced platelet counts 
(reviewed by Tanabe [5]). Several factors are presumed to contribute to the loss 
of coagulation factors and platelets. First, consumption of coagulation factors 
through continuous activation of coagulation may be involved, since markers of 
active coagulation, such as thrombin-antithrombin complexes (TAT), and markers of 
fibrinolysis, such as D-dimers, are both elevated in these patients. This activation of 
coagulation can be induced by the parasite itself, but it is also assumed that immune 
responses to schistosomes play a role in the development of hemostatic abnormalities 
in hepatosplenic schistosomiasis mansoni, for example through stimulation of 
monocyte tissue factor expression [6]. Second, the majority of coagulation factors 
are synthesized by the liver. Therefore, impaired liver function, resulting in reduced 
hepatic synthesis or clearance of activated coagulation factors, could contribute 
to the bleeding phenotype. It remains challenging to unravel the contribution of 
the parasite and liver damage to the development of hemostatic abnormalities in 
hepatosplenic schistosomiasis mansoni patients, since these factors cannot be 
separated in hepatosplenic disease. 
This pilot study aims to elucidate the contribution of the parasite to the development 
of coagulation abnormalities in Schistosoma infections by studying hemostatic 
parameters in schoolchildren infected with S. haematobium. Since S. haematobium 
infections primarily cause urogenital schistosomiasis, strict selection on S. 
haematobium infected individuals without hepatosplenomegaly limits the influence of 
impaired hepatic function and allows investigation of the effect of only the parasitic 
infection on the development of coagulation abnormalities. 
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Materials and methods
Participants and sample collection
Ten schoolchildren with non-hepatosplenic schistosomiaisis haematobium and four 
healthy controls without S. haematobium infection were recruited at the Centre de 
Recherches Médicales de Lambaréné (CERMEL), Lambaréné, Gabon. The study was 
approved by the CERMEL Institutional Ethics Committee (CEI, CEI-MRU 002 26/1/2016). 
Participants were schoolchildren without hepatosplenic complaints from Zilé-PK15 
areas, S. haematobium endemic areas surrounding Lambaréné [7]. Informed consent 
was obtained from parents or legal guardians of all children and all infected individuals 
received treatment with praziquantel after sample collection. Venous blood was 
collected in a tube containing 1:10 volume of anticoagulant 3.2% sodium citrate solution. 
Whole blood was analyzed with the Pentra 60 analyzer (Horiba, Kyoto, Japan). Citrated 
platelet poor plasma was obtained by two-fold centrifugation of citrated blood at 
2000xg for 15 minutes. Citrated plasma was aliquoted and stored at -80˚C.
Determination of S. haematobium infection
Circulating anodic antigen (CAA) levels were determined in 20 μL citrated plasma with 
the wet reagent SCAA20 (standard serum/plasma circulating anodic antigen test on 
20 μL TCA extract) lateral flow assay as described by Corstjens et al. [8]. Samples were 
treated with 4% trichloroacetic acid (TCA) to remove interfering components. CAA 
levels were calculated with a four parametric curve fitting method, using a standard 
dilution curve of the TCA-soluble fraction of schistosome adult worm antigen (AWA-
TCA), which contains approximately 3% (w/w) CAA. The lower detection limit of the 
SCAA20 was 150 pg/mL AWA-TCA (= 5 pg CAA/mL). Participants were considered 
positive when CAA levels were above 5 pg/mL. In addition, for all participants a 
midstream urine sample was collected during the daytime and at least 10 mL urine 
was passed through a 12.0 μm polyamide N filter (Millipore, City, State, Country). S. 
haematobium eggs were detected by microscopic examination. 
Enzyme-linked immunosorbent assay
Levels of D-dimer were measured in plasma with the Technozym D-dimer ELISA kit 
(Stago BNL, Leiden, The Netherlands) according to manufacturer’s instructions. 
Levels of von Willebrand Factor (VWF) antigen (VWF:ag), active VWF, ADAMTS-13 
antigen (ADAMTS-13:ag), osteoprotegerin (OPG), and thrombin-antithrombin (TAT) 
complexes were measured in plasma with ELISA. 96-well or 384-well white maxisorp 
microtiter plates (Thermo Scientific, Roskilde, Denmark) were coated overnight at 
4˚C with polyclonal rabbit-anti-human VWF (0.775 μg/mL; A0082; DAKO, Carpinteria, 
California, U.S.A.), AU/VWFa-11 nanobody [9] (1.98 μg/mL; LKCH), D053 (0.5 μg/mL; 
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Sanquin, Amsterdam, The Netherlands), mouse-anti-human OPG/TNFRSF11B (1 μg/mL; 
R&D Systems, Minneapolis, Minnesota, U.S.A.), or sheep-anti-human Thrombin (1 μg/mL; 
Stago BNL, Leiden, The Netherlands) in coating buffer (40mM Na
2
CO
3
, 35 mM NaHCO
3
, 
3 mM NaN
3
, pH 9.6). Plates were washed four times with washing buffer (phosphate 
buffered saline (PBS (ThermoFisher Scientific, Waltham, Massachusetts, U.S.A.), 0.05% 
Tween20, pH 7.4) between all incubation steps and blocked for one hour at room 
temperature with blocking buffer (PBS, 1% BSA, pH 7.4). Citrated plasma and standard 
were diluted in blocking buffer: 125-fold for VWF:ag ELISA, 5- and 10-fold for active VWF 
ELISA, 40-fold for ADAMTS-13:ag ELISA, and 4-fold for OPG and TAT ELISAs and incubated 
for one hour at room temperature. Used standards were serial dilutions of normal pooled 
plasma (Sanquin, Amsterdam, The Netherlands) with a known concentration of VWF:ag 
for VWF:ag and ADAMTS-13:ag, normal pooled serum with known concentrations of TAT 
and OPG for TAT and OPG ELISAs and VWF depleted plasma (Affinity Biologicals, Ancaster, 
Canada) supplemented with recombinant R1341Q-VWF for active VWF ELISA. Following 
sample incubation the plates were incubated at room temperature for one hour with 
the following detection and secondary antibodies diluted in blocking buffer: peroxidase-
conjugated rabbit-anti-human VWF (0.325 μg/mL; DAKO, Carpinteria, California, U.S.A.), 
peroxidase-conjugated rabbit-anti-human VWF (1.2 μg/mL; DAKO, Carpinteria, California, 
U.S.A.), biotinylated polyclonal sheep-anti-human ADAMTS-13 (0.25 μg/mL; R&D Systems, 
Minneapolis, Minnesota, U.S.A.) and streptavidin-mono-HRP (0.83 μg/mL; DAKO, 
Carpinteria, California, U.S.A.), biotinylated goat-anti-human OPG/TNFRSF11B (100 ng/
mL; R&D Systems, Minneapolis, Minnesota, U.S.A.) and streptavidin-mono-HRP (0.25 μg/
mL; DAKO, Carpinteria, California, U.S.A.), and peroxidase-conjugated sheep-anti-human 
antithrombin (0.5 μg/mL; Stago BNL, Leiden, The Netherlands). ELISAs were developed 
with SuperSignal West Pico Chemiluminescent Substrate (ThermoFisher Scientific, 
Waltham, Massachusetts, U.S.A.) and luminescence was detected with the Synergy2 
ELISA reader (BioTek, Winooski, Vermont, U.S.A.). Antigen concentrations were calculated 
with a five parametric curve fitting method, using a dilution curve of the standard. The 
lower detection limits of the ELISAs were: 6.8 ng/mL (VWF:ag), 16ng/mL (active VWF), 1.6% 
(ADAMTS-13:ag), 10.6 pg/mL (OPG), and 2.8 pM (TAT).
Ristocetin co-factor activity assay
Citrated plasma was diluted 7-fold in imidazole buffer (100 mM imidazole, 100 mM 
NaCl, pH 7.4). A standard dilution curve was prepared of diluted normal pooled 
plasma (Sanquin, Amsterdam, The Netherlands). To 70 μl sample 200 μl BC von 
Willebrand Reagent (Siemens healthcare, Erlangen, Germany) was added in a 96-well 
clear maxisorp microtiter plate (Thermo Scientific, Roskilde, Denmark). Following 10 
minutes incubation at 37˚C and 20 minutes incubation at room temperature to allow 
platelet aggregates to precipitate, 100 μl of the mixture was transferred to a new 
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plate and non-aggregated platelets were measured at 350 nm. Ristocetin co-factor 
activity (VWF:RCo) was calculated with a five parametric curve fitting method, using a 
dilution curve of the standard. The lower detection limit of the assay was 3% VWF:RCo. 
ADAMTS-13 activity measurement
ADAMTS-13 activity was measured in a kinetic assay using the fluorescence resonance 
energy transfer substrate VWF73 (FRETS-VWF73; Peptide institute, Osaka, Japan) as 
previously described [10]. Samples were 10-fold diluted in Tris buffer (5 mM Tris, 25 mM 
CaCl
2
, 0.005% Tween20, pH 6.0). FRETS-VWF73 was added to a final concentration 
of 2 μM and fluorescence (λ
ex
 340 nm, λ
em
 450 nm) was measured in a 96-well black 
microtiter plate (Thermo Scientific, Roskilde, Denmark) every 30 seconds for one hour 
at 30˚C with a Spectramax M2e device (Molecular devices, Sunnyvale, U.S.A.). 
Statistical analysis
Analyses were done using PRISM software (GraphPad, San Diego, California, U.S.A., 
version 6.01). Infected and non-infected control groups were compared using Mann-
Whitney test and P ≤ 0.05 was considered statistical significant.
Results and discussion
We included ten schoolchildren with schistosomiasis haematobium and four healthy 
children from S. haematobium endemic, rural areas surrounding Lambaréné (Gabon) 
(Table 1). Infection status was based on circulating anodic antigen (CAA) levels in 
plasma [8] combined with detection of viable eggs in urine, since detection of eggs 
in urine as only method to confirm infection (gold standard) has a low sensitivity [1]. 
Hepatomegaly was absent in all studied individuals and splenomegaly was absent 
in nine out of ten infected and in all non-infected individuals, therefore, all infected 
children were characterized as strictly urogenital schistosomiasis haematobium. 
In hepatosplenic schistosomiasis mansoni levels of von Willebrand Factor (VWF) 
antigen (VWF:ag) are highly elevated and inversely correlate with platelet counts, as 
patients experience thrombocytopenia [11]. To determine the effect of Schistosoma 
infection on VWF levels in urinary schistosomiasis, we determined VWF:ag, active 
VWF, and von Willebrand Factor ristocetin cofactor activity (VWF:RCo) in our study 
participants. VWF is secreted by endothelial cells and circulates in a globular 
conformation in which the platelet binding A1-domain is inaccessible [9]. Under blood 
flow VWF unfolds and adopts an active platelet-binding conformation (active VWF) 
that can be detected using the AU/VWFa-11 nanobody [9]. Besides flow, ristocetin can 
also be used to unfold VWF and study its binding to platelets (VWF:RCo). Levels of 
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Table 1. Participant characteristics.
S. haematobium infected children Controls
Number, n 10 4
Age (y), mean (SD) 11 (3) 8 (1)
Male, n (%) 5/10 (50) 3/4 (75)
Weight (kg), mean (SD) 37 (13) 27 (2)
Height (m), mean (SD) 1.47 (0.16) 1.34 (0.03)
CAA (pg/mL), mean (SD) 2166 (3062) 0 (0)
Egg count positive, n (%) 9/10 (90) 0/4 (0)
Egg count/10 mL urine, mean (SD) 272 (289) 0 (0)
Parasitic co-infections, n (%)
 Ascaris 0/8 (0) 0/3 (0)
 Ancylostoma 0/8 (0) 0/3 (0)
 Trichuris 3/8 (38) 1/3 (33)
 Missing 2 1
Whole blood analysis, mean (SD)
 Hemoglobin (g/dL) 11.0 (1.9) 11.7 (1.3)
 Missing 1 0
 Platelets (n x 109/L) 253 (66) 322 (54)
 Missing 1 0
 White blood cells (n x 109/L) 10.5 (3.5) 10.1 (2.9)
 Missing 1 0
 Eosinophils (n x 109/L) 1.8 (0.8) 1.9 (1.3)
 Missing 5 1
 Lymphocytes (n x 109/L) 4.2 (0.9) 3.6 (0.5)
 Missing 1 0
 Monocytes (n x 109/L) 0.7 (0.2) 0.9 (0.2)
 Missing 1 0
Splenomegaly, n (%) 1/9 (11) 0/4 (0)
Missing 1 0
Hepatomegaly, n (%) 0/9 (0) 0/4 (0)
Missing 1 0
Data are number with percentage or mean with SD. CAA indicates circulating anodic antigen.
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VWF:ag and active VWF were significantly increased in infected children compared 
to non-infected controls (Fig. 1a and b, P = 0.002 and P = 0.004, respectively, dotted 
lines indicate normal range). The elevated VWF:ag levels indicate either increased 
secretion or reduced breakdown of VWF. The proportion of VWF that is active 
(percentage active VWF) is slightly decreased in infected children compared to 
non-infected individuals, indicating that increased conformational activation of 
circulating VWF is not responsible for the observed increase in active VWF (Fig. 1c, P 
= 0.024). In contrast to increased VWF:ag and active VWF levels, VWF:RCo was low 
or absent in all individuals (Fig. 1d, P = 0.6234, dotted lines indicate normal range). 
As all individuals had normal platelet counts ((253 ± 66) x 109/L and (322 ± 54) x 109/L 
in infected and non-infected individuals, respectively (P = 0.1063)) and plasma from 
Dutch controls showed normal VWF:RCo activity (data not shown), this observation 
cannot be explained by low platelet counts or poor performance of the VWF:RCo 
assay. Reduced or absent platelet aggregation on ristocetin in Africans compared 
to Europeans has been reported previously [12,13]. Reduced platelet function was 
attributed to a plasma inhibitor of ristocetin-induced platelet aggregation [12,13], 
though genetic polymorphisms in VWF could also affect the ristocetin-based activity 
assay [14]. It is, however, unclear whether these accounted for the observed low 
VWF:RCo activity in our study. In summary, in urinary schistosomiasis haematobium 
VWF:ag and active VWF levels are elevated and do not correlate with platelet counts 
as thrombocytopenia is absent.
Changes in levels of VWF:ag and active VWF could reflect defects in the VWF-
degrading protease ADAMTS-13 [9], but could also indicate endothelial activation 
[15]. To study functionality of ADAMTS-13, both ADAMTS-13:ag levels and ADAMTS-13 
activity were determined. ADAMTS-13:ag levels and ADAMTS-13 activity were normal 
in both infected and non-infected children (Fig. 1e and f, P = 0.4116 and P = 0.5774, 
respectively), so no defects in VWF-degradation are present. 
Next, endothelial activation was determined using osteoprotegerin (OPG) levels as 
marker for inflammation-mediated endothelial activation [16]. Elevated levels of OPG 
were observed in the S. haematobium infected children versus non-infected controls 
(Fig. 2g, P = 0.036, dotted line indicates cut-off value). Simultaneous elevation of both 
VWF:ag and OPG during schistosomiasis haematobium indicates inflammation-
mediated endothelial activation and is in line with the reported co-localization of 
these markers in endothelial Weibel Palade bodies and their simultaneous secretion 
upon endothelial cell stimulation [16].
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Figure 1. Hemostatic parameters in S. haematobium infected schoolchildren.
VWF:ag levels (a), active VWF levels (b), ADAMTS-13:ag levels (e), OPG levels (g), TAT levels (h), and D-dimer levels 
(i) were measured with ELISA in citrated plasma of S. haematobium infected schoolchildren and non-infected 
controls. Percentage of active VWF (c) was calculated with the determined active VWF and VWF:ag levels. 
VWF:RCo (d) was determined with the BC von Willebrand Reagent. ADAMTS-13 activity (f) was determined with 
the FRETS-VWF73 assay. Dotted lines indicate normal ranges (a, d) or cut-off values (g, h, i). Statistical analysis 
was performed with a Mann-Whitney test. P ≤ 0.05 was considered statistical significant (ns = not significant).
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Several mechanisms may explain activation of the vessel wall. Secretion of OPG is 
stimulated by the inflammatory cytokines TNF-α and IL-1β [16]. In hepatosplenic 
schistosomiasis mansoni patients TNF-α production by PBMC is elevated and plasma 
levels of soluble TNF receptor I and II are increased [17], suggesting contribution of 
inflammatory cytokines produced during infection to the observed increased OPG 
levels. However, no correlation between serum levels of TNF-α and infection status 
or disease severity is observed in schistosomiasis haematobium [18]. Passage of 
schistosome eggs through the vessel wall or egg-derived materials could also induce 
endothelial activation [19]. Furthermore, endothelial adhesion of adult S. mansoni 
through their ventral sucker could damage the endothelium [20] and the presence of 
the adult worm pair in the small veins could alter blood flow, leading to endothelial 
activation [4].
The observation that endothelial activation occurs during urinary schistosomiasis 
is of importance as elevated levels of VWF, OPG, and endothelial activation are 
associated with thrombosis and cardiovascular disease [21,22]. Ongoing coagulation 
has been demonstrated in hepatosplenic schistosomiasis mansoni, reflected by 
increased levels of TAT and D-dimer [5]. We therefore investigated whether the 
observed endothelial activation in urinary schistosomiasis haematobium results in 
a procoagulant phenotype in urinary schistosomiasis. In contrast to hepatosplenic 
schistosomiasis mansoni patients, TAT and D-dimer levels were generally low in our 
study population and we could not demonstrate differences in urinary schistosomiasis 
patients compared to the non-infected individuals (Fig. 2h and i, P = 0.4116 and P = 
0.7524, respectively, dotted line indicates cut-off value), indicating that there is no 
ongoing coagulation or fibrinolysis in these individuals. However, five of the infected 
children had TAT levels above the normal threshold, without elevated D-dimer levels. 
Coagulation activation may have occurred in these individuals leading to low-level 
thrombin activation, followed by subsequent inhibition of the formed thrombin by 
antithrombin, leading to the formation of TAT without fibrin formation, which explains 
the absence of D-dimers in these individuals. 
We here report the first study on direct effects of S. haematobium on hemostatic 
abnormalities in urinary schistosomiasis haematobium patients without 
hepatosplenic complaints. Despite the small sample size of this pilot study, our 
observations indicate that S. haematobium directly alters the activation status of 
the vessel wall. This is not unexpected as the relatively large size of the adult worm 
pairs in the blood vessel will provoke substantial turbulence and increased shear 
stress along the vessel wall, processes known to induce endothelial activation [4]. In 
contrast to reports on coagulation abnormalities in hepatosplenic schistosomiasis 
mansoni, ongoing coagulation and fibrinolysis, which is reflected by elevated levels 
of TAT and D-dimer, was absent in urinary schistosomiasis patients. In schistosomiasis 
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mansoni the reported coagulopathy may be aggravated as a result of impaired liver 
function [5]. The direct effects of the parasite on the vessel wall are also of interest, 
as endothelial activation and elevated levels of VWF are linked to thrombosis. We 
therefore hypothesize that direct activation of the endothelium by S. haematobium 
may be involved in initiation of coagulation abnormalities in schistosomiasis. 
Interestingly, a VWF-cleaving peptidase was recently discovered in S. mansoni, which 
suggests that schistosomes have strategies to counteract  endothelial activation and 
elevated levels of VWF, which are unfavorable for both the parasite and its host, as 
this can lead to thrombosis (Mebius et al., manuscript in preparation). Larger studies 
on endothelial activation in schistosomiasis haematobium patients with various 
disease severities are required to confirm our observations and elucidate mechanisms 
involved in schistosomal-induced endothelial activation and consequences of this 
endothelial activation on hemostasis.
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Abstract
ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 
motif, member 13) cleaves von Willebrand Factor (VWF) multimers to control their 
thrombogenicity. The fibrinolytic enzyme plasmin can cleave VWF in a similar manner. 
However, plasmin can also cleave ADAMTS13, which ultimately inactivates it. This 
leaves the overall role of plasmin in primary haemostasis uncertain. 
We investigated the combined molecular effects of plasmin on VWF and ADAMTS13. We 
first identified that plasmin destroys FRETS-VWF73 substrate by cleaving the ADAMTS13 
binding region in a buffered system. We next investigated how plasmin affects both 
VWF and ADAMTS13 under static conditions in plasma by western blotting. We found 
that globular VWF is largely protected from plasmin cleavage. However, ADAMTS13 
is rapidly cleaved under these conditions, suggesting inactivation. Surprisingly, we 
observed that plasmin enhances ADAMTS13 activity in a modified two-stage FRETS-
VWF73 assay that protects FRETS-VWF73 substrate from degradation. In direct 
binding studies under the same conditions, we found that plasmin generates multiple 
C-terminally truncated forms of ADAMTS13 with VWF-binding capacity. In an effort 
to seek evidence for this mechanism in vivo, we analysed plasma from patients with 
systemic amyloidosis, which is hallmarked by a hyperfibrinolytic state. We found that 
their plasma contained increased levels of C-terminally truncated forms of ADAMTS13, 
which correlated with their hyperfibrinolytic state.
We propose that truncation of ADAMTS13 by plasmin abolishes intramolecular self-
association, which improves interaction with unfolded VWF.
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Introduction
The metalloproteinase ADAMTS13 (a disintegrin and metalloproteinase with a 
thrombospondin type 1 motif, member 13) cleaves von Willebrand Factor (VWF) 
multimers to control their thrombogenicity. As a result, low or absent ADAMTS13 
activity is associated with thrombotic thrombocytopenic purpura (TTP), a rare form 
of thrombotic microangiopathy [1]microangiopathic haemolytic anaemia and a 
variable degree of ischaemic organ damage, particularly affecting the brain, heart 
and kidneys. Acute TTP was almost universally fatal until the introduction of plasma 
therapy, which improved survival from <10% to 80-90%. However, patients who survive 
an acute episode are at high risk of relapse and of long-term morbidity. A timely 
diagnosis is vital but challenging, as TTP shares symptoms and clinical presentation 
with numerous conditions, including, for example, haemolytic uraemic syndrome and 
other thrombotic microangiopathies. The underlying pathophysiology is a severe 
deficiency of the activity of a disintegrin and metalloproteinase with thrombospondin 
motifs 13 (ADAMTS13. TTP attacks are accompanied by plasminogen activation [2]. 
We previously found preclinical evidence for a protective role of plasmin in TTP: it can 
degrade platelet-VWF complexes and stimulation of plasmin activity has therapeutic 
value in a mouse model for TTP [2]. However, unrestricted exposure of ADAMTS13 
to plasmin in a buffered system destroys its activity [3]. These seemingly opposite 
functions of plasmin leave its overall contribution in physiological primary haemostasis 
unclear. In the present study, we aimed to obtain insight into the effects that plasmin 
simultaneously exerts on both VWF and ADAMTS13 under static conditions in plasma.
A monoclonal antibody mapping study previously showed that plasmin cleaves VWF 
into three fragments. This indicates the presence of two distinct cleavage sites, rather 
than random cleavage after one of the 108 lysine residues (4% of all residues) in a 
VWF monomer [4]. One of the plasmin cleavage sites was mapped to a region within 
VWF A2 domain (1476-1643 numbering includes pro-peptide), where the ADAMTS13 
cleavage site is also located (1605-1606 numbering includes pro-peptide) [4]. This 
helps to explain our finding that plasmin cleaves VWF in a conformation-dependent 
manner similar to ADAMTS13 [2]. The diagnostic ADAMTS13 activity assay (FRETS-
VWF73 assay) uses a synthetic peptide based on the VWF A2 domain, including 
the ADAMTS13 cleavage site, flanked by a fluorophore and quencher. (Figure 1A) [5]
ADAMTS13, cleaves von Willebrand factor (VWF. The long sequence that follows the 
quencher is required for ADAMTS13 binding, and subsequent cleavage [5]ADAMTS13, 
cleaves von Willebrand factor (VWF. In our study, we first investigated the effect of 
plasmin on FRETS-VWF73 substrate and VWF in plasma. Subsequently we investigated 
the effect of plasmin on ADAMTS13 activity and structure.
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Material and Methods
Reagents
The following reagents were used: normal pooled platelet-poor citrated plasma (hereafter 
called plasma; 50 healthy donors, Sanquin, the Netherlands); FRETS-VWF73 substrate 
(AnaSpec, Fremont, California, United States); plasmin substrate (I-1390; Bachem, 
Bubendorf, Switzerland); rabbit polyclonal anti-VWF (A0082; DAKO, Carpinteria, California, 
United States); goat polyclonal anti-ADAMTS13 (A300-391A; Bethyl, Montgomery, Texas, 
United States); goat polyclonal anti-plasminogen (GAPG-AP; Affinity Biologicals, Ancaster, 
ON, Canada); donkey-anti-goat IR dye 800 (926-32214; LI-COR, Lincoln, Nebraska, United 
States); goat-anti-rabbit Alexa Fluor 680 (A21076; Thermo Fisher Scientific, Waltham, 
Mississippi, United States); streptokinase (CSL Behring, Marburg, Germany); aprotinin 
(Sigma-Aldrich, St Louis, Missouri, United States); PPACK (D-Phenylalanine-Proline-Arginine 
Chloromethyl Ketone; Haemtech, Essex Junction, Vermont, United States); hirudin (Pharmion, 
Tiel, the Netherlands); bovine serum albumin (BSA; Sigma-Aldrich) and purified VWF (Biotest 
AG, Dreieich, Germany). Plasminogen was purified from plasma as previously described [6].
In silico prediction of cleavage sites
Cleavage sites for trypsin-like serine proteases in FRETS-VWF73 substrate were 
predicted with ExPASy PeptideCutter software [7].
Direct effects of plasmin on FRETS-VWF73 substrate
We investigated the influence of plasmin on FRETS-VWF73 substrate in a two-stage 
experimental setup. FRETS-VWF73 substrate was dissolved at a concentration of 100 μM in 
25% (v/v) dimethyl sulfoxide (DMSO) and diluted to 4 μM in assay buffer (5 mM Bis-Tris, 25 
mM CaCl
2
, 0.005% Tween-20, pH 6.0) prior to experiments. Plasminogen (1.2 mg/mL) was 
activated with streptokinase (50 U/mL) for 30 minutes at 37°C in HEPES-buffered saline 
(HBS; 10 mM HEPES, 150 mM NaCl, pH 7.4). 
Stage 1: To investigate whether plasmin cleaves between the fluorophore and quencher of 
FRETS-VWF73 substrate, we incubated 0.2 nmol FRETS-VWF73 in 30 μL assay buffer with 20 
μL streptokinase-activated plasminogen in HBS. To prevent coagulation of plasma at a later 
stage in the experiment, 100 U/mL hirudin (final concentration) was added. The resulting 
pH of these 50 μL reactions was 6.85. Buffer controls without streptokinase-activated 
plasminogen were included in the experiments. Generation of fluorescence was monitored 
for 10 minutes at 30°C in a 96-well white MaxiSorp microtiter plate (Thermo Scientific, 
Roskilde, Denmark) on a SpectraMax M2 fluorescence microplate reader (MTX Laboratory 
Systems, Bradenton, Florida, United States) equipped with a 340 nm excitation filter and 450 
nm emission filter. The reaction rate was calculated by linear regression analysis using PRISM 
software (version 7.02; GraphPad, San Diego, California, United States). 
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Stage 2: We next assessed whether FRETS-VWF73 substrate remains sensitive to 
plasma ADAMTS13 after exposure to plasmin. After following the procedure of stage 1, 
we subsequently added 10 μL of inhibitor cocktail in HBS to all samples (100 μM PPACK, 
250 KIU/mL aprotinin; final in-assay concentrations) and incubated for 10 minutes at 
30°C to block plasmin activity. Subsequently, 30 μL of assay buffer was added. Finally, 
10 μL of diluted plasma in HBS (20% v/v) was added to initiate the assay. In this way, 
the ratio between assay buffer and HBS (and resulting pH of 6.85) was maintained 
between the two stages of the experiment. Generation of fluorescence was monitored 
for 1 hour at 30°C on the SpectraMax M2 fluorescence microplate reader.
Effects of plasmin on ADAMTS13 activity
The direct influence of plasmin on ADAMTS13 activity in plasma was studied by 
activating plasminogen in 100 μL plasma by adding 25 μL streptokinase in HBS 
(1,000 U/mL; final concentration) or HBS (buffer control) for 30 minutes at 37 °C. Next, 
ADAMTS13 activity was measured by FRETS-VWF73 assay as published with minor 
modifications [5]ADAMTS13, cleaves von Willebrand factor (VWF. In brief, plasma was 
diluted in assay buffer (2% v/v, final dilution) and FRETS-VWF73 substrate (0.2 nmol) 
was added to initiate the assay and fluorescence was measured for 1 hour at 30°C. 
The reaction volume of this experiment consists for 97.5% of assay buffer (pH 6.0), 2% 
plasma and 0.5% HBS (accommodates streptokinase). In further experiments, plasmin 
activity was inhibited prior to determination of plasma ADAMTS13 activity by addition 
of 10% (v/v) inhibitor cocktail in HBS and 100 U/mL hirudin (final concentration) and 
incubation for 10 minutes at 37°C. Next, 2% (v/v) plasma in assay buffer supplemented 
with inhibitor cocktail was incubated with FRETS-VWF73 substrate (0.2 nmol) to 
initiate the assay. Fluorescence was measured for 1 hour at 30°C. The reaction volume 
of this experiment consists for 90% of assay buffer (pH 6.0), 8% HBS (accommodates 
streptokinase and inhibitor cocktail) and 2% plasma. 
Plasmin activity assay
In control experiments, we confirmed activation and inhibition of plasma purified 
plasminogen under the conditions as described in ‘direct effects of plasmin on FRETS-
VWF73 substrate’ and of plasma plasminogen under the conditions as described in 
‘Effects of plasmin on ADAMTS13 activity’. Hereto, samples were diluted 20-fold in 
HBS in 96-well white MaxiSorp plates. Where indicated, HBS was supplemented with 
inhibitor cocktail to demonstrate efficacy of plasmin inhibition. A final concentration 
of 12.5 μM I-1390 (plasmin substrate) was added and fluorescence was measured at 
37 °C with excitation at 380 nm and emission at 460 nm. Initial reaction rates were 
calculated by linear regression analysis.
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SDS-PAGE and immunoblotting
Plasminogen, ADAMTS13, and VWF were investigated by immunoblotting 0.5 μL of 
plasma in which plasminogen had been activated and inhibited as described in ‘Effects 
of plasmin on ADAMTS13 activity’. Plasma samples were diluted 43-fold in sample 
buffer (62.3 mM Tris-HCl [pH 6.8], 10% glycerol, 2% SDS, 0.001% bromophenol blue) 
and supplemented where indicated with 8.3 mM dithiothreitol (DTT) for reduction. 
Samples were boiled at 95°C for 10 minutes and 30 μL (containing 0.5 μL of original 
plasma) was separated by SDS-PAGE on 7.5% gels. For separation of ADAMTS13 and 
plasminogen under reducing conditions, 4 to 12% gradient gels were used. Proteins 
were transferred to immobilon-FL polyvinylidene fluoride (PVDF) membrane (Merck 
Millipore, Tullagreen, Ireland) and blocked with 1:1 odyssey blocking buffer (LI-COR) 
and Tris-buffered saline (TBS; 10 mM Tris, 150 mM NaCl, pH 7.4), followed by overnight 
incubation with the anti-ADAMTS13, anti-plasminogen or anti-VWF, diluted 1:2,500 
at 4 °C. The anti-ADAMTS13 antibody is affinity purified using an epitope specific to 
ADAMTS13 mapping between residues 250 and 350 (part of the metalloproteinase and 
disintegrin domain) using the numbering given in entry NP_620594.1 (GeneID 11093). 
Membranes were subsequently incubated with donkey-anti-goat IR dye 800 (for 
anti-ADAMTS13 and anti-plasminogen) or goat-anti-rabbit Alexa Fluor 680 antibody 
(for anti-VWF) diluted 1:10,000 for 2 hours at room temperature. Membranes were 
scanned on a near-infrared scanner (Odyssey) and band intensities were quantified 
with Odyssey V3.0 software (LI-COR). 
ADAMTS13 binding to immobilized VWF
Binding of ADAMTS13 to immobilized VWF in control and streptokinase activated and 
inhibited plasma (prepared as described in the section ’Effects of plasmin on ADAMTS13 
activity’) was investigated as published with minor modifications [8]a metalloprotease, 
cleaves von Willebrand factor (VWF. Ninety-six-wells Nunc-Immuno MaxiSorp microtiter 
plates (Thermo Scientific) were coated with VWF overnight at RT (100 μL/well; 10 μg/mL 
VWF in phosphate buffered saline [PBS; 137 mM NaCl, 2.7 mM KCl, 9.2 mM Na₂HPO₄ • H₂O, 
1.76 mM KH₂HPO₄, pH 7.4]) and blocked with 200 μL/well blocking buffer (PBS, 2.5% BSA, 0.1% 
Tween-20) for 1 hour at RT. Where indicated, plasmin activity was triggered and terminated 
in plasma samples prior to binding experiments (as described in the section ‘Effects 
of plasmin on ADAMTS13 activity’), buffer controls were included to correct for sample 
dilution. All plasma samples were supplemented with 5 mM ethylenediaminetetraacetic 
acid (EDTA; to block ADAMTS13 activity). A sample of 100 μL was incubated in each well for 
2 hours at RT. Next, the wells were washed three times with PBS 0.1% Tween-20 and bound 
ADAMTS13 was eluted in three times the sample buffer. The eluted ADAMTS13 from 48 wells 
per condition was combined and equally divided into a non-reduced, and a reduced 
sample (to which DTT was added) prior to analyses. 
93
Truncation of ADAMTS13 by plasmin enhances its activity in plasma
5
Patient plasma samples 
Citrated plasma was collected from systemic amyloidosis patients and controls 
without systemic amyloidosis (i.e., localized amyloidosis) at Groningen University 
Medical Center under institutional ethical approval and informed consent as 
described earlier [9,10]AL type in 80, hereditary ATTR type in 27, and localized 
amyloidosis in 22 cases. SAP scintigrams were obtained 24 hours after tracer injection 
and were analyzed for abnormal patterns of uptake. Sensitivity and specificity were 
determined, and scintigraphic findings were compared with clinical data. RESULTS 
Diagnostic sensitivity of SAP scintigraphy for systemic AA, AL, and ATTR amyloidosis 
was 90%, 90%, and 48% respectively, and specificity was 93%. The distribution of 
amyloid was less diverse in AA than in AL type. Myocardial uptake was not visualized in 
any patient. Splenic amyloid was very frequent (80%. Selection was based on positive 
Congo red biopsies and number and location of sites with amyloid depositions. In 
a previous study, plasmin-α2 antiplasmin (PAP) complex levels were determined in 
duplicate within 5 months using a commercially available ELISA (Technoclone GmbH, 
Vienna, Austria, Cat. No. TC11060), according to the manufacturer’s instructions [11]. 
ADAMTS13 activity was determined as described earlier. The binding of ADAMTS13 in 
patient plasma to immobilized VWF was investigated by incubating 30 μL plasma 
samples (undiluted) for more than 2 hours on immobilized VWF. Per patient six wells 
were combined and analyzed on western blot. Band intensities of uncleaved 190-kDa 
and truncated 170-kDa ADAMTS13 products were quantified by densitometry with 
Odyssey V3.0 software (LI-COR). The fraction of truncated ADAMTS13 was expressed 
relative to the fraction of uncleaved ADAMTS13 in individual patients. 
Statistical analysis
Statistical analysis was performed with PRISM software (version 7.02; GraphPad) 
using Wilcoxon matched-pairs signed rank test or Friedman test with Dunn’s 
multiple comparisons test. Correlation was tested using non-parametric Spearman’s 
correlation. Results were statistically significant when p ≤ 0.05.  
Results
The ADAMTS13 binding tail of FRETS-VWF73 substrate is sensitive 
to plasmin cleavage
ExPASy PeptideCutter software predicts that the FRETS-VWF73 sequence contains five 
cleavage sites for trypsin-like enzymes [7]. Four of these are located in the sequence 
that mediates ADAMTS13 binding (Figure 1A), but no cleavage sites are predicted 
between the fluorophore and quencher. 
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We exposed FRETS-VWF73 substrate to different concentrations of purified streptokinase-
activated plasminogen (plasmin activity was confirmed in Supplementary Figure S1). 
We found that no fluorescence was generated (Figure 1B), confirming the sequence 
between fluorophore and quencher does not contain a plasmin cleavage site [12,13]. 
When FRETS-VWF73 was exposed to plasmin activity for 10 minutes and subsequently 
blocked with inhibitor cocktail (efficacy confirmed in Supplementary Figure S1B), 
its functionality to act as a substrate for plasma ADAMTS13 was dose dependently 
impaired. (Figure 1C; grey circles). The inhibitor cocktail protects the substrate from 
plasmin-mediated destruction, which eliminates potential analytical threats in our next 
experiments (Figure 1C; black circles).
Figure 1.  Plasmin cleaves the ADAMTS13 (a disintegrin and metalloproteinase with a 
thrombospondin type 1 motif, member 13) binding tail of FRETS-VWF73 substrate in buffer.
(A) Predicted cleavage sites with a probability of greater than 75% for trypsin-like serine proteases in FRETS-
VWF73 substrate (highlighted K and R residues) and the cleavage site for ADAMTS13 (indicated by arrow). (B) 
FRETS-VWF73 substrate conversion in the presence of a concentration series of streptokinase (SK)-activated 
plasminogen (PLG). As a positive control, FRETS-VWF73 substrate conversion by plasma ADAMTS13 is shown 
(indicated by plasma). (C) FRETS-VWF73 substrate functionality towards plasma ADAMTS13 was tested after 
pre-exposure to plasmin, which was terminated with inhibitor cocktail prior to analysis (grey circles). In control 
experiments, we found that inhibitor cocktail protects the substrate from plasmin-mediated destruction (black 
circles). (B,C) Initial rates of fluorescence as mean ± standard deviation (SD) of three separate experiments, 
performed in duplicate. (B) Statistical analysis was performed with Friedman’s test with Dunn’s multiple 
comparisons test where all values are compared with 0 μg/mL plasmin. (C) Statistical analysis was performed 
with Wilcoxon matched-pairs signed-rank test. Results were considered statistically significant when p ≤ 0.05 (ns, 
non-significant; *p ≤ 0.05; ** p ≤ 0.01).
 
Plasmin predominantly cleaves ADAMTS13 in plasma under static 
conditions
We next triggered plasmin activity in plasma with streptokinase (confirmed in 
Supplementary Figure S2), terminated its activity with inhibitor cocktail and investigated 
VWF and ADAMTS13 by immunoblotting under reduced conditions. We found that VWF 
monomer content did not significantly diminish after plasmin activity (Figure 2A and B), 
although a 176-kDa cleavage product appeared [4]. This indicates that globular VWF 
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is largely resistant against plasmin cleavage, which fits well with the earlier reported 
shear-dependent cleavage by us [2] and others [12]. Under the same conditions, the 
ADAMTS13 band at 190 kDa was consumed (-78.7 ± 13.2%, P = 0.0039; Figure 2C and D) 
and there was some evidence for the generation of truncated products at approximately 
130 and 90 kDa (Figure 2C). These findings together show that under static conditions in 
plasma, plasmin favors cleavage of ADAMTS13 over globular VWF.
Plasmin cleavage enhances ADAMTS13 activity in plasma
It was previously reported that plasmin cleaves recombinant ADAMTS13 [3]. In 
a buffered system, this cleavage is extensive and ultimately results in ADAMTS13 
inactivation [3]. It is noteworthy that the first stages of plasmin cleavage take place 
at the C-terminus, resulting in truncated products with an intact metalloprotease 
domain. In hyperfibrinolytic (α2-antiplasmin deficient) plasma, cleavage of 
recombinant ADAMTS13 by plasmin takes place much less rapidly than in a buffered 
system, but identical C-terminally truncated products are formed first [13]. It was 
suggested that these fragments were no longer active.
Figure 2. Plasmin predominantly cleaves ADAMTS13 (a disintegrin and metalloproteinase  
with a thrombospondin type 1 motif, member 13) in plasma under static conditions.
(A-D) The effect of plasmin on von Willebrand Factor (VWF) and ADAMTS13 in plasma was investigated by 
triggering plasminogen (PLG) activation with streptokinase (SK; 1,000 U/mL, 30 minutes at 37°C), followed by 
addition of inhibitor cocktail (100 μM PPACK, 250 KIU/mL aprotinin, 100 U/mL hirudin) to terminate plasmin 
activity. As a control, plasma was incubated with buffer without streptokinase and inhibited with inhibitor 
cocktail as before. (A, C) Plasma (0.5 μL) was separated per lane by SDS-PAGE and immunoblotted for VWF (A), 
and ADAMTS13 (C), under reduced conditions. Representative immunoblots are shown. (B,D) Quantification of 
band densities of multiple experiments (n = 9) presented as median ± interquartile range. Statistical analysis was 
performed with Wilcoxon matched-pairs signed-rank test (average band density of three control samples per 
experiment was set to 100%). Results were considered statistically significant when p ≤ 0.05 (ns, non-significant; 
** p ≤ 0.01).
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During our next experiments, we made a striking observation. When plasminogen 
activation was triggered in plasma, FRETS-VWF73 conversion was increased by 21.6 
± 6.6%, compared with buffer control plasma samples (P = 0.0313; Figure 3A). In our 
previous experiment (Figure 1B), we had found that plasmin does not elicit FRETS-VWF73 
substrate fluorescence in a buffered system. This led us to hypothesize that plasmin 
indirectly contributes to increased FRETS-VWF73 conversion in plasma. To investigate 
this, we modified the FRETS-VWF73 assay into a two-step procedure. First, plasmin activity 
was triggered. Second, inhibitor cocktail was added to reduce plasmin activity to less 
than 1% ( Figure 3B). When FRETS-VWF73 conversion was determined in plasma in which 
plasmin had been active, we consistently detected an increase in substrate conversion 
compared with buffer control plasma samples (21.2 ± 6.9%, P = 0.0313; Figure 3C). 
This indicates that, although plasmin cleaves ADAMTS13, its apparent activity increases. 
Next, we set out to identify the responsible mechanism. 
Figure 3: Plasmin enhances ADAMTS13 (a disintegrin and metalloproteinase  
with a thrombospondin type 1 motif, member 13) activity in plasma.
(A) Activation of plasminogen (PLG) with streptokinase (SK) in plasma (1,000 U/mL, 30 minutes at 37°C) increases 
ADAMTS13 activity (+21.6 ± 6.6%, p = 0.0313) measured in the FRETS-VWF73 assay compared with the buffer 
control (i.e., without SK). (B) Plasmin activity that is generated in plasma by SK is effectively inhibited by inhibitor 
cocktail (grey bars = uninhibited buffer control, black bars = inhibitor cocktail). (C) Transient plasmin activity 
also increases ADAMTS13 activity (+21.2 ± 6.9%, p = 0.0313) measured in a modified two-stage FRETS-VWF73 
assay. In this assay setup, plasma plasminogen was temporarily activated with streptokinase (buffer without 
streptokinase was included as a control) and subsequently inhibited with inhibitor cocktail. Panels (A) and (C) 
represent initial rates of substrate conversion presented as median ± interquartile range, whereas panel (B) is 
presented as mean ± standard deviation (SD). Statistical analysis was performed with Wilcoxon matched-pairs 
signed-rank test. All values represent compound data of three separate experiments, performed in duplicate. 
Results were considered statistically significant when p ≤ 0.05 (ns, non-significant; *p ≤ 0.05). 
 
Plasmin generates C-terminally truncated ADAMTS13 products 
with VWF-binding properties
The interaction between the spacer domain of ADAMTS13 and the A2 domain of (unfolded) 
VWF is important for efficient VWF cleavage. A recent study elegantly demonstrates 
that the C-terminal complement C1r/C1s, Uegf, Bmp1 (CUB) domains of ADAMTS13 limit 
its function by intramolecular binding to the spacer domain [14]. The resulting ‘closed’ 
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conformation can be opened by binding to globular VWF, unlocking the full activity of 
ADAMTS13. Interestingly, this same study, as well as an earlier study [15], showed that 
recombinant ADAMTS13 variants either lacking the C-terminal tail or the CUB domains 
displayed an increased activity without initial binding to globular VWF.
In our next experiments, we investigated the effect of plasmin on the VWF-binding 
properties of ADAMTS13. Hereto, we incubated plasma samples on immobilized VWF 
in microtiter plates. 
Figure 4: Plasmin generates truncated ADAMTS13 (a disintegrin and metalloproteinase with 
a thrombospondin type 1 motif, member 13) variants with VWF-binding properties and a 
metalloprotease domain.
(A-D) The binding of plasma ADAMTS13 to immobilized VWF was analysed by immunoblotting with an antibody 
against the metalloprotease domain under reducing (A,B) and non-reducing conditions (C,D). Plasmin activity 
was transiently triggered with the two-stage approach in which plasma plasminogen is activated with 
streptokinase and subsequently inhibited with inhibitor cocktail prior to the incubation of the plasma samples 
on immobilized VWF (in presence of ethylenediaminetetraacetic acid [EDTA]). As a control, buffer without 
streptokinase was included. (A-D) Representative immunoblots and quantification of band densities from 
repeated experiments (median ± interquartile range, n = 7). Statistical analysis was performed with Wilcoxon 
matched-pairs signed-rank test. Results were considered statistically significant when p ≤ 0.05 (*p ≤ 0.05).
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After washing, bound ADAMTS13 was eluted with sample buffer and analysed 
by western blotting with an antibody against the metalloprotease domain [8]a 
metalloprotease, cleaves von Willebrand factor (VWF. In plasma, the major product 
that is captured is 190 kDa (Figure 4A and B; reducing conditions). A second minor 
product is seen at approximately 170 kDa. When plasmin activity is triggered and 
terminated in plasma before incubation on immobilized VWF, less full-length protein 
(190 kDa) binds. In this case, multiple truncated species of approximately 170, 130 
and 90 kDa are captured. ADAMTS13 contains intramolecular disulfide linkages; 
therefore, these fragments could remain covalently associated under non-reducing 
conditions. Analyses under non-reducing conditions show a highly similar picture: 
intact ADAMTS13 is captured from plasma before, but much less after exposure to 
plasmin. Instead, truncated variants that contain the protease domain are captured 
(Figure 4C and D). 
Truncated ADAMTS13 in systemic amyloidosis
Patients with systemic amyloidosis are in a chronic hyperfibrinolytic state, which 
may contribute to their reduced haemostatic potential and bleeding problems 
[16]. We investigated ADAMTS13 in these patients and control samples (n = 11 and 8, 
respectively), of which PAP had been previously determined. In line with our earlier 
report, PAP complex levels differed significantly between controls (median; 171.5 ng/mL; 
inter quartile range [IQR] 130.8-221.8 ng/mL) and patients (median; 1,238 ng/mL; IQR 
475.8-4,103 ng/mL) (Figure 5A). We next investigated ADAMT13 truncation in these patient 
plasmas. As before, we analysed ADAMTS13 binding to immobilized VWF. In our earlier 
experiments (Figure 4A), plasmin generates a 170-kDa C-terminally truncated ADAMTS13. 
To a minor extent, this product is already present in normal plasma (Figure 4A). 
We found that this 170-kDa band was represented more strongly in plasma of patients 
with systemic amyloidosis than of controls (Figure 5B shows a representative blot). 
To correct for inter-individual differences, we expressed truncated 170-kDa ADAMTS13 
relative to 190-kDa ADAMTS13 for each plasma sample. The presence of truncated 170-
kDa ADAMTS13 correlates with the extent of fibrinolytic activity (i.e., PAP complexes; r = 
0.5491, p = 0.0149). These findings were not dependent on the patient with the highest 
PAP complex levels and accompanying ADAMTS13 truncation (r = 0.4696, p = 0.0493 
after exclusion). ADAMTS13 activity in these samples was determined with the FRETS-
VWF73 assay (Figure 5D), but no significant difference was found between the control 
and patient groups. We observed greater than 20% variation in ADAMTS13 activity 
between various plasma samples, which is in good correspondence to earlier reports 
[5]ADAMTS13, cleaves von Willebrand factor (VWF. This may obscure increased activity 
as a function of plasmin-mediated truncation. 
99
Truncation of ADAMTS13 by plasmin enhances its activity in plasma
5
Figure 5. Truncated ADAMTS13 (a disintegrin and metalloproteinase  
with a thrombospondin type 1 motif, member 13) in systemic amyloidosis.
(A) Plasmin-α2-antiplasmin complex levels (PAP) in systemic amyloidosis patients and controls without systemic 
amyloidosis (n = 11 and 8, respectively). Plasma samples were incubated on immobilized VWF for ADAMTS13 
binding (in presence of EDTA). (B) Bound ADAMTS13 was analyzed by immunoblotting. (C) Correlation plot of PAP 
complex levels and truncated ADAMTS13 (170/190 kDa ADAMTS13 ratio) of these samples (r = 0.5491, p = 0.0149). 
(D) ADAMTS13 activity of systemic amyloidosis patients and controls, measured with the FRETS-VWF73 assay. 
(A,D) Statistical analysis was performed with Wilcoxon matched-pairs signed-rank test. (B) Representative 
immunoblot. (C) Correlation was tested using non-parametric Spearman correlation. Results were considered 
statistically significant when p ≤ 0.05 (ns, non-significant; ****p ≤ 0.0001). 
Discussion
We here report the finding that plasmin under static conditions in plasma rapidly truncates 
ADAMTS13 and this is accompanied by increased ADAMTS13 activity in the FRETS-VWF73 
assay. Moreover, multiple truncated forms of ADAMTS13 retain the capacity to bind to VWF.
In our study, we ruled out that plasmin is responsible for the observed increased 
FRETS-VWF73 substrate fluorescence. In contrast, we found that plasmin can destroy 
FRETS-VWF73 substrate in a buffered system. Although this effect is modest in normal 
plasma that contains the powerful plasmin inhibitor α2-antiplasmin, it might generate 
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an analytic threat in plasma samples with partial [2] or complete [13] α2-antiplasmin 
deficiency. If needed, this potential analytical threat can be averted with the use of 
plasmin-blocking serine protease inhibitors, as we used in this study.
Plasmin can cleave ADAMTS13 in buffer at multiple positions: at Arg-257/Ala-258 
(metalloprotease domain), at Arg-888/Thr-889 (linker region between the fourth and 
fifth thrombospondin type 1 repeat [TSP-1]) and at Arg-1176/Arg-1177 [3,17]. It is likely 
that similar cleavage events take place during plasminogen activation in plasma, 
corresponding to the truncated ADAMTS13 products that can bind to immobilized 
VWF (Figure 4A and B). Intramolecular disulphide-linkage assures covalent 
association of the fragments generated by cleavage at Arg-257/Ala258 or Arg-888/
Thr-889 [3,18]ADAMTS13. It is unclear how ADAMTS13 activity is regulated within the 
vascular system. In the absence of a regulatory mechanism, ADAMTS13 activity might 
compromise platelet adhesion at sites of vascular injury. We hypothesized that at 
sites of vascular injury, ADAMTS13 activity could be regulated locally by coagulation 
proteinases. Initiation of coagulation in human plasma resulted in the disappearance 
of added full-length recombinant ADAMTS13. This loss was inhibited by hirudin. Using 
purified proteins, we showed that ADAMTS13 is proteolyzed at several cleavage 
sites by thrombin in a time- and concentration-dependent manner. Furthermore, 
this proteolysis ablated ADAMTS13 activity against purified von Willebrand factor. 
Preincubation of thrombin with soluble thrombomodulin, but not heparin, inhibited 
the proteolysis of ADAMTS13, suggesting the involvement of thrombin exosite I (and not 
exosite II. However, C-terminal truncation after cleavage at Arg-1176/Arg-1177 truncates 
ADAMTS13 by removal of the eighth TSP-1 and both CUB domains [17,18]thrombotic 
thrombocytopenic purpura. We established a simple and efficient method to purify 
plasma ADAMTS13 (pADAMTS13. This is consistent with the capture of truncated 
ADAMTS13 under non-reduced conditions (Figure 4C and D). 
Based on our findings, we proposed that monomeric ADAMTS13 is C-terminally 
truncated by plasmin. However, it is noteworthy that we observed a second plasmin-
sensitive ADAMTS13-immunoreactive high-molecular weight product (~350 kDa) 
product in plasma (Supplementary Figure S3). Future studies will have to determine 
whether this species of ADAMTS13 contributes to the observed increased ADAMTS13 
activity after plasminogen activation.
When ADAMTS13 is not ‘in action’, its CUB domains interact with its spacer region to 
ensure a closed conformation. During VWF binding, these CUB domains interact with 
VWF [19]. This causes ADAMTS13 to change conformation, which increases its activity 
(‘conformational activation’) [14]. We hypothesize that plasmin-mediated removal of CUB 
domains causes ADAMTS13 to adopt an open conformation (resembling conformational 
activation [14]) with increased accessibility of the spacer domain for unfolded VWF. 
We propose that our findings reflect a physiological mechanism to enhance ADAMTS13 
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activity. When the microvasculature senses hypoxia, as may occur during microthrombosis, 
plasmin is locally generated on endothelial cells. Besides its direct effects on VWF [4,20]176, 
and 140 kD fragments cleaved from the 225 kD subunit. A monoclonal antibody map of 
vWF, based on the reactivity of individual antibodies with cyanogen bromide and tryptic 
fragments of known carboxy and/or amino termini, showed that in normal and IIA von 
Willebrand disease (vWD and platelet-VWF complexes [2], plasmin cleaves ADAMTS13, 
leading to enhanced activity. It is attractive to hypothesize that similar truncation of 
ADAMTS13 and associated increased activity contributes to the haemorrhagic phenotype 
in hyperfibrinolytic disorders, such as systemic amyloidosis.
Conclusions
Our findings indicate that under static conditions in plasma, plasmin cleaves 
ADAMTS13 more rapidly than VWF. C-terminally truncated ADAMTS13 can bind to 
immobilized VWF and is associated with an enhanced activity. Matching C-terminally 
truncated ADAMTS13 forms are generated in vivo during increased fibrinolytic activity.
Supplementary data to Clark et al. ‘Truncation of 
ADAMTS13 by plasmin enhances its activity in plasma.’
Supplementary results
Plasmin releases ADAMTS13 from a disulfide-linked complex.
Under non-reducing conditions, we observed a ~350 kDa ADAMTS13-immunoreactive 
band in plasma that almost completely disappears after exposure to plasmin (-91.0% ± 10.1%, 
p = 0.0039, Supplementary Figure S3A and B). It is noteworthy this product normally does 
not bind to immobilized VWF (Figure 4C; upper part of the immunoblot) and is not seen 
in the presence of DTT (i.e., the product is disulfide-linked). Interestingly, plasma also 
contains a VWF-immunoreactive product that migrates at an identical height (~350 kDa) 
and is modestly consumed by plasmin (- 23.1% ± 13.1%, p = 0.0078, Supplementary Figure 
S3C and D). This latter product is proposed to represent a disulfide-linked homodimer 
of C-terminally truncated VWF molecules [1-3]. More precise electrophoretic separation 
revealed that the ~350 kDa product actually consists of multiple bands. The lower is 
immunoreactive for both VWF and ADAMTS13 prior to, but not after plasmin activity 
(Supplementary Figure S3E). This suggests that a fraction of ADAMTS-13 circulates in 
disulfide-linked high molecular weight complexes [1,4-6]. 
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Supplementary Figure S1. Activation of purified plasminogen with streptokinase.
(A) Representative immunoblot of purified plasminogen (PLG) after incubation with 50 U/mL streptokinase (SK) 
or vehicle for 30 minutes at 37 °C.  100 ng per lane of purified plasminogen was separated on 4-12% gradient gel 
under reducing conditions and immunoblotted for plasminogen. Activation of plasminogen with streptokinase 
results in conversion of Glu-plasminogen (86 kDa) into Lys-plasminogen (83 kDa) and formation of two-chain 
plasmin, indicated by appearance of the plasmin heavy chain (60 kDa). (B) Streptokinase-triggered plasmin 
activity and inhibition with inhibitor cocktail. Streptokinase-activated plasminogen (25-200 μg/mL in HBS) was 
incubated with 12.5 μM plasmin substrate I-1390 in the absence or presence of inhibitor cocktail. Bars represent 
initial rates of fluorescence as mean ± SD of three separate experiments, performed in duplicate. Statistical 
analysis was performed with Friedman test with Dunn’s multiple comparisons test where all values are compared 
to 0 μg/mL activated plasminogen. 
Supplementary Figure S2. Activation of plasma plasminogen with streptokinase.
(A) Representative immunoblot of plasma plasminogen (PLG) that was activated with different concentrations 
of streptokinase (SK) and inhibited with inhibitor cocktail. 0.25 μL of reduced plasma sample was loaded per 
lane. Activity assays are shown in Figure 3B. 
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(A and C) Immunoblotting of plasma under non-reducing conditions revealed a high molecular-weight product, 
which is immunoreactive for both ADAMTS13 and VWF, respectively. (B and D) This product is susceptible to 
plasmin activity. (E) Detailed electrophoretic separation and immunoblotting for ADAMTS13 and VWF revealed 
that one of these bands is immunoreactive for both proteins. Panels A-D represent representative immunoblots 
and quantification of bands densities (median ± interquartile range) are shown. Statistical analysis was 
performed with Wilcoxon matched-pairs signed rank test (average band density of three control samples on the 
same blot was set to 100%). Results were considered statistically significant when P ≤ 0.05 (** indicates P ≤ 0.01).
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Abstract
Plasminogen binding to the outer surface of pathogens is a well-known virulence 
factor for many pathogens, facilitating invasion, dissemination, and evasion of the 
immune system and blood coagulation system. Plasminogen binding has been 
studied extensively in parasitic worms belonging to the Schistosoma genus, leading to 
the identification of several proteins that bind and activate plasminogen. In S. mansoni, 
plasminogen activation at the outer surface occurs exclusively in the presence of 
tissue-type plasminogen activator (tPA). This led us to investigate the schistosomal 
proteins involved in tPA binding at the outer surface of the parasite. Using ligand 
blotting and pull-down experiments, numerous tPA binding proteins were identified. 
This indicates that S. mansoni contains many proteins that can interact with tPA and 
could be involved in localization of tPA to the outer surface of the parasite, which can 
facilitate the acceleration of activation of plasminogen to plasmin.
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Interaction with the mammalian fibrinolytic system, of which its main enzyme plasmin is 
involved in degradation of fibrin and extracellular matrix proteins, has been described 
for a broad range of pathogens, including several parasitic worms. Plasminogen-
pathogen interactions facilitate tissue invasion, dissemination, immune evasion, and 
evasion of blood coagulation [1]. Blood-dwelling parasitic worms belonging to the 
Schistosoma genus, such as Schistosoma bovis, S. japonicum, and S. mansoni, have also 
been described to interact with the fibrinolytic system of their mammalian host. The 
binding and activation of plasminogen at the outer surface, or tegument, of these 
species, has been extensively studied [2–6] and revealed several plasminogen-binding 
proteins. The first of these studies was performed in S. bovis and showed plasminogen 
binding by up to ten plasminogen-binding proteins present on the outer surface [2] 
(reviewed by de la Torre-Escudero et al.) [7]). Plasminogen-binding proteins identified 
were enolase, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), and fructose-
bisphosphate aldolase (FBA), of which FBA was shown not to be associated with the 
S. bovis tegument and was therefore ruled out as a putative physiological receptor 
for plasminogen. Additionally, an S. bovis annexin has been identified in the worm 
tegument that was capable of binding plasminogen [5]. In addition to plasminogen-
binding, the conversion of plasminogen to plasmin is also enhanced by tegument 
extracts, both in the presence and absence of the natural activator of plasminogen, 
tissue-type plasminogen activator (tPA) [2]. Of the plasminogen-binding proteins, 
only enolase and annexin were able to activate plasminogen to plasmin and this 
conversion was dependent on the presence of tPA [3,5]. Later, enolase proteins were 
also identified on the surface of S. japonicum and S. mansoni species [4,6] and were 
both shown to be involved in plasminogen-binding. Enhancement of plasminogen 
conversion to plasmin has only been found for the S. mansoni enolase and was also 
dependent on the presence of tPA [6].
Pathogens that use the fibrinolytic system to their advantage, have been described 
to bind not only plasminogen to their surface, but often also tPA [1]. However, to date, 
no studies have been performed on the interaction between Schistosoma species and 
tPA. This study, therefore, focusses on the interaction between S. mansoni and tPA to 
further elucidate how S. mansoni interacts with the fibrinolytic system of their host.
We first examined the conversion of plasminogen to plasmin by determining cleavage 
of a fluorogenic plasmin substrate by S. mansoni worm homogenate (WH) (Fig. 1A). 
This showed that plasminogen activation by S. mansoni WH occurs exclusively in the 
presence of tPA, which is in line with the finding of Figueiredo et al. [6]. Similarly, intact 
live male worms were able to convert plasminogen to plasmin in a dose-dependent 
manner (Fig. 1B), again, exclusively in the presence of tPA (not shown). This finding 
of tPA-dependent plasminogen activation on intact male worms indicates that the 
plasminogen activating molecules of S. mansoni are located on the outer surface 
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Figure 1. S. mansoni enhances plasminogen activation in a tPA dependent manner.
A) Plasmin activity detected by cleavage of the plasmin substrate (Boc-Val-Leu-Lys-AMC, Bachem, Bubendorf, 
Switzerland) (33 μM) in HBS (10 mM HEPES, 150 mM NaCl, pH 7.4) in the presence or absence of 333 μg/mL S. mansoni 
worm homogenate (WH). WH was prepared in HBS by homogenization (10% v/v) of intact adult S. mansoni pairs 
isolated from Golden hamsters in HBS followed by centrifugation at 500x g for 5 minutes at 4 °C. Where indicated 
13 μg/mL plasminogen (purified from plasma as described by de Maat et al. [14]) and/or 0.1 μg/mL tPA (Actilyse, 
alteplase, Boehringer Ingelheim, Ingelheim, Germany) was added. Fluorescence was monitored for 2 hours at 37°C 
on a Spectromax M2 fluorescence microplate reader (MTX Lab Systems, Bradenton, FL, USA) equipped with a 390 
nm excitation filter and 460 nm emission filter. B) Plasmin activity detected by cleavage of the plasmin substrate 
(33 μM) in HBS supplemented with plasminogen (13 μg/mL) and tPA (0.1 μg/mL) in the presence or absence of live 
S. mansoni males or 167 μg/mL WH. C) Plasmin activity detected by cleavage of the plasmin substrate (33 μM) in 
HBS in the presence of tPA (0. 1 μg/mL) and 2.6 μg/mL - 167 μg/mL of different fractions of S. mansoni: WH (○), S. 
mansoni soluble protein fraction (□] (obtained by 14000g centrifugation of WH for 30 minutes at 4°C), tegumental 
membrane fraction (D), and total membrane fraction (Ñ). Both membrane fractions were isolated by a freeze–
thaw method according to Roberts et al. [15] as described by Brouwers et al. [16]. D) Plasmin activity detected by 
cleavage of the plasmin substrate (33 μM) in HBS supplemented with plasminogen (13 μg/mL) and tPA (0.1 μg/mL) 
and 2.6 μg/mL - 167 μg/mL WH in the presence or absence (○) of 5 mM EDTA (□) and 5 mM CaCl2+ (D). E) Plasmin 
activity generated by 2.6 μg/mL - 333 μg/mL WH in 25% normal platelet poor plasma (Sanquin, Amsterdam, the 
Netherlands) in the presence (○) or absence (□) of tPA (0.1 μg/mL) as detected by cleavage of the plasmin substrate 
(33 μM). For all experiments, initial rates of fluorescence are represented as mean ± SD. All values represent three 
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replicates of duplo measurements. Statistical analyses were performed using GraphPad Prism 7 (GraphPad 
Software, Inc., La Jolla, CA, USA). Significant differences from control conditions (reagents themselves without 
parasites) were calculated using a one-way analysis of variance (ANOVA) and Bonferroni as the post hoc test. 
p-values were considered significant at p ≤ 0.05 (**** indicates p ≤ 0.0001).
of the parasite and is in line with the findings of Fiqueiredo et al. [6]. In contrast, 
the conversion of plasminogen to plasmin by S. bovis tegument extracts has been 
described to occur in the absence of tPA as well [2], indicating the possibility of species 
differences in the mechanisms used for plasminogen activation. 
To further elucidate the S. mansoni molecules that could be involved in the interaction 
with the fibrinolytic system, we examined to what extent different extracts of S. 
mansoni are able to convert plasminogen to plasmin (Fig. 1C). Four different extracts 
were examined: WH, a soluble protein fraction, a tegumental membrane fraction 
and a total membrane fraction. Plasminogen activating activity was found in all 
examined fractions of the worm. The profound differences in protein composition of 
these fractions indicate that it is unlikely that a single S. mansoni protein is responsible 
for the observed conversion of plasminogen to plasmin. This hypothesis is further 
strengthened by the fact that suppression of enolase expression by RNAi described by 
Figueiredo et al. did not affect the ability of the worms to activate plasminogen, while 
S. mansoni enolase is known to enhance the conversion of plasminogen to plasmin 
[6]. Furthermore, addition of a chelating agent (EDTA) or an excess of Ca2+-ions did 
not significantly alter the conversion of plasminogen to plasmin by S. mansoni WH 
(Fig. 1D), indicating that the observed activity is most likely not mediated by the known 
S. mansoni plasminogen-binding protein, enolase [6], or a homologue to the annexin 
protein described for S. bovis [5], as both their activity is dependent on bivalent metal 
ions. However, it is not known whether the catalytic activity, dependent on bivalent 
metal ions, is necessary for the role of enolase and annexin in the conversion of 
plasminogen to plasmin. 
Next, we examined whether the conversion of plasminogen to plasmin by S. mansoni 
also occurs in a plasma environment, as all plasminogen activation experiments 
performed to date have been done with purified plasminogen in a buffer environment. 
As shown in Fig. 1E, the S. mansoni soluble protein fraction can activate plasminogen 
in plasma. The activation of plasminogen by S. mansoni soluble proteins is strongly 
enhanced by the addition of tPA. However, some activation of plasma plasminogen is 
observed without addition of tPA, which suggests some tPA-independent conversion 
of plasminogen to plasmin at high concentrations of S. mansoni soluble proteins.
The strict tPA-dependence of S. mansoni plasminogen converting activity, led us to the 
hypothesis that tPA may be bound by components at the outer surface of S. mansoni, 
similar to what was described for plasminogen. Therefore, we examined the presence 
of tPA binding proteins in adult S. mansoni. An S. mansoni soluble protein fraction was 
separated by SDS-PAGE and tPA binding proteins were visualized with subsequent 
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ligand blotting (Fig. 2A). This revealed the presence of numerous tPA binding proteins 
with sizes varying from 15 kDa to 250 kDa. Although tPA is also known to bind to partially 
denatured proteins through specific recognition of cross-β structures by the tPA finger 
domain [8], it is unlikely that this is the reason why so many tPA binding proteins in the 
ligand blot are observed. Clear bands are detected instead of a smear and there are 
clear differences between the bands observed in the SDS-PAGE and the ligand blot. 
This suggests the recognition of specific (linear) epitopes of S. mansoni proteins by tPA. 
Further experiments demonstrated that the interactions between tPA and S. mansoni 
proteins are not affected by the addition of the lysine-analog ε-aminocaproic acid 
(ε-ACA) as demonstrated by ligand blotting (Fig. 2B), suggesting that the interaction 
between tPA and S. mansoni proteins is lysine-independent. 
Next, a pull-down assay with tPA was performed on the S. mansoni soluble protein 
fraction (Fig. 2C). The aim of this experiment was to identify tPA binding proteins 
exposed on the outer surface of the worm. A limitation of this pull-down assay is that 
it can only be performed with solubilized or soluble proteins, and thus a tegumental 
membrane fraction cannot be used in this assay. However, there is considerable 
overlap between proteins present in the soluble protein fraction and in the S. mansoni 
tegument, which is why we choose to analyze the S. mansoni soluble protein fraction 
in the pull-down assay. The pull-down assay was performed with biotin-labeled tPA 
(tPA-PPACK-biotin), in which tPA is inhibited in its active site by biotin-labeled Phe-Pro-
Arg-Chloromethyl ketone (PPACK-biotin). In interaction studies, the use of this indirect 
labeling strategy is advantageous over the more commonly used amine-coupling 
based strategy, as labeling with PPACK-biotin does not affect binding sites on relevant 
domains of tPA. After separation of the proteins with SDS-PAGE, three bands were 
observed that clearly differed between the pull-down with and without tPA-PPACK-
biotin at ~100 kDa, ~70 kDa, and ~30 kDa, respectively. The protein band with a 
molecular weight of ~70 kDa that was observed only in the tPA-PPACK-biotin positive 
condition, most likely consists of the tPA that has been used in the pull-down, as tPA 
has a molecular weight of 68 kDa. In order to identify tPA binding proteins from the 
pull-down assay, lanes were divided into 12 bands of approximately equal size and 
proteins were subjected to in-gel tryptic digestion as described by Shevchenko et al. 
[9] and analyzed with LC-MS/MS. Analysis of the data was performed with Proteome 
Discoverer using the Swiss-Prot database limited to Rodentia as taxonomy, to exclude 
any contaminating host (Golden hamster) proteins from the analysis, and the S. 
mansoni database (Schistosoma_mansoni_v5.2.fa, Wellcome Trust Sanger Institute, 
Hinxton, UK, accessible from ftp://ftp.sanger.ac.uk/pub/pathogens/Schistosoma/
mansoni/Latest_assembly_annotation_others/) for annotation of the peptides. 
Tegument localization of the identified proteins was based upon a literature search 
for tegumental proteome studies performed for S. mansoni [10–12]. LC-MS/MS analysis 
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Figure 2. tPA Ligand blotting and pull-down experiments reveal tPA binding proteins of S. mansoni.
A) SDS-PAGE and tPA ligand blot of S. mansoni soluble protein fraction. SDS-PAGE was performed 
with 30 μg S. mansoni soluble protein fraction per lane in 3x sample buffer (187 mM Tris-Cl (pH 6.8), 
30% (v/v) glycerol, 6% SDS, 0.003% Bromophenol blue) on a 10-wells Bolt™ 4-12% Bis-Tris Plus Gel 
(ThermoFischer Scientific, Waltham, MA, USA). SDS-PAGE was performed in Bolt™ MOPS SDS Running 
Buffer (Thermo Fisher Scientific, Waltham, MA, USA) for 45 minutes at 165V. Protein bands were 
visualized with PageBlue™ Protein Staining Solution (Thermo Fisher Scientific, Waltham, MA, USA) for 1h 
at RT. For ligand blotting, SDS-PAGE separated proteins were transferred onto an Immobilon®-FL PVDF 
membrane (Merck, Darmstadt, Germany) at 125V for 60 minutes in blotting buffer (25 mM Tris-HCl, 192 
mM glycine, 20% ethanol) and blocked with blocking buffer (0.5x Odyssey® Blocking Buffer (TBS) (LI-
COR Biosciences, Lincoln, NE, USA)) for 1 hour at RT. Blots were washed with TBS-0.05% Tween20 (TBST) 
and incubated with 50 ug/mL tPA in blocking buffer overnight at 4°C. Blots were washed with TBST and 
bound tPA was detected by incubation with a monoclonal mouse anti-human tPA antibody (ab21049, 
Abcam, Cambridge, UK) in blocking buffer (1:3,000) for 2 hours at RT. Blots were washed with TBST and 
the primary antibody was detected with IRDye 800 donkey anti-mouse IgG in blocking buffer (1:5000) 
for 2 hours at RT. Blots were washed with TBST and analyzed on a near-infrared Odyssey scanner 
(LI-COR Biosciences, Lincoln, NE, USA). B) Ligand blots of S. mansoni soluble protein fraction (30 μg/
lane) with or without the addition of 25 mM ε-aminocaproic acid (ε-ACA) during the tPA incubation 
step. C) Pull-down experiment of S. mansoni soluble protein fraction with PPACK-biotin-labelled tPA. tPA 
(2 mg/mL in water) was incubated with PPACK-biotin (339 μM) (Biotinylated FPR-chloromethylketone, 
BFPRCK-06, Haematologic Technologies Inc., Essex Junction, VT, USA) for 1 hour at 37°C, followed by 
purification of the PPAC-biotin-labelled tPA with a 5 mL Zeba Spin Desalting Columns (Thermo Fisher 
Scientific, Waltham, MA, USA) following the manufacturer’s instructions. S. mansoni soluble protein 
fraction (1.6 mg/mL) was incubated with or without PPACK-biotin-labelled tPA (100 μg/mL) for 1 hour 
at RT, followed by 30 minutes incubation at RT with 4.6% Pierce™ streptavidin agarose (Thermo Fisher 
Scientific, Waltham, MA, USA). Beads were washed twice with HBS, transferred in 3x sample buffer 
and boiled for 10 minutes at 100 °C. Samples were separated with SDS-PAGE and protein bands were 
visualized with PageBlue™ Protein Staining Solution as described above. Protein bands that are 
exclusively visualized in the pull-down with tPA-PPACK-biotin are indicated by black arrowheads. 
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revealed the presence of at least 10 tegumental proteins that were exclusively present in 
the tPA-PPACK-biotin positive lane (Supplemental Table 1A). Additionally, 24 tegumental 
proteins were found that were enriched in the tPA-PPACK-biotin positive lane, but also 
present in the control lane (Supplemental Table 1B). Supplemental table 1C and 1D 
show the non-tegumental proteins that were exclusively present (35) or enriched 
(30) in the tPA-PPACK-biotin positive lane compared to the tPA-PPACK-biotin negative 
lane, respectively. Amongst the tegumental proteins that were enriched or exclusively 
present in the tPA-PPACK-biotin positive lane, several classical tegument proteins were 
identified, including glutathione S-transferase, GAPDH, and leucine aminopeptidase 
[13]. Interestingly, the tegumental proteins that are identified exclusively in the tPA-
PPACK-biotin positive lane have very diverse functions, including signal transduction, 
metabolic functions, cytoskeletal organization, stress response and chaperones, and 
peptidase activities. This would indicate that proteins with diverse functions have an 
affinity for tPA, which would explain why so many proteins were found to bind tPA. 
Several identified proteins that were enriched in the tPA-PPACK-biotin positive lane 
were previously identified as plasminogen-binding proteins, such as GAPDH, FBA, and 
enolase, suggesting a potential double role for these proteins in the interaction with 
the fibrinolytic system. However, some of the identified tPA binding proteins in the 
tegument may not be exposed on the outside of the worm, as has been described for 
FBA [7], and therefore these proteins may not be available for binding of tPA. 
Of the 10 tegumental proteins exclusively present in the tPA-PPACK-biotin positive lane, 
major vault protein and chaperonin containing TCP1 are the most abundant proteins, and 
these proteins are involved in signal transduction and protein folding, respectively. Of the 
24 tegumental proteins that were found to be enriched in the tPA-PPACK-biotin positive 
lane, tubulin and GAPDH were the most abundant proteins. Tubulin is a cytoskeletal 
protein, while GAPDH is a metabolic protein and has additionally been demonstrated to 
be able to bind plasminogen and enhance its conversion to plasmin. However, the most 
enriched proteins are cathepsin B, a gut cysteine peptidase, a heat shock 70 kDa protein, 
involved in stress responses, and calpain, a calcium-dependent cysteine peptidase.
Of the non-tegumental proteins exclusively present in the tPA-PPACK-biotin positive 
lane glutamyl tRNA synthetase is the most abundant protein identified, while for the 
non-tegumental proteins enriched in the tPA-PPACK-biotin positive lane again tubulin 
and actin proteins are the most abundant. 
Further investigation is required to identify the S. mansoni proteins that could interact 
with tPA on the outer surface of the parasite. Nonetheless, the large number of 
tegumental proteins identified as enriched or exclusively present in the tPA-PPACK-
biotin positive lane indicates that S. mansoni tegument contains many proteins that 
can interact with tPA and could be involved in binding of tPA to the outer surface of 
the parasite, allowing acceleration of activation of plasminogen to plasmin.
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Supplementary methods
LC-MS/MS analysis of tPA-PPACK-biotin pull-down and control samples
After digestion samples were analyzed on an Orbitrap Q-Exactive (Thermo Fisher 
Scientific, Waltham, MA, USA) connected to a UHPLC Proxeon Easy-nLC 1000 
(Thermo Fisher Scientific, Waltham, MA, USA). Peptides were trapped on a double-
fritted trap column (Dr. Maisch Reprosil C18, 3 μm, 2 cm × 100 μm (Dr. Maisch HPLC 
GmbH, Ammerbuch-Entringen, Germany)) and separated on an analytical column 
(Agilent Zorbax SB-C18, 1.8 μm, 40 cm × 75 μm (Agilent, Santa Clara, CA, USA)). Solvent 
A consisted of 0.1 M acetic acid, solvent B of 0.1 M acetic acid in 80% acetonitrile. 
Samples were loaded at a pressure of 800 bar with 100% solvent A. Peptides were 
separated by a 30 min gradient of 10–37% buffer B followed by 30–100% B in 2 min, 
100% B for 2.5 min at a flow rate of 150 nL/min. Full scan MS spectra were acquired in 
the Orbitrap (350-1500 m/z, resolution 35,000, AGC target 3e6, maximum injection 
time 250 ms). The 20 most intense precursors were selected for HCD fragmentation 
(isolation window 1.2 Da, resolution 17,500, AGC target 5e4, maximum injection time 
120 ms, first m/z 100, NCE 33%, dynamic exclusion 60 s). The results were filtered using 
Percolator (Käll et al.[1] and Spivak et al.[2]) to a false discovery rate (FDR) below 1%. 
We further only accepted peptides with at least six amino acid residues, a Mascot 
ion score of at least 20, and search engine rank of 1 and at least 2 identified peptides 
for protein identification. Scores (Mascot ion score) and peptide spectrum matches 
(PSM; total number of identified peptide spectra matched for the protein) were used 
to compare the samples. Only proteins that showed a minimum PSM score of 4 and at 
least a two times enrichment in PSM were considered as enriched proteins.
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Supplementary Table 1A: Tegumental protein identifications present exclusively in the tPA-
PPACK-biotin pull-down fraction and absent in the control fraction.
Score PSM
Accession 
number
Product Control 
lane
Positive 
lane
Control 
lane
Positive 
lane
Localization
Smp_006740.1 Major vault protein - 718 - 35 Tegument and non-tegumenta
Smp_149900.1 Chaperonin containing TCP1,  
subunit 7 (eta)
- 496 - 40 Tegument and non-tegumenta
Smp_143150.1 Elongation factor 2 - 334 - 22 Tegument and non-tegumenta
Smp_037230.1 Fimbrin - 207 - 9 Tegumentb
Smp_075790.1 Hemoglobinase (C13 family) - 178 - 10 Tegumentc
Smp_030000.1 Leucine aminopeptidase (M17 family) - 172 - 12 Tegument and non-tegumenta
Smp_054160.1 Glutathione S-transferase class-mu  
28 kDa isozyme
- 172 - 11 Tegument and non-tegumenta
Smp_059790.1 Transketolase - 150 - 7 Tegument and non-tegumenta
Smp_004600.1 T complex protein 1 subunit delta - 136 - 8 Tegumentd
Smp_050390.1 Aldehyde dehydrogenase - 57 - 6 Tegument and non-tegumenta
a Proteins reproducibly identified by van Balkom et al. in both the tegumental and non-tegumental fraction of S. 
mansoni (van Balkom et al., supplemental table 1c [3])
b Proteins reproducibly and exclusively identified by van Balkom et al. in the tegumental fraction of S. mansoni 
(van Balkom et al., supplemental table 1a [3])
c Tegumental proteins identified through enzymatic shaving of the tegument surface of S. mansoni by Castro-
Borges et al. (Castro-Borges et al., table 1 [4]).
d Tegumental proteins of S. mansoni identified by Braschi et al. (Braschi et al., table 1 [5]).
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Supplementary Table 1B: Tegumental protein identifications present in both pull-down fractions, 
but enriched in the tPA-PPACK-biotin fraction compared to the control fraction.
Score PSM
Accession 
number
Product Control 
lane
Positive 
lane
Ratio Control 
lane
Positive 
lane
Ratio Localization
Smp_078040.1 Tubulin subunit beta 5906 15031 2.5 232 501 2.2 Tegument and 
non-tegumenta
Smp_056970.1 Glyceraldehyde 3 phosphate 
dehydrogenase
5238 10924 2.1 216 427 2.0 Tegument and 
non-tegumenta
Smp_043670.1 ATP-dependent  
6-phosphofructokinase
338 2105 6.2 15 83 5.5 Tegument and 
non-tegumenta
Smp_041740.1 T complex protein 1 subunit gamma 76 740 9.8 4 49 12.3 Tegumentc
Smp_042160.2 0-bisphosphate aldolase 227 734 3.2 6 21 3.5 Tegument and 
non-tegumente
Smp_030300.2 Endoplasmin 249 676 2.7 8 26 3.3 Tegument and 
non-tegumenta
Smp_017360.1 T complex protein 1 subunit alpha 55 630 11.5 3 38 12.7 Tegumentc
Smp_099870.1 Eukaryotic translation elongation  
factor 1 alpha
350 623 1.8 14 31 2.2 Tegument and 
non-tegumenta
Smp_103610.1 Cathepsin B-like cysteine proteinase 84 612 7.3 6 35 5.8 Tegument and 
non-tegumenta
Smp_049270.1 Major egg antigen (p40) 174 580 3.3 11 26 2.4 Tegumentb
Smp_038950.1 Lactate dehydrogenase protein 57 536 9.3 5 23 4.6 Tegument and 
non-tegumenta
Smp_148530.1 Major egg antigen 100 398 4.0 6 15 2.5 Tegumentc
Smp_004990.1 T complex protein 1 subunit zeta 83 390 4.7 8 23 2.9 Tegumentc
Smp_106930.1 Heat shock 70 kDa protein homolog 31 374 11.9 1 22 22.0 Tegument and 
non-tegumenta
Smp_065610.2 Pyruvate kinase isozymes M1:M2 72 373 5.2 2 20 10.0 Tegument and 
non-tegumenta
Smp_054340.1 Chaperonin containing t complex 
protein 1 beta
96 359 3.8 15 34 2.3 Tegumentc
Smp_214190.1 Calpain 26 348 13.5 1 21 21.0 Tegument and 
non-tegumenta
Smp_067060.1 Cathepsin B-like cysteine proteinase 22 316 14.5 1 23 23.0 Tegument and 
non-tegumente
Smp_024110.1 Enolase 65 249 3.8 2 15 7.5 Tegument and 
non-tegumenta
Smp_043120.1 Universal stress protein 129 233 1.8 3 10 3.3 Tegument and 
non-tegumenta
Smp_214060.1 Phosphoglycerate kinase 39 159 4.1 1 7 7.0 Tegument and 
non-tegumenta
Smp_186020.1 Major egg antigen 74 144 1.9 6 13 2.2 Tegumentb
Smp_027610.1 Ribosomal protein S3 98 110 1.1 8 7 2.0 Tegument and 
non-tegumente
Smp_079430.1 GTP binding nuclear protein Ran 45 80 1.8 2 8 4.0 Tegumentd
a Proteins reproducibly identified by van Balkom et al. in both the tegumental and non-tegumental fraction of S. 
mansoni (van Balkom et al., supplemental table 1c [3])
b Proteins reproducibly and exclusively identified by van Balkom et al. in the tegumental fraction of S. mansoni 
(van Balkom et al., supplemental table 1a [3])
c Tegumental proteins of S. mansoni identified by Braschi et al. (Braschi et al., table 1 [5]).
d Proteins exclusively identified by van Balkom et al. in the tegumental fraction of S. mansoni (van Balkom et al., 
supplemental table 2a [3])
e Proteins identified by van Balkom et al. in both the tegumental and non-tegumental fraction of S. mansoni (van 
Balkom et al., supplemental table 2c [3])
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Supplementary Table 1C: Non-tegumental protein identifications present exclusively in the tPA-
PPACK-biotin pull-down fraction and absent in the control fraction.
Score PSM
Accession number Product Control 
lane
Positive 
lane
Control 
lane
Positive 
lane
Smp_138930.1 Glutamyl tRNA synthetase cytoplasmic - 607 - 25
Smp_099310.1 Protein transport protein SEC23 - 452 - 9
Smp_033040.1 L lactate dehydrogenase - 348 - 13
Smp_000030.2 26s proteasome regulatory particle subunit - 303 - 12
Smp_034670.1 Tubulin gamma 1 chain - 286 - 14
Smp_004910.1 RAB14, member RAS oncogene family - 255 - 9
Smp_142630.1 Talin - 243 - 4
Smp_123440.1 Cytoplasm protein - 236 - 11
Smp_099800.1 Uncharacterized protein - 204 - 11
Smp_101290.1 Actin protein 2, arp2 - 183 - 7
Smp_134860.1 Translational activator gcn1 - 181 - 8
Smp_213550.1 Pad1 homolog - 171 - 6
Smp_095910.1 Signal recognition particle receptor subunit - 162 - 8
Smp_003660.1 Spliceosome RNA helicase DDX39B - 149 - 7
Smp_033250.1 Hypothetical protein - 134 - 7
Smp_056890.1 Nitrilase - 131 - 5
Smp_032260.1 Ribosomal protein L15 - 129 - 7
Smp_133390.1 CAP Gly domain containing linker protein 4 - 126 - 4
Smp_157410.1 Dynein heavy chain - 123 - 8
Smp_194910.1 Saposin B domain containing protein - 121 - 5
Smp_149040.1 Phosphorylase b kinase regulatory - 119 - 5
Smp_210430.1 Ras protein Rab 1A - 118 - 5
Smp_074020.1 AP 2 complex subunit alpha 2 - 106 - 4
Smp_145700.1 Ankyrin :unc - 104 - 6
Smp_132690.1 RuvB protein 2 - 96 - 6
Smp_155720.1 Glycogen synthase kinase 3 - 92 - 5
Smp_015090.1 Coatomer subunit beta' - 89 - 6
Smp_000870.1 FYVE, RhoGEF and PH domain containing protein 4 - 89 - 5
Smp_053220.2 Aldo keto reductase family 1, member B4 - 87 - 5
Smp_064050.1 Ruvb reptin and pontin - 83 - 6
Smp_009580.1 Ubiquitin - 75 - 5
Smp_079000.1 Charged multivesicular body protein 1b 2 - 70 - 4
Smp_149610.1 Hypothetical protein - 63 - 5
Smp_099030.1 Casein kinase ii subunit alpha - 53 - 4
Smp_049550.1 78 kDa glucose regulated protein - 45 - 4
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Supplementary Table 1D: Non-tegumental protein identifications present in both pull-down 
fractions, but enriched in the tPA-PPACK-biotin fraction compared to the control fraction.
Score PSM
Accession number Product Control 
lane
Positive 
lane
Ratio Control 
lane
Positive 
lane
Ratio 
Smp_030730.1 Tubulin beta 2B chain 7065 16234 2.3 259 537 2.1
Smp_090120.2 Alpha tubulin 1633 4203 2.6 87 218 2.5
Smp_072330.1 Heat shock protein 233 2865 12.3 14 117 8.4
Smp_102040.3 Receptor for activated PKC 528 1530 2.9 20 64 3.2
Smp_147050.1 V type proton atpase catalytic subunit a 150 1196 8.0 4 37 9.3
Smp_018240.2 Transitional endoplasmic reticulum atpase 98 874 8.9 4 50 12.5
Smp_069130.1 Heat shock protein 105 kDa 49 695 14.1 2 18 9.0
Smp_119310.1 26S proteasome subunit RPT6 73 610 8.3 3 32 10.7
Smp_072870.1 Alpha centractin 58 579 9.9 7 26 3.7
Smp_090080.1 Estrogen regulated protein EP45 83 472 5.7 6 16 2.7
Smp_048560.1 Four and a half LIM domains protein 2 131 465 3.6 5 15 3.0
Smp_013470.2 small subunit ribosomal protein S2e 34 464 13.8 1 24 24.0
Smp_097660.1 Eukaryotic initiation factor 4A 82 456 5.6 5 29 5.8
Smp_042270.1 26S proteasome subunit ATPase 3 291 382 1.3 7 19 2.7
Smp_057320.1 Vesicle fusing ATPase 1 38 303 8.0 1 18 18.0
Smp_056360.4 P30 dbc protein 29 303 10.4 1 12 12.0
Smp_207010.1 Signal recognition particle 72 kDa subunit 44 247 5.6 1 10 10.0
Smp_071140.1 Adducin related protein 46 219 4.8 2 11 5.5
Smp_025510.1 Vacuolar protein sorting associated protein 4A 38 193 5.1 1 10 10.0
Smp_012470.1 26S proteasome subunit ATPase 2 42 174 4.1 2 9 4.5
Smp_059290.2 Dual specificity protein phosphatase 23 77 168 2.2 3 9 3.0
Smp_017070.1 26S proteasome subunit RPT4 30 157 5.2 2 13 6.5
Smp_138920.2 COP9 signalosome complex subunit 59 156 2.7 2 4 2.0
Smp_173840.1 26S proteasome subunit ATPase 4 35 140 4.0 1 4 4.0
Smp_011570.2 Ribosomal protein S4 24 120 5.1 2 10 5.0
Smp_170110.1 High density lipoprotein binding protein 46 100 2.2 3 6 2.0
Smp_001040.1 Kinesin heavy chain 21 98 4.8 1 8 8.0
Smp_058650.1 26S proteasome non ATPase regulatory subunit 43 95 2.2 2 6 3.0
Smp_072340.1 26S proteasome subunit RPT3 35 92 2.6 1 6 6.0
Smp_061650.1 26S proteasome non ATPase regulatory subunit 0 42 - 1 6 6.0
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Abstract 
Cathepsin peptidases form a major component of the secreted proteins of the blood-
feeding trematodes Fasciola hepatica and Schistosoma mansoni. These peptidases 
fulfill many functions, from facilitating infection to feeding and immune evasion. In 
this study, we examined the Fasciola cathepsin L peptidases FhCL1, FhCL2, and FhCL3 
and the schistosomal cathepsin peptidases SmCB1 and SmCL3 for their anticoagulant 
properties. Although no direct anticoagulant effect of these peptidases was 
observed, we discovered that cathepsin peptidases from Fasciola, but not from 
Schistosoma, were able to degrade purified fibrinogen, with FhCL1 having the highest 
fibrinogenolytic activity. Additionally, FhCL1 and FhCL2 both efficiently degraded 
fibrin. The lack of a direct anticoagulant or fibrinolytic effect of these peptidases is 
explained by their inhibition by plasma components. However, within the parasite gut, 
high concentrations of these peptidases could induce an anticoagulant environment, 
facilitating blood-feeding for extended periods.
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Secreted peptidases play a crucial role in the life cycle of trematodes, both in the 
immature and mature stages. Of special interest are cathepsin peptidases, which are 
papain-like cysteine peptidases, that make up a large proportion of the transcriptome 
of trematodes (10-27%) [1] and their secretome [2]. These secreted cathepsin 
peptidases fulfill a broad range of functions from facilitating infection, acquisition 
of nutrients, tissue migration, and immune suppression [1]. In addition, secretomes 
of blood-feeding parasites, such as leeches or hookworm species, often contain a 
repertoire of peptides and peptidases with anticoagulant properties, to allow blood-
feeding for extensive periods [3,4]. 
Fasciola and Schistosoma species are well studied examples of trematodes that feed 
on blood components. Cathepsins are the major components of the secretome of 
both Fasciola hepatica and Schistosoma mansoni [5–7]. In this study, we examined the 
anticoagulant capacities of several cathepsin peptidases from these blood-feeding 
trematodes: F. hepatica Cathepsin L 1 (FhCL1), FhCL2, FhCL3, S. mansoni Cathepsin B 1 
(SmCB1), and S. mansoni Cathepsin L 3 (SmCL3). Cathepsin L peptidases are the most 
abundantly secreted peptidases from F. hepatica. FhCL3 is known to cleave collagen and is 
mostly secreted by newly excysted juveniles (NEJs) upon penetration through the gut wall, 
accounting for 37% of the NEJs secretome [7]. FhCL1 and FhCL2 are major components 
of bile duct-residing, adult parasite secretions, and represent 69% and 22% of the adult 
secretome, respectively [7]. They are known to be involved in the cleavage of hemoglobin, 
collagen, IgG, fibronectin, and laminin [8–11]. SmCB1 is the most abundant cysteine 
peptidase in adult S. mansoni residing in the mesenteric veins and is, like FhCL1 and FhCL2, 
involved in the cleavage of hemoglobin, IgG, serum albumin, but also α-2-macroglobulin 
[5,12]. SmCL3 is a gut-associated, but not secreted, peptidase of schistosomula and adult 
S. mansoni and is involved in the digestion of host proteins such as serum albumin and 
hemoglobin [13]. All five peptidases were recombinantly expressed in Pichia pastoris and 
activated as previously described [6,13–15]. Anticoagulant properties of these peptidases 
were first examined with clot lysis time assays [16], with thrombin generation assays [17], 
and with fibrin formation assays in which fibrin was formed in 3x diluted trisodiumcitrate 
anticoagulated plasma by addition of 4 μM phospholipids (40% phosphatidylcholines, 
40% phosphatidylethanolamines, and 20% phosphatidylserines), 10 mM CaCl
2
, in the 
absence or presence of tissue factor (1 pM or 5 pM). However, no anticoagulant effect of 
the peptidases was found with these assays (data not shown). 
In order to assess whether the expressed peptidases may have a fibrinolytic effect, 
cleavage of the plasmin substrate Boc-val-leu-lys-AMC was examined (Fig. 1A). FhCL1, 
FhCL2 and SmCB1 were able to cleave the plasmin substrate, generating a fluorescent 
signal. This indicates a potential fibrinolytic activity of these peptidases. 
To examine this potential fibrinolytic activity, lysis of fibrin was assessed for the F. 
hepatica and schistosomal peptidases on a fibrin gel using plasmin as a positive 
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control (Fig. 1B, C). FhCL1 and FhCL2 demonstrated lysis of the fibrin gel after the 
incubations as visible by the formation of transparent circles (Fig. 1B). FhCL3 did not 
lyse the fibrin gel, consistent with the absence of cleavage of the plasmin substrate 
(Fig. 1B). We also found that none of the schistosomal peptidases was able to lyse 
the fibrin gel within 24 hours (Fig. 1C), despite the ability of SmCB1 to cleave plasmin 
substrate (Fig. 1A). 
Next, fibrinogenolytic activity of the studied cysteine peptidases was assessed 
through analysis of the hydrolysis of purified fibrinogen with SDS-PAGE, as described 
previously [18] (Fig. 1D-H), and compared to cleavage of fibrinogen by plasmin (Fig. 
1i). Interestingly, all three tested F. hepatica peptidases were able to cleave fibrinogen, 
as demonstrated by degradation of the fibrinogen α-chain (66 kDa), β-chain (52 kDa) 
and γ-chain (46.5 kDa) (Fig. 1D-F). FhCL1 has a larger fibrinogenolytic activity than 
FhCL2 and FhCL3 and is capable of degradation of the fibrinogen α-chain, β-chain, 
and γ-chain. FhCL2 and FhCL3 demonstrate only minor cleavage of the γ-chain and 
slower cleavage of the α-chain and β-chain compared to FhCL1. For all F. hepatica 
peptidases cleavage of the α-chain proceeded faster than cleavage of the β-chain and 
γ-chain. The cleavage pattern of the F. hepatica peptidases showed major differences 
with that of plasmin, indicating distinct cleavage sites of these peptidases. Plasmin 
seemed to degrade first the β-chain and γ-chain, with the α-chain still present after 4h 
of incubation. Lastly, consistent with the lack of fibrinolytic activity, both schistosomal 
peptidases did not demonstrate any fibrinogenolytic activity (Fig. 1G,H).
These results show that FhCL1 compared to FhCL2, is much more active in degrading 
the plasmin-substrate (Fig. 1A) and fibrinogen (Fig. 1D,E), but their activity towards 
fibrin is similar (Fig 1B). Therefore, the activity of these peptidases is strongly dependent 
on the actual substrate. Differences in substrate specificity have been described for 
the F. hepatica peptidases [6], where FhCL1 most efficiently cleaves substrates with 
hydrophobic residues at the P2 position (including Z-FR-NHMec and Boc-VLK-NHMec) 
while FhCL2 and FhCL3 have a preference for Pro-containing substrates and they 
cleave substrates with Phe and Leu in the P2 position much less effectively. Likewise, 
different K
m
 values of SmCB1 and SmCL3 for the Z-FR-AMC substrate have been 
described [12,13], indicating differences in substrate specificity for substrates with a 
hydrophobic residue at the P2 position. 
From these experiments it is clear that the studied F. hepatica peptidases, but not the 
schistosomal peptidases, contain both fibrinogenolytic (FhCL1, FhCL2 and FhCL3) and 
fibrinolytic (FhCL1 and FhCL2) activity on purified fibrinogen and fibrin. This, however, 
contrasts with our first findings that these peptidases do not affect fibrin formation 
and clot lysis times in plasma. Therefore, we next sought an explanation for this 
discrepancy by examining the effect of plasma on the proteolytic activity of these 
peptidases (Fig. 2). Proteolytic activity of FhCL1, FhCL2, FhCL3, and SmCL3 on fluorogenic
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Figure 1. Fibrinogenolytic and fibrinolytic activities  
of secreted peptidases of F. hepatica and S. mansoni.
A) Cleavage of plasmin substrate (Boc-Val-Leu-Lys-AMC, Bachem, Bubendorf, Switzerland) in HBS (10 mM HEPES, 
150 mM NaCl, pH 7.4) by 20 nM of peptidases of F. hepatica (FhCL1, FhCL2, and FhCL3) and S. mansoni (SmCL3 and 
SmCB1). Recombinant peptidases were produced in Pichia pastoris and purified as previously described [6,13,14] 
and activated for 10 min at 37°C in reaction buffer (2.5 mM EDTA, 0.1 M Sodium Citrate, 2 mM DTT, pH 5.0). SmCB1 
was activated with activation buffer (0.1M sodium acetate, 0.1% PEG6000, 1 mM EDTA, 2.5 mM DTT, 10 mg/ml 
Dextran sulphate (Mw 500 kDa), pH 4.5) for 2 h at 37°C [15]. Fluorescence was monitored for 120 minutes at 37°C 
on a Spectromax M2 fluorescence microplate reader (MTX Lab Systems, Bradenton, FL, USA) equipped with a 
390 nm excitation filter and 460 nm emission filter. Initial rates of fluorescence are represented as mean ± SD. All 
values represent three replicates of duplo measurements. Fibrinolytic activity of F. hepatica (B) and schistosomal 
(C) peptidases was assessed on a fibrin gel (representative image of three experiments). Fibrin gels were 
prepared by coagulating 4.9 mg/ml purified human fibrinogen (Enzyme research laboratories, South Bend, IN, 
USA) in HBS with 1 U/ml human alpha-thrombin (Haematologic Technologies, Essex Junction, VT, USA) followed 
by addition of peptidase samples and subsequent incubation at 37°C for up to 24 h. B) Fibrinolytic activity of 10 
μl aliquots of reaction buffer (2.5 mM EDTA, 0.1 M Sodium Citrate, 2 mM DTT, pH 5.0) (1), FhCL1 (10 μM in reaction 
buffer) (2), FhCL2 (10 μM in reaction buffer) (3), FhCL3 (10 μM in reaction buffer) (4), plasmin (streptokinase-
activated plasminogen, 100 μg/ml in reaction buffer) (5), and plasmin (streptokinase-activated plasminogen, 
10 μg/ml in reaction buffer) (6), spotted on a fibrin gel. C) Fibrinolytic activity of 10 μl aliquots of reaction buffer 
(1), SmCL3 (3 μM in reaction buffer) (2), SmCB1 (250 nM in reaction buffer) (3), plasmin (streptokinase-activated 
plasminogen, 100 μg/ml in reaction buffer) (4), and plasmin (streptokinase-activated plasminogen, 10 μg/ml in 
reaction buffer) (5) spotted on a fibrin gel. D-I) Fibrinogenolytic activity of F. hepatica and schistosomal secreted 
peptidases and plasmin was determined on Coomassie brilliant blue stained 10% SDS-PAGE gels with a modified 
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fibrinogenolytic assay [18]. Purified fibrinogen (2 μg/ml in HBS) was incubated at 37°C with 100 nM FhCL1 (D), 100 
nM FhCL2 (E), 100 nM FhCL3 (F), 100 nM SmCL3 (G), 25 nM SmCB1 (H), or 100 nM Plasmin (streptokinase-activated 
plasminogen) (I), respectively. Reactions were terminated by adding denaturing solution (SDS-Page sample 
buffer containing 6.7 M urea, 2% SDS, and 25 mM dithiothreitol) and heating at 100 °C for 10 min (representative 
image of three experiments). The numbers at the top of each lane represent the time (in minutes) when samples 
were taken during the digestion.
peptide substrates was examined in the presence of either citrated or heparinized 
plasma (Fig. 2A-D). Since SmCB1 was activated by dextran sulphate [15] and dextran 
sulphate is a non-physiological trigger for contact system activation in vitro, factor 
XII depleted citrated plasma was used to examine proteolytic activity of SmCB1 in 
plasma (Fig. 2E). Examination of proteolytic activity showed that all five examined 
peptidases were inhibited by plasma components at low concentrations (< 0.1% 
plasma). This inhibition of the peptidases by plasma components explains the 
absence of anticoagulant effects observed in the performed clot lysis and thrombin 
generation assays.
Reduced glutathione (GSH) has been described as an activating agent for FhCL1 
through reduction of the active site cysteine [19]. Therefore, we also examined 
whether addition of GSH to plasma could counteract the inhibitory effect of plasma 
components for FhCL1 and FhCL2 (Fig. 2F,G). However, addition of GSH did not reverse 
the effect of plasma components. Most likely the GSH did not have an additional effect 
to the DTT that was already present in the buffer used to activate the peptidases. 
In the present study, we report the discovery of fibrinogen and fibrin as novel substrates 
for the F. hepatica cathepsin peptidases FhCL1 and FhCL2 and the fibrinogenolytic 
activity of FhCL3. We also examined two schistosomal cathepsin peptidases, SmCL3 
and SmCB1, for their fibrinogenolytic and fibrinolytic activity and found that fibrinogen 
and fibrin are not substrates for these peptidases. As all tested peptidases are 
inhibited by plasma components, we suggest that they most likely do not affect blood 
coagulation in their host. However, secretion of F. hepatica cathepsin L peptidases at 
high concentrations in the parasite gut implies that this may locally overcome the 
inhibitory effect of plasma components and induce an anticoagulant environment 
in the gut through cleavage of fibrinogen and fibrin, allowing blood-feeding by the 
parasite for extended periods. Our finding that schistosomal peptidases are not 
able to cleave fibrinogen or fibrin is in line with the presence of other anticoagulant 
and fibrinolytic strategies adopted by schistosomes (reviewed in [20]). This allows 
schistosomes to counteract fibrin formation at their surface, allowing blood-feeding 
and survival of the parasite within its host.
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Figure 2. Proteolytic activity of F. hepatica  
and schistosomal secreted peptidases is inhibited by human plasma.
Proteolytic activity of FhCL1 (20 nM) (A) or FhCL2 (20 nM) (B) on Boc-Val-Leu-Lys-AMC substrate (Bachem, 
Bubendorf, Switzerland) in HBS in the presence of citrated (open circles) or heparinized human platelet poor 
plasma from healthy donors (closed circles). C) Proteolytic activity of FhCL3 (20 nM) on Z-Pro-Arg-AMC substrate 
(Bachem, Bubendorf, Switzerland) in HBS in the presence of citrated (open circles) or heparinized human platelet 
poor plasma from healthy donors (closed circles). D) Proteolytic activity of SmCL3 (20 nM) on Z-Phe-Arg-AMC 
substrate (Bachem, Bubendorf, Switzerland) in HBS in the presence of citrated (open circles) or heparinized 
human platelet poor plasma from healthy donors (closed circles). Proteolytic activity of dextran sulfate-activated 
SmCB1 (20 nM) on Z-Phe-Arg-AMC substrate (Bachem, Bubendorf, Switzerland) in HBS in the presence of FXII 
depleted human plasma. Proteolytic activity of FhCL1 (20 nM) (F) or FhCL2 (20 nM) (G) on Boc-Val-Leu-Lys-AMC 
substrate (Bachem, Bubendorf, Switzerland) in HBS in the presence of citrated human platelet poor plasma from 
healthy donors without (open circles) or with addition of glutathione (3.3 mM of which 90% was the reduced 
form) (closed circles). Fluorescence was monitored for 120 minutes at 37°C on a Spectromax M2 fluorescence 
microplate reader (MTX Lab Systems, Bradenton, FL, USA) equipped with a 390 nm excitation filter and 460 nm 
emission filter. Proteolytic activity is displayed as a percentage (mean ± SD) of the activity without addition of 
plasma (100%, dotted line). All values represent three replicates of duplo measurements.
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Parasitic worms interact with their host on multiple levels and often for prolonged 
periods. The parasite interacts with a variety of host cells during migration, acquisition 
of nutrients, and reproduction. Additionally, parasites are continuously exposed to the 
host immune system and have to evade ongoing immune responses. Furthermore, 
blood-dwelling and blood-feeding parasites interact for prolonged periods with the 
haemostatic system of their host. Indeed, changes in blood coagulation have been 
observed in infections with various helminths, including Schistosoma and Fasciola [1,2]. 
These helminths, as well as other blood-feeding or blood-dwelling parasites, have 
been proposed to possess a variety of molecular mechanisms to modify their host’s 
coagulation system. The work described in this thesis provides (1) an overview of the 
currently identified blood coagulation modification mechanisms of schistosomes, (2) 
insight in coagulopathy in urinary schistosomiasis without hepatic dysfunction, and 
(3) identification of novel mechanisms of coagulation modification by the parasitic 
helminths S. mansoni and F. hepatica. These findings will contribute to a better 
understanding of the complex interactions between host haemostasis and parasitic 
helminths.
Coagulation modification by schistosomes: current status
Chapter 2 provides an overview of currently known mechanisms of coagulation 
modification by schistosomes. The large variety of mechanisms that are equipped by 
the parasite, demonstrates that the parasite has a remarkably strong ability to modify 
the host haemostatic response at all levels. In order to modify host haemostasis, the 
parasite uses schistosome-specific mechanisms that inhibit key steps in coagulation 
and exploits or mimics host mechanisms for regulation of haemostasis. 
This overview of coagulation modification raised the question how complete our 
current knowledge of coagulation modification by schistosomes is, and whether it is 
likely that schistosomes possess yet unknown coagulation modification strategies. In 
the five years after the review in Chapter 2 has been published, the research on the 
interactions between schistosomes and haemostasis has continued, which has led 
to novel insights and discoveries in this field. It therefore goes without saying that the 
overview presented in this thesis is now incomplete and requires some updating. 
Several novel molecular mechanisms have been described in adult schistosomes that 
are proven or suggested to affect haemostasis. It has been described that S. mansoni 
can cleave both fibronectin and high-molecular weight kininogen (HK). Fibronectin 
is a plasma protein that is incorporated into blood clots and increases stability of 
platelet aggregates [3]. S. mansoni has been demonstrated to cleave both purified 
fibronectin and plasma fibronectin through a surface associated cysteine peptidase 
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activity [4]. Two calpains, named SmCalp1 and SmCalp2, were recently discovered on 
the outer surface of the adult S. mansoni tegument [4]. These calpains are suggested 
to be involved in both the cleavage of fibronectin [4] and HK [5]. HK is a co-factor 
of the contact activation pathway and acts as a scaffold to localize coagulation 
factor XII (FXII), FXI, and plasma kallikrein (PK) in close proximity of each other on 
anionic surfaces. Cleavage of HK by PK at two cleavage sites results in the release 
of the peptide bradykinin, that stimulates vasodilatation and the release of tissue-
type plasminogen activator (tPA) from the endothelium [6,7]. Additionally, the two 
cleavages of HK by PK convert HK into a two-chain form, which has increased affinity 
for anionic surfaces [8]. The cleavage of HK by schistosomal cysteine peptidases 
is different from cleavage by PK, resulting in different degradation fragments and 
no bradykinin generation [5]. A secreted trypsin-like serine peptidase from adult S. 
mansoni, SmSP2, has also been demonstrated to cleave HK, resulting, in contrast to 
the cysteine peptidase activity, in the release of the vasodilatory peptide bradykinin 
[9]. It was also shown that SmSP2 inactivates the vasoconstrictor vasopressin and 
degrades fibronectin [9]. Furthermore, SmSP2 cleaves tPA into a more active double-
chain tPA form and activates plasminogen to plasmin, thereby both indirectly and 
directly enhancing fibrinolysis [9]. Orthologues of SmSP2 can be found in S. japonicum 
and S. haematobium [9]. Enhancement of fibrinolysis has also been shown for another 
protein of S. mansoni. The tegument associated S. mansoni enolase (SmEno) has 
been demonstrated to bind plasminogen and enhance its activation to plasmin 
in the presence of tPA [10]. However, knock-down of expression of SmEno did not 
affect the capacity of the parasite to enhance fibrinolysis, suggesting redundancy in 
schistosomal mechanisms that enhance fibrinolysis [10].
In addition to several novel peptidases of schistosomes that interact with 
haemostasis, several peptidase inhibitors of schistosomes have been described to 
inhibit components of the haemostatic system and/or affect coagulation times. 
A Kunitz-type peptidase inhibitor, SmKI-1, localized in the tegument and present in 
excretory/secretory products of S. mansoni, was found to inhibit FXa and PK, but not 
thrombin [11]. It delayed blood clot formation approximately three-fold, as reflected 
by increased activated partial thromboplastin time (APTT; contact activation/intrinsic 
pathway) and prothrombin time (PT; extrinsic pathway) [11]. A Kunitz-type peptidase 
inhibitor, SjKI-1, was also identified in S. japonicum [12]. SjKI-1 is highly transcribed in 
adults and eggs, but could only be detected by immunolocalization in eggs trapped 
in the infected mouse intestine wall. [12]. Like SmKI-1, SjKI-1 inhibits FXa and PK, but not 
thrombin. [12]. SjKI-1 prolonged APTT by approximately two-fold, but did not affect 
coagulation times of the extrinsic pathway [12]. Both Kunitz-type peptidase inhibitors, 
SmKI-1 and SjKI-1, also inhibited chymotrypsin, trypsin, and neutrophil elastase [11,12]. 
A second peptidase inhibitor from S. japonicum, SjSPI, is highly expressed in the egg-
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laying adult worm [13]. SjSPI is a serine peptidase inhibitor and inhibits thrombin, 
chymotrypsin, and trypsin [13]. However, the biological significance of SjSPI is not 
clear, since it is not secreted and it is continuously expressed from schistosomula to 
adult worms. As its expression is highest in the egg and adult stages, a possible role in 
maintaining egg physiology or regulation of endogenous serine peptidases has been 
suggested and effects on blood coagulation have not been studied [13].
Besides interactions between adult schistosomes and haemostasis, interactions 
between other schistosome life stages and haemostasis have also been studied. 
A study on the interaction between the eggshell and plasma components has led 
to the finding that the eggshell binds VWF, fibrinogen, and fibronectin [14]. This 
interaction is suggested to facilitate adherence of the eggs to the endothelium 
and mediate subsequent extravasation of eggs [14]. Also, binding of plasminogen 
and enhancement to plasmin does not seem to be restricted to the adult parasite. 
Secretions by S. mansoni cercariae contain the protein SmVAL18, that has been 
demonstrated to bind plasminogen and enhance its conversion to plasmin in the 
presence of urokinase-type plasminogen activator [15]. In contrast to the adult 
parasite where enhancement of plasmin activation is linked to fibrinolysis of blood 
clots, it is suggested that the activation of plasmin by cercariae aids in degradation 
of extracellular matrix components in order to facilitate invasion of the human host. 
Apart from discovery of novel mechanisms for coagulation modification, several studies 
have also provided further insight into already known mechanisms for coagulation 
modification. It is well-known that schistosomes express a number of enzymes that 
catabolize extracellular ATP to adenosine, which has been suggested to interfere with 
platelet activation during schistosomiasis, as described in Chapter 2. Adenosine is 
an inhibitor of ADP-induced platelet aggregation and has immunoregulatory effects, 
which are mostly anti-inflammatory. The schistosomal enzymes that convert ATP 
to adenosine include alkaline phosphatase (SmAP), phosphodiesterase (SmNPP-5), 
and ATP-diphosphohydrolase (SmATPDase1). Based on homology with human 
enzymes, it was implied that all of these enzymes participate in the degradation 
of ATP and ADP, and only SmAP and SmNPP-5 would degrade AMP. Research into 
the relative importance of these three different enzymes in ATP, ADP, and AMP 
conversion, was performed by knocking-down these enzymes [16]. Only the knock-
down of SmATPDase1 significantly impaired the ability of the worm to catabolize ATP 
or ADP, implying that the cleavage steps of ATP and ADP are, unlike these steps in 
humans, non-redundant in schistosomes [16]. In another study, knock-down of SmAP 
has been described to greatly reduce the capacity of the parasite to degrade AMP, 
suggesting that SmAP , and not SmNPP-5, is the major enzyme for the conversion of 
AMP to adenosine [17]. It was therefore concluded that SmNPP-5 does not participate 
in the cleavage of ATP, ADP, or AMP, and that the function of this enzyme at the worm 
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surface is unknown [16]. However, it has been described that parasites in which the 
SmNPP-5 gene is suppressed, fail to establish a robust infection in mice, indicating 
that SmNPP-5 does fulfil an important role during infection [18]. A more recent study 
challenged this conclusion, by demonstrating that SmNPP-5 is capable of hydrolysing 
ADP to inorganic phosphate and that recombinant SmNPP-5 strongly inhibits both 
ADP and collagen induced platelet aggregation [19]. The lack of effect of knock-down 
of SmNPP-5 on the capability to cleave ADP is attributed to the fact that SmATPDase1 
is found in approximately 5-fold greater relative abundance than SmNPP-5 and this 
does not exclude a function of SmNPP-5 in regulation of extracellular ADP [19].
Further studies on schistosomes and haemostasis will, without doubt, lead to further 
understanding of coagulation modification mechanisms of schistosomes and it is to 
be expected that novel coagulation modification strategies will be discovered. This 
is already demonstrated by the content of this thesis, as Chapter 4 of this thesis 
describes a novel interaction between adult schistosomes and VWF, and Chapter 6 
provides further insight into the capacity of schistosomes to enhance fibrinolysis. 
Coagulopathy in schistosomiasis: lessons from 
urogenital schistosomiasis
Having gained more insight into coagulation modification mechanisms of 
schistosomes in Chapter 2, we next focussed on the consequences of coagulation 
modification and schistosomiasis on haemostasis in schistosomiasis patients. 
Clinical studies have demonstrated that patients with hepatosplenic schistosomiasis 
develop complex haemostatic abnormalities, linked to the risk of fatal bleeding from 
gastro-oesophageal varices [1]. These haemostatic abnormalities are characterized 
by decreased levels of both procoagulant and anticoagulant factors, impaired 
coagulation, ongoing thrombin generation, and continuous fibrinolysis, as described 
in more detail in Chapter 3 and reviewed in detail by Tanabe [1]. The liver plays a 
key role in haemostasis as it is the site of both synthesis and clearance of most of 
the proteins involved in coagulation and fibrinolysis, as well as their inhibitors [20]. 
Advanced hepatic disease will therefore result in alterations in haemostasis [20]. 
Nearly all of the studies investigating coagulation changes in schistosomiasis have 
been performed in patients suffering from chronic schistosomiasis with hepatic or 
hepatosplenic pathology. Insight into the contribution of the parasitic infection to 
the observed haemostatic abnormalities is therefore lacking. In Chapter 3 we have 
addressed this by studying haemostatic changes in a small number of schistosomiasis 
haematobium patients without advanced hepatic disease. In the absence of hepatic 
disease, inflammation-mediated endothelial activation results in increased secretion 
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of VWF by the endothelium. Despite the fact that plasma levels of VWF are increased, 
coagulation and fibrinolysis are not activated in these patients, reflected by unaffected 
levels of thrombin-antithrombin complex and D-dimers. Although the small size of the 
study described in Chapter 3 forms a limitation in the generalization of the results to all 
schistosomiasis patients, it still provides the first evidence that the parasite itself does 
not cause the major haemostatic changes observed in hepatosplenic schistosomiasis. 
However, endothelial activation as a result of the parasitic infection could be involved 
in initiation of coagulation abnormalities in hepatosplenic schistosomiasis. Larger 
studies into coagulation abnormalities in schistosomiasis without advanced hepatic 
disease are needed to confirm this.
This raises the question what the contribution of hepatic pathology, the parasitic 
infection, and coagulation modification by the parasite is to the observed coagulation 
changes in hepatosplenic schistosomiasis. Patients with liver disease frequently 
develop complex haemostatic abnormalities, which can lead to both thrombosis 
and bleeding complications. These haemostatic abnormalities can be described as 
“rebalanced haemostasis”. Decreased hepatic function results in parallel decreased 
production of both prothrombotic and antithrombotic coagulation factors [20,21]. 
Thrombin generation is thus preserved in liver disease, and in advanced liver disease 
even hypercoagulation is observed [21]. In schistosomiasis, there is also evidence of 
elevated thrombin generation, as demonstrated by increased levels of thrombin-
antithrombin complex [1]. In liver disease, decreased platelet counts are compensated 
by increased VWF levels [20], which is also observed in schistosomiasis [22] and 
described in Chapter 3. This rebalanced haemostatic system is however easily 
knocked out of balance when the system is stressed, for example during infection, 
resulting in bleeding or thrombotic complications [20,23]. Although bleeding from 
gastro-oesophageal varices also occurs in liver disorders, it is believed that this is not 
a result of altered haemostasis, but rather the result of portal hypertension combined 
with local vascular abnormalities, as both anticoagulant and procoagulant therapy 
do not affect the severity of bleeding [21,24–26]. Also, a hyperfibrinolytic state is 
described in patients with liver disease [20,21] and also in schistosomiasis [1], although 
it remains uncertain whether this is true accelerated fibrinolysis, or whether it reflects 
decreased hepatic clearance of markers of fibrinolysis, such as D-dimer [1,21]. 
Thus, in liver disease there is a state of rebalanced haemostasis that is more easily 
tipped out of balance when the system is stressed, for example during infection [23]. The 
coagulopathy observed in schistosomiasis has all the characteristics of rebalanced 
haemostasis, where the parasitic infection and the resulting immune response could 
bring the system out of balance. The highly procoagulant nature of the eggshell 
[14,27] and pro-inflammatory cytokines produced during infection, such as TNF-α 
and IL-1β [28,29], could trigger inflammation-mediated endothelial activation, as 
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described in Chapter 3, leading to the release of VWF from the endothelium [30]. The 
local anticoagulant mechanisms of schistosomes are not expected to affect systemic 
haemostasis. Thromboelastography experiments on murine blood pre-incubated 
with S. mansoni and blood from mice infected with the parasite, provided some more 
insight into the effects of schistosomes on local and systemic coagulation [31]. These 
experiments revealed that blood from infected mice shows hypercoagulation, leading 
to faster clot formation, but with less stable clots formed, reflecting lower blood platelet 
numbers and lower levels of antifibrinolytic proteins leading to hyperfibrinolysis. This 
mirrors the haemostatic abnormalities observed in hepatosplenic schistosomiasis in 
humans [1]. Interestingly, these coagulation changes do not occur in early infection, 
but are only detected after considerable organ pathology as result of entrapment of 
eggs is present, strongly indicating that the haemostatic abnormalities result from 
liver disease [31]. This is consistent with the lack of increased coagulation activation 
and the lack of increased fibrinolysis activation that was observed in schistosomiasis 
haematobium patients without hepatic disease, as described in Chapter 3. 
However, pre-incubation of murine blood with schistosomes, resulted in remarkably 
different coagulation changes. Blood clots were formed slower and clot stability is 
not affected. This indicates that schistosomes act as strong local anti-coagulants, 
without significant effects on systemic haemostasis [31]. However, direct effects of 
schistosomes on fibrinolysis were not determined in this study, and it could be that 
schistosomes contribute to the hyperfibrinolysis observed in chronic schistosomiasis.
The occurrence of coagulopathy in hepatosplenic schistosomiasis raises the 
question whether we should treat haemostatic abnormalities with anticoagulants 
or antifibrinolytic drugs. As the parasitic infection forms the trigger that brings the 
rebalanced haemostatic system out of balance, it is expected that treatment of the 
infection with praziquantel resolves haemostatic abnormalities. Indeed, for bacterial 
infections in cirrhosis patients it was shown that successful treatment of the infection 
restored haemostatic parameters to pre-infection levels in 5 days [32]. Furthermore, 
liver fibrosis, but not cirrhosis, is often a reversible process, so hepatic function can 
be restored in fibrosis patients. It has been demonstrated that praziquantel itself 
may also have anti-fibrotic effects and could thus contribute even further to restore 
hepatic function, although effects on haemostatic parameters were not examined 
in this study [33]. Furthermore, it is interesting to consider whether the use of 
anticoagulation, procoagulant treatment, or antifibrinolytic treatment should be 
used to prevent thrombosis or bleeding complications in schistosomiasis. In liver 
fibrosis and cirrhosis, preventative anticoagulation has been studied in the prevention 
of portal vein thrombosis [21,34,35]. However, since portal vein thrombosis only occurs 
in approximately 5% of hepatosplenic schistosomiasis patients [36], the application 
of preventative anticoagulation in all hepatosplenic schistosomiasis patients without 
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further identification of the patients at risk for portal vein thrombosis would most likely 
not be beneficial. Administration of procoagulant drugs in order to prevent bleeding 
from gastro-oesophageal varices is unlikely to be beneficial to schistosomiasis 
patients, as a study in cirrhosis patients demonstrated that administration of FVIIa 
did not affect severity and outcome of variceal bleeding [21,26], and the occurrence 
of variceal bleeding is most likely linked to portal hypertension and local vascular 
abnormalities instead of hypocoagulation [21]. Administration of antifibrinolytic 
drugs has been useful in some cirrhosis cases in the management of active bleeding 
[21]. However, it has not been well studied whether prophylactic treatment with 
antifibrinolytic drugs could prevent bleeding in patients with liver disease [21]. 
Although a hyperfibrinolytic state is present in hepatosplenic schistosomiasis patients, 
it therefore remains unknown whether antifibrinolytic treatment could be applied to 
prevent bleeding in patients. In conclusion, early treatment with praziquantel in order 
to clear the infection, thereby taking away the trigger for the haemostatic imbalance, 
would be preferred over preventative treatment that affects the haemostatic system.
Modification of blood coagulation: novel mechanisms
The research presented in this thesis has led to the discovery of several novel 
mechanisms used by helminth parasites for modification of blood coagulation, 
presented in Chapters 4 and 6. Additionally, the study described in Chapter 5 
provides more insight into regulation of the VWF-cleaving peptidase ADAMTS13 
during normal haemostasis.
Targeting VWF: alternative routes to control multimer size
S. mansoni VWF-cleaving peptidase
Schistosome eggs are known to interact with plasma VWF [14], however, the interaction 
between VWF and the adult life stage of schistosomes has not been investigated. 
Plasma levels of VWF are elevated in schistosomiasis, without apparent thrombosis, 
as described in Chapter 3. VWF binds platelets at sites of endothelial damage and is 
thereby involved in initiation of the formation of a platelet plug [37]. The apparent lack 
of coagulation activation, despite elevated VWF levels, suggest that schistosomes may 
counteract increased VWF secretion. In Chapter 4 we have investigated the interactions 
between S. mansoni and VWF and discovered that SmCB2, a known cysteine peptidase 
of S. mansoni, can cleave VWF. The finding of an S. mansoni VWF-cleaving peptidase 
suggests that while the eggs require binding of VWF for extravasation, the adult worm 
actively degrades VWF to create a local anticoagulant environment around itself, which 
may explain the lack of platelet binding to the outer surface of the adult worm [27].
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SmCB2 is a cysteine peptidase of S. mansoni, that is localized in the tegumental outer-
surface structure of the adult worm [38]. The proteolytic activity of SmCB2 towards the 
FRETS-VWF73 substrate demonstrates that SmCB2 has the capacity to cleave VWF in 
vitro. Additional experiments need to be performed in order to examine this capacity 
under more physiological conditions. First the proteolytic activity of SmCB2 towards 
purified, native VWF will be examined. Additionally, the use of a flow chamber model 
of VWF-string formation on either HEK293 cells or blood outgrowth endothelial cells 
would allow visualization of degradation of VWF by SmCB2 under flow conditions and 
would be an interesting addition to the characterization of this peptidase [39,40].
Discovery of a novel VWF-cleaving peptidase could have implications beyond 
schistosomiasis, for example in disorders where regulation of VWF is disturbed. In 
Chapter 4 we have shown that the peptidase is not sensitive to components specific 
for TTP patient plasma. In these patients regulation of VWF is disturbed as a result of 
a deficiency of the VWF-cleaving peptidase ADAMTS13. This ADAMTS13 deficiency can 
be congenital, caused by mutations in the ADAMTS13 gene, or more often idiopathic, 
caused by inhibition of ADAMTS13 activity or enhanced clearance through binding of 
autoantibodies directed at ADAMTS13 [41,42]. As we have shown that the S. mansoni 
VWF-cleaving peptidase is not sensitive to autoantibodies present in TTP patient 
plasma and is likely to have low immunogenicity as reflected by the longevity of the 
parasite, we postulate that SmCB2 can have applications in the treatment of TTP. 
The applicability of SmCB2 in TTP could be assessed in an animal model for TTP. 
Several different mice models of TTP have been developed and a baboon model 
for acquired TTP is available [43]. ADAMTS13-deficient mice do not spontaneously 
develop TTP symptoms, but require an additional trigger such as Shiga toxin or 
recombinant UL-VWF, in order to develop TTP symptoms [43]. Acquired TTP can 
be induced in baboons and mice through administration of an inhibitory antibody 
against ADAMTS13 [43,44]. In baboons this results, without the need for an additional 
trigger, in the development of early-stage TTP symptoms, without progression to 
end-stage disease [43]. However, in mice an additional trigger is required for the 
development of symptoms [44]. The UL-VWF-induced congenital and acquired TTP 
models in mice and the baboon model for acquired TTP have been used to test novel 
therapies for TTP [44–46], and could similarly be of value to test the therapeutic value 
of SmCB2 in congenital and acquired TTP. 
Plasmin as activator of ADAMTS13
Having discovered an alternative route employed by S. mansoni to control VWF 
multimer length, we next investigated alternative routes for control of VWF functionality 
during normal haemostasis in Chapter 5. The fibrinolytic protein plasmin has been 
demonstrated to cleave VWF and has been proposed as a backup for ADAMTS13 [47]. 
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Additionally, amplified plasmin activity resolved TTP symptoms in a mouse model 
of acquired TTP [44]. In contrast to the positive effects of plasmin, several reports 
indicate that plasmin may cause proteolytic inactivation of ADAMTS13, which has 
been suggested to present a risk of TTP [48–50]. In Chapter 5 we demonstrated that 
plasmin truncates ADAMTS13, which in contrast to earlier reports, increases the activity 
of ADAMTS13. Differences in methodology may account for the observed differences 
in the effect of plasmin on ADAMTS13. In the previously reported studies, ADAMTS13 
was incubated for prolonged periods with plasmin, 2 – 24 hours, before assessment 
of functionality of the peptidase [48–50], while we incubated plasma only for 30 
minutes in the presence of plasmin. The first stages of plasmin cleavage of ADAMTS13 
take place at the C-terminus [49], which as we demonstrated in Chapter 5, results 
in increased ADAMTS13 activity. However, it is possible be that prolonged incubation 
(hours) of ADAMTS13 with plasmin results in additional cleavage of ADAMTS13 at 
different sites, eventually resulting in loss of activity [48,50]. 
The increased ADAMTS13 activity in plasmin cleaved ADAMTS13 is an interesting 
finding, because it provides new insights into regulation of ADAMTS13 activity. Until 
recently, it was believed that ADAMTS13 was present in plasma as an active enzyme, 
which activity was regulated solely by the conformational changes in its substrate, 
VWF. This view changed with identification of the existence of two conformations of 
ADAMTS13, closed and open, with different levels of proteolytic activity [51–53]. In its 
closed, less active conformation the C-terminal CUB domains of ADAMTS13 interact 
with its spacer region, causing ADAMTS13 to fold upon itself [51]. VWF binding through 
the CUB domains leads to conformational changes in ADAMTS13, a process called 
conformational activation, resulting in the open conformation of ADAMTS13 which 
is proposed to have increased proteolytic activity [51]. We propose that C-terminal 
truncation of ADAMTS13 by plasmin, removing the eighth thrombospondin type-1 
repeat and both CUB domains, causes ADAMTS13 to adopt an open conformation, 
resembling the conformational activation of ADAMTS13 and resulting in increased 
proteolytic activity. This discovery implies that not only substrate binding is involved 
in regulation of ADAMTS13 activity, but that also the plasma enzyme plasmin can 
regulate the proteolytic activity of ADAMTS13. This could reflect a physiological 
mechanism to enhance ADAMTS13 activity at sites of microthrombus formation. This 
would suggest two additional roles for plasmin at sites of microthrombus formation, 
besides the degradation of fibrin clots: 1) enhancing ADAMTS13 activity, thereby 
indirectly enhancing VWF cleavage, and 2) direct cleavage of VWF by plasmin [47]. 
Further research into the proteolytic regulation of ADAMTS13 by plasmin is required to 
identify the exact cleavage sites of plasmin, thereby confirming that indeed the eighth 
thrombospondin type-1 repeat and both CUB domains are removed from ADAMTS13, 
which would convert ADAMTS13 to a more open conformation. Additionally, it would 
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be interesting to see if the increased activity of the truncated ADAMTS13 towards FRETS-
VWF73 can be confirmed using a more physiological substrate, such as multimeric 
VWF, or in a flow chamber model of VWF-string formation [39,40]. 
Effects of helminths on fibrinogen, fibrin, and fibrinolysis 
S. mansoni tPA binding proteins
The serine peptidase plasmin is the main enzyme of the fibrinolytic system, where it 
breaks down formed thrombi through degradation of fibrin [54]. However, plasmin is 
a versatile peptidase, as demonstrated in Chapter 5, and has many other proteolytic 
substrates besides fibrin, such as extracellular matrix components, growth factors, 
complement proteins and IgG [55,56]. Many pathogens, including bacteria, fungi and 
parasites, have been described to use plasminogen activation to their advantage 
[55,56]. Many bacteria recruit plasminogen to their surface through surface-exposed 
plasminogen-binding proteins [56]. This immobilization of plasminogen induces 
conformational opening of plasminogen, which enhances activation of plasminogen 
by host-derived activators, facilitating bacterial invasion and dissemination [55,56]. 
Additionally, immobilized plasminogen is protected against inhibition by the serine 
peptidase inhibitor α2-antiplasmin [56]. Surface binding and activation of plasminogen 
to plasmin by schistosome species has been extensively studied [10,57–60] and 
revealed several plasminogen-binding proteins. Several schistosomal proteins have 
been demonstrated to enhance the conversion of plasminogen to plasmin. These 
are enolase of S. bovis, S. japonicum, and S. mansoni, and annexin of S. bovis, and all 
require the presence of the natural activator of plasminogen, tissue-type plasminogen 
activator (tPA), for enhancement of plasminogen activation [10,58–60]. Although the 
interaction between plasminogen and schistosomes has been studied in detail, no 
studies have focussed on the interaction between schistosomal tegumental proteins 
and tPA, which is therefore the topic of Chapter 6 of this thesis. In Chapter 6 we have 
identified many tPA binding proteins of S. mansoni that are reported to be localized in 
the tegument. This would indicate binding of tPA at the host-parasite interface, which 
could aid in enhancement of fibrinolytic pathways by the adult parasite. Future studies 
are required to demonstrate binding of tPA to the outer surface of the worm. We have 
attempted several microscopy strategies to visualize binding of tPA to the outer surface, 
but without success. This could be attributed to auto-fluorescence of the adult worm, 
which hampered the use of fluorescent microscopy. Otherwise, it is possible that only a 
small amount of tPA binding to the surface is required for enhancement of fibrinolysis, 
which would make it difficult to detect using a microscopy approach. 
As mentioned above, many pathogens, including bacteria use the fibrinolytic system 
to their own advantage. Two strategies can be discriminated in the way bacteria 
activate the fibrinolytic system: 1) the use of bacterial plasminogen activators, or 2) 
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plasminogen binding to the surface and use of host-derived activators. Schistosomes 
use the second strategy, while both Streptococcus and Staphylococcus species employ 
the first strategy. These bacteria produce the plasminogen activators streptokinase 
and staphylokinase that form a complex with plasminogen, which leads to its activation 
[56]. Both streptokinase and staphylokinase are used as thrombolytic treatment in 
patients with acute myocardial infarction or arterial thrombosis [61,62]. The second 
strategy, using host-derived activators for the activation of immobilized plasmin, 
which is used by schistosomes, is likely not suitable to be used as a thrombolytic 
therapy in the clinic. This strategy relies on recruitment of host protein activators of 
plasminogen, such as tPA, which allows plasminogen activation by pathogens when 
no fibrin clot is present. However, during a thrombotic event it is unlikely that this 
strategy will have a beneficial therapeutic effect, as the fibrin fibres present in the 
thrombus would form a sufficiently strong substrate for plasminogen activation and 
recruitment of plasminogen activators. This assumption is strengthened by the fact 
that, although to date many bacterial plasminogen receptors have been identified 
[56], none of these are currently used as thrombolytic therapies.
F. hepatica cathepsin L peptidases
Not only blood-dwelling parasites, such as schistosomes, interact with the haemostatic 
system of their host. Also blood-feeding parasites, such as Fasciola species encounter 
the blood coagulation system. In order to feed for prolonged periods on the blood 
of their host, many blood-feeding parasites have evolved mechanisms to prevent 
coagulation. Moreover, some of these have turned out to be potent antithrombotic 
agents, such as the leech-derived thrombin inhibitor hirudin [63]. In Chapter 7 we 
have studied several cathepsin peptidases of Fasciola hepatica and Schistosoma 
mansoni for their anticoagulant properties. In Chapter 7 we demonstrated that the F. 
hepatica cathepsin L peptidases (FhCL) 1, 2, and 3 degraded purified fibrinogen and 
that additionally FhCL1 and FhCL2 both efficiently degraded fibrin.
Haemostatic abnormalities during fascioliasis have been studied in infected cattle 
and sheep. The studies performed in cattle show contradicting results on the 
presence of coagulation changes in fascioliasis: where one study demonstrates a 
prolongation of PT [64], the other study reports no changes in clotting time [65]. Only 
a single study has examined clotting times during fascioliasis in sheep and reports an 
acceleration of APTT and prolonged PT and thrombin time (TT; common pathway), 
both in plasma of infected sheep as well as in vitro using excretory/secretory products 
of the parasite [2]. Although coagulopathy during fascioliasis has been described in 
several studies, the outcome varies between the studies which makes establishing the 
exact coagulation changes during fascioliasis difficult. It has been suggested that 
the observed coagulopathy is a result of both decreased production of coagulation 
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factors caused by liver damage and increased consumption of coagulation factors, 
in particular prothrombin, caused by activation of the intrinsic coagulation pathway 
[2]. This will result in prolongation of PT and TT, but a direct effect of parasite excretory/
secretory products on fibrinogen or thrombin cannot be excluded. The suggested 
involvement of liver damage and coagulation factor consumption in the arise of 
coagulopathy is in line with the observation that all in Chapter 7 tested peptidases 
are strongly inhibited by human plasma components. This is not surprising as plasma 
contains a large array of peptidase inhibitors [66]. Therefore it is likely that the tested 
cathepsin peptidases do not affect the haemostatic system of their host. Instead, we 
propose that they function in the Fasciola gut in the degradation of fibrinogen and 
fibrin. Secretion of these cathepsin peptidases at high concentrations in the Fasciola 
gut would allow them to locally overcome the effects of plasma peptidase inhibitors, 
facilitating blood-feeding of the parasite for prolonged periods. Many pathogens 
are known to interact with fibrinogen and/or fibrin, and many bacterial factors 
have been described that degrade fibrinogen or fibrin. This plays an important role 
in bacterial invasion and dissemination, through clearance of fibrin networks that 
restrict bacterial movement, but is also involved in immune evasion, as fibrin(ogen) is 
involved in stimulation of host immune cell activity [67,68]. Degradation of fibrinogen 
and fibrin by Fasciola cathepsin peptidases may thus also be involved in local immune 
modification to allow long-term survival of the parasite.
Haemostasis and parasitic helminths: future perspectives
In this thesis we have focussed on the interaction between the haemostatic system 
and parasitic helminths, in particular Schistosoma and Fasciola species. The blood-
dwelling schistosomes have developed a broad and complex set of strategies to 
modify the coagulation system at different levels. The work in this thesis has revealed 
that adult schistosomes interact with the plasma protein VWF, an interaction that 
was previously only known for schistosome eggs. Additionally, we have demonstrated 
the presence of tPA binding proteins associated with the tegument of schistosomes, 
and thereby provided more insight into modification of fibrinolysis by schistosomes. 
As mentioned before, it is unlikely that this thesis provides a complete overview on 
coagulation modification by schistosomes and novel discoveries will provide further 
insight into the complex host-parasite relationship. 
Further studies are needed to examine whether SmCB2 can be applied in disorders in 
which regulation of VWF functionality by ADAMTS13 is disturbed, such as thrombotic 
thrombocytopenic purpura. Additionally, VWF has been implied to contribute to 
other thrombotic diseases and complications, including stroke, myocardial infarction, 
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venous thrombosis, and renal and cardiovascular complications in diabetes mellitus 
[69]. Targeting VWF in these disorders with SmCB2 as a VWF-cleaving peptidase could 
provide novel preventive or therapeutic options.
The in Chapter 7 examined cathepsin L peptidases of Fasciola have been extensively 
studied for their potential as vaccine candidates [70]. Cathepsin L peptidases are 
vital in host-parasite interactions of Fasciola and are involved in blood-feeding and 
immune evasion [70,71]. Their importance during infection makes these cathepsin L 
peptidases interesting targets for the development of novel anti-parasitic therapies. 
Cysteine peptidase inhibitors have been studied as novel chemotherapy against 
schistosomiasis. Worm burden and pathology were significantly reduced by 
administration of a vinyl sulfone cysteine peptidase inhibitor in a murine model of 
schistosomiasis mansoni [72]. Similarly, administration of cysteine peptidase inhibitors 
in fascioliasis may have potential as a novel anti-parasitic therapy of fascioliasis.
Conclusion
With the work described in this thesis, we have provided novel insight into the 
mechanisms underlying coagulopathy during schistosomiasis and the mechanisms 
used by helminth parasites to modify coagulation activation. Identification of new 
coagulation modification strategies opens new doors for the development of drugs 
and vaccines against these parasites. Additionally, some of these mechanisms may 
have applications beyond parasitic disease, as novel antithrombotic or thrombolytic 
agents in haemostatic disorders. Especially the identification of SmCB2 as a VWF 
cleaving peptidase might be applicable as a novel treatment for disorders in which 
regulation of VWF functionality by ADAMTS13 is disturbed, such as thrombotic 
thrombocytopenic purpura (TTP).
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Introductie
De biologische term “parasitisme” beschrijft de relatie tussen twee organismen, waarbij 
één organisme (de parasiet) leeft ten koste van het andere organisme (de gastheer). 
Hoewel zeer veel organismen een parasitaire levensstijl hebben, wordt de term “parasiet” 
slechts gebruikt voor (I) parasitaire eencellige eukaryoten (de protozoa), (II) parasitaire 
wormen (de helminthen), en (III) ectoparasieten. Dit proefschrift is gericht op de parasitaire 
wormen, in het bijzonder de in de bloedbaan levende platwormen behorend tot het genus 
Schistosoma en de bloed-consumerende platwormen behorend tot het genus Fasciola. 
Beide parasitaire wormen zijn humane ziekteverwekkers en vormen voornamelijk in 
tropische landen een groot gezondheidsprobleem. Schistosomen zijn de veroorzakers 
van de tropische ziekte schistosomiasis en wereldwijd zijn meer dan 200 miljoen mensen 
geïnfecteerd met deze parasiet. Platwormen behorend tot het genus Fasciola, ook wel 
leverbotten genoemd, zijn de veroorzaker van fasciolose. Wereldwijd lijden minstens 2.4 
miljoen mensen aan fasciolose. Daarnaast zijn leverbotten een belangrijke verwekker van 
parasitaire worminfecties bij vee en hebben daardoor een grote economische impact. 
Beide helminthen hebben een complexe levenscyclus, die zowel een volwassen 
stadium in een zoogdier (de eindgastheer), als een tussenstadium in een 
zoetwaterslak (de tussengastheer) omvat. Infectie met schistosomen vindt plaats 
na contact met besmet zoet water, waarbij de Schistosoma larve (cercaria) door de 
huid naar binnen gaat en vervolgens een bloedvat binnendringt. De onvolwassen 
wormen (schistosomula) verplaatsen zich via de bloedbaan naar de lever, waar de 
volwassen wormen paren vormen. Hierna migreren de gepaarde wormen naar de 
bloedvaten rondom de darm (Schistosoma mansoni en S. japonicum soorten), of de 
vaten rondom de urineblaas (S. haematobium soort). De volwassen mannelijke en 
vrouwelijke worm blijven in deze bloedvaten gepaard aanwezig voor een periode 
van soms wel tientallen jaren. De symptomen van schistosomiasis worden niet zo 
zeer veroorzaakt door de aanwezigheid van het wormpaar, maar door de eieren 
die worden geproduceerd door de vrouwelijke worm. Een substantieel deel van de 
gelegde eieren wordt niet met de feces of urine uitgescheiden en komt vast te zitten in 
het leverweefsel (voornamelijk bij S. mansoni en S. japonicum infecties) of in de wand 
van de urineblaas (S. haematobium), met weefselschade en klinische symptomen tot 
gevolg. Wanneer uitgescheiden eieren in contact komen met zoet water, komt de larve 
(miracidium) uit het ei en infecteert de tussengastheer, een in de (sub)tropen levende 
zoetwaterslak. In de tussengastheer vermenigvuldigen en ontwikkelen de larven zich 
tot een voor de mens infectieuze larve (cercaria) die in het water uitgescheiden wordt. 
Infectie met leverbotten vindt plaats na ingestie van met ingekapselde larven 
(metacercariae) besmette (water)planten. In de dunne darm komen deze larven 
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uit hun kapsel en migreren door de darmwand en de buikholte naar de lever. Na 
een migratie door het leverweefsel die weefselschade en klinische symptomen 
veroorzaakt, komen de wormen meerdere weken na infectie aan in de galgang, 
waar ze volwassen worden. Volwassen leverbotten kunnen meerdere jaren aanwezig 
blijven in de galgang, waar ze zich voeden met bloed van hun gastheer. De eieren 
die de parasiet produceert, worden met de gal naar de darm vervoerd en met de 
feces uitgescheiden. In zoet water komt de larve (miracidium) uit het ei en infecteert 
de tussengastheer, een zoetwaterslak. In de tussengastheer vermenigvuldigen en 
ontwikkelen de larven zich tot cercariae die in het water uitgescheiden worden. De 
cercariae binden aan planten die aanwezig zijn in het besmette water en kapselen 
zichzelf in tot metacercariae die voor mens en dier infectieus zijn.
Hoewel de Schistosoma en Fasciola parasieten sterk van elkaar verschillen, 
hebben ze beide tijdens hun levenscyclus voor langere periode contact met het 
bloedstollingssysteem van hun gastheer, omdat ze zich in de bloedbaan bevinden 
en/of zich voeden met het bloed van hun gastheer. 
Het bloedstollingssysteem van mensen bestaat uit verschillende sterk gereguleerde 
mechanismen die samen bloedverlies voorkomen op plekken waar de bloedvatwand 
beschadigd is. Daarnaast speelt het bloedstollingssysteem ook een belangrijke rol 
in de afweer tegen ziekteverwekkers. Beschadigingen aan de vaatwand of activatie 
van endotheelcellen stimuleren de binding (via von Willebrand Factor (VWF) en 
collageen) en de activatie en aggregatie van bloedplaatjes. Dit leidt op de plek waar 
de vaatwand beschadigd is tot vorming van een plaatjesprop die de beschadiging 
afdicht. Deze plaatjesprop is echter instabiel en moet gestabiliseerd worden tot een 
stabiel stolsel door de vorming van fibrinedraden (door het enzym trombine) die 
de plaatjes aan elkaar verbinden in een proces dat bloedstolling wordt genoemd. 
Bloedstolling is een sterk gereguleerde opeenvolging van enzymatische reacties 
waarbij diverse bloedstollingseiwitten in bloedplasma worden geactiveerd, waarna 
uiteindelijk trombine actief wordt en fibrinogeen kan omzetten in fibrinedraden. 
Deze activatie van bloedstollingseiwitten kan geïnduceerd worden door factoren 
op beschadigd weefsel (tissue factor route), maar ook door de aanwezigheid van 
een negatief geladen oppervlak (contact activatie route). Na reparatie van de 
beschadiging in de vaatwand moet het stolsel afgebroken worden. Dit proces heet 
fibrinolyse en het enzym plasmine speelt hierin de hoofdrol door klieving van de 
fibrinedraden die het stolsel stabiliseren.
Contact tussen een parasitaire worm en het bloed van de gastheer zou op verschillende 
manieren kunnen leiden tot activatie van het bloedstollingssysteem van de gastheer. 
De aanwezigheid van de parasiet in de bloedbaan en binding aan de vaatwand 
kan leiden tot activatie of beschadiging van de vaatwand en verstoring van de 
bloedstroom, wat een sterke stimulus vormt voor de activatie van bloedplaatjes en 
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stollingseiwitten in plasma. Daarnaast vormt het oppervlak van de parasiet een sterke 
stimulus voor activatie van de in plasma aanwezige stollingseiwitten via de contact-
activatie. Echter, zowel schistosomen als leverbotten overleven lange perioden 
van blootstelling aan het bloedstollingssysteem van hun gastheer. Het is daarom 
waarschijnlijk dat de parasieten strategieën ontwikkeld hebben om de activatie van 
het bloedstollingssysteem in te perken. Het doel van het onderzoek beschreven in dit 
proefschrift is daarom om: (I) een overzicht te geven van de tot op heden bekende 
mechanismen die door schistosomen gebruikt worden voor de beïnvloeding van het 
bloedstollingssysteem van de gastheer, (II) inzicht te krijgen in de directe effecten van 
Schistosoma parasieten op de bloedstolling van de gastheer tijdens infecties met S. 
haematobium waarin leverschade niet opgetreden is, en (III) om tot nu toe onbekende 
strategieën voor de beïnvloeding van het bloedstollingssysteem door schistosomen 
en leverbotten te identificeren.
Effecten van schistosomen op de bloedstolling: huidige status
Hoofdstuk 2 van dit proefschrift beschrijft de grote verscheidenheid aan 
mechanismen die schistosomen gebruiken om de verschillende onderdelen van het 
bloedstollingssysteem van de gastheer te beïnvloeden. Schistosomen gebruiken 
hiervoor parasiet-specifieke mechanismen, maar bootsen ook mechanismen 
van de gastheer na of maken gebruik van mechanismen van de gastheer voor 
regulering van bloedstolling. Schistosomen hebben mechanismen die de activatie en 
aggregatie van bloedplaatjes remmen en daarmee de vorming van een plaatjesprop 
inperken. Daarnaast produceren schistosomen remmers van stolling en produceren 
ze moleculen die de mechanismen van de gastheer voor regulering van stolling 
activeren. Tot slot zijn schistosomen in staat het fibrinolyse-enzym plasmine te 
activeren op hun oppervlak, waardoor ze de afbraak van gevormde stolsels aan hun 
oppervlak kunnen stimuleren.
De grote variatie aan mechanismen beschreven in Hoofdstuk 2 die door de 
parasiet worden gebruikt om bloedstolling te remmen, laat zien dat de parasiet een 
opvallend sterk vermogen heeft om het bloedstollingssysteem van zijn gastheer op 
alle verschillende niveaus te beïnvloeden, wat activatie van bloedstolling rondom de 
parasiet voorkomt.
Afwijkingen in bloedstolling tijdens Schistosoma infectie: wat 
leren we van S. haematobium infecties?
Het vermogen van schistosomen om het bloedstollingssysteem van zijn gastheer te 
beïnvloeden, leidt tot de vraag of deze mechanismen alleen lokaal of ook systemisch 
de bloedstolling van de gastheer beïnvloeden. Er is veel onderzoek gedaan naar 
afwijkingen in de bloedstolling tijdens infecties met S. mansoni en S. japonicum, waarbij 
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tijdens langdurige infecties afwijkingen aan de bloedstolling op systemisch niveau 
aanwezig zijn. Hieruit kan echter niet geconcludeerd worden dat dit een direct effect is 
van beïnvloeding van bloedstolling door de volwassen worm. Chronische infectie met 
S. mansoni of S. japonicum leidt namelijk ook tot ernstige beschadiging van de lever 
door Schistosoma eieren die vast komen te zitten in het leverweefsel. De lever speelt 
een belangrijke rol in de bloedstolling, aangezien zeer veel bloedstollingseiwitten 
geproduceerd worden in de lever. Leveraandoeningen gaan daarom vaak hand 
in hand met afwijkingen in de bloedstolling. De afwijkingen in de bloedstolling die 
tijdens chronische infectie met S. mansoni of S. japonicum detecteerbaar zijn, kunnen 
dus zowel een direct effect van de volwassen parasiet op systemische bloedstolling, 
als effecten van leverschade reflecteren. Om hier onderscheid in te maken hebben we 
in Hoofdstuk 3 de bloedstolling bestudeerd in een groep schoolkinderen uit Gabon 
die geïnfecteerd zijn met S. haematobium. Aangezien deze parasiet zich bevindt in 
de bloedvaten rondom de urine-blaas en niet of nauwelijks in de vaten rondom de 
darm, komt alleen tijdens zeer ernstige infecties met deze parasiet leverschade voor. 
Dit maakt het dus mogelijk om de effecten van de volwassen worm op systemische 
bloedstolling te bekijken in de afwezigheid van leverschade. Uit de resultaten 
van deze studie blijkt dat schistosomen ontstekings-gemedieerde activatie van 
endotheelcellen veroorzaken, wat wordt gekenmerkt door verhoogde niveaus van de 
eiwitten VWF en osteoprotegerin in plasma. Deze endotheelcelactivatie leidt echter 
niet tot systemische activatie van bloedstolling of fibrinolyse mechanismen in deze 
patiënten. Dit suggereert dat de aanwezigheid van de volwassen parasiet niet leidt 
tot systemische afwijkingen in de bloedstolling en dat de systemische afwijkingen in 
bloedstolling die worden gezien tijdens infectie met S. mansoni of S. japonicum dus 
zeer waarschijnlijk veroorzaakt worden door leverschade als gevolg van eieren die in 
het leverweefsel vast komen te zitten. 
Beïnvloeding van de hemostase door helminthen: nieuwe 
mechanismen
Alternatieve manieren om von Willebrand Factor activiteit te reguleren
De observatie dat de concentratie van VWF in plasma verhoogd is tijdens infectie met 
schistosomen, zonder dat dit leidt tot activatie van stolling suggereert dat schistosomen 
mechanismen hebben om deze verhoogde uitscheiding van VWF door de vaatwand 
tegen te gaan en zo binding en activatie van bloedplaatjes te voorkomen. Normaal wordt 
de activiteit van VWF gereguleerd door het VWF-klievende peptidase ADAMTS13, wat altijd 
aanwezig is in plasma. Het is echter mogelijk dat schistosomen hun eigen mechanismen 
hebben ontwikkeld om de activiteit van VWF te reguleren. In Hoofdstuk 4 is daarom het 
onderzoek beschreven waarin onderzocht is of volwassen schistosomen effecten hebben 
op VWF, wat heeft geresulteerd in de ontdekking van een VWF-klievend cysteïne peptidase 
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dat geproduceerd wordt door S. mansoni. We konden aantonen dat dit peptidase SmCB2 
is, een cathepsine B peptidase uit het tegument van adulte Schistosoma wormen. Deze 
ontdekking geeft aan dat S. mansoni in staat is de activiteit van VWF te reguleren om zo 
activatie van bloedstolling te voorkomen. Dit peptidase zou mogelijk toegepast kunnen 
worden in ziekten waar de activiteit van VWF niet goed gereguleerd is, zoals trombotische 
trombocytopenische purpura (TTP), wat wordt gekenmerkt door een verlaagde activiteit 
van het VWF-klievende peptidase ADAMTS13. Het onderzoek beschreven in Hoofstuk 4 
heeft namelijk ook aangetoond dat het S. mansoni VWF-klievende peptidase niet wordt 
geremd door plasmafactoren specifiek aanwezig in het plasma van TTP patiënten.
Het feit dat S. mansoni in staat is om op een alternatieve manier VWF te reguleren, spoorde 
ons aan om te onderzoeken of er ook alternatieve routes voor regulatie van VWF activiteit 
bestaan in de mens (Hoofdstuk 5). Eerder is gevonden dat het fibrinolytische enzym 
plasmine in staat is VWF af te breken en is gesuggereerd dat plasmine een back-up 
mechanisme zou kunnen zijn voor het VWF-regulerende enzym ADAMTS13 dat vermindert 
actief is in TTP patiënten. Er zijn echter ook negatieve effecten van plasmine op ADAMTS13 
beschreven, aangezien verschillende studies beschrijven dat ADAMTS13 wordt afgebroken 
door plasmine, wat mogelijk een risico zou kunnen vormen in TTP patiënten. De resultaten 
beschreven in Hoofdstuk 5 van dit proefschrift laten echter zien dat klieving van ADAMTS13 
door plasmine de activiteit van het ADAMTS13 enzym verhoogt en dus geen negatief effect 
heeft op het ADAMTS13 enzym. Deze resultaten laten voor het eerst enzymatische regulatie 
van ADAMTS13 activiteit zien. Tot op heden werd namelijk aangenomen dat de activiteit van 
ADAMTS13 gereguleerd wordt door conformatieveranderingen in VWF, onder invloed van 
de snelheid van de bloedstroom, en in ADAMTS13 zelf, na binding aan VWF. Plasmine kan 
dus een alternatief mechanisme vormen om lokaal ADAMTS13 activatie, en daarmee dus 
indirect ook de activiteit van VWF, te reguleren en zo lokaal bloedstolling te beïnvloeden. 
Effecten van Schistosoma en Fasciola op fibrinogeen, fibrine en de fibrinolyse
Plasmine vormt ook het belangrijkste enzym in het fibrinolytische systeem dat 
verantwoordelijk is voor de afbraak van stolsels. Veel studies hebben aangetoond 
dat schistosomen in staat zijn om plasminogeen te binden aan hun oppervlak en 
de activatie tot plasmine te stimuleren. Al deze studies tonen echter ook aan dat dit 
alleen gebeurt in de aanwezigheid van tissue-type plasminogeen activator (tPA) dat 
plasminogeen om kan zetten in plasmine. Het is echter onduidelijk of tPA ook kan binden 
aan het oppervlak van de worm. Daarom hebben we onderzocht of er tPA-bindende 
eiwitten aanwezig zijn op het oppervlak van S. mansoni parasieten (Hoofdstuk 6). Dit 
onderzoek toont aan dat de parasiet een groot aantal tPA bindende eiwitten bevat, 
die ten dele ook aan het oppervlak van de parasiet voorkomen. Dit suggereert dat 
binding van zowel plasminogeen als tPA op het oppervlak van de worm zorgt voor 
lokale activatie van plasmine en een fibrinolytische omgeving creëert rondom de 
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worm. Tot slot is onderzocht of gezuiverde cathepsine peptidases van S. mansoni en 
F. hepatica ook direct fibrinogeen en fibrinedraden af kunnen breken (Hoofdstuk 7). 
Hoewel de S. mansoni peptidases fibrinogeen en fibrine niet direct konden afbreken, 
konden drie verschillende cathepsine L peptidases van F. hepatica (FhCL1, FhCL2, en 
FhCL3) dit wel. Hoewel fibrinogeen en fibrine een substraat vormen voor bepaalde 
cathepsine L peptidases van F. hepatica, betekent dit niet direct dat deze peptidases 
ook een effect hebben op het bloedstollingssysteem van de gastheer. Uit het 
onderzoek beschreven in Hoofdstuk 7 blijkt namelijk ook dat deze peptidases sterk 
geremd worden door componenten aanwezig in humaan plasma wat suggereert dat 
de peptidases waarschijnlijk de bloedstolling van de gastheer niet beïnvloeden. Veel 
waarschijnlijker is dat deze peptidases in de darm van de parasiet betrokken zijn bij 
de afbraak van fibrinogeen en fibrine, waardoor het door de parasiet opgenomen 
bloed niet stolt in de darm van de parasiet wat de consumptie van bloed door de 
parasiet mogelijk maakt.
Conclusie
Het onderzoek beschreven in dit proefschrift geeft nieuwe inzichten in de 
mechanismen die parasitaire wormen gebruiken om lokaal de bloedstolling van 
de gastheer te beïnvloeden. Daarnaast heeft ons onderzoek naar afwijkingen in 
de bloedstolling tijdens infecties met S. haematobium ook meer inzicht gegeven in 
de directe effecten van de volwassen parasiet op het bloedstollingssysteem van de 
gastheer. De identificatie van nieuwe mechanismen die door parasitaire wormen 
worden gebruikt om bloedstolling te beïnvloeden, kunnen leiden tot de ontwikkeling 
van nieuwe medicijnen voor de behandeling van infecties met deze parasieten. 
Daarnaast kunnen sommige van deze mechanismen mogelijk toegepast worden als 
nieuwe antistollingsmiddelen.
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